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i 
Abstract 
Wisam Tatari 
Using Pharmacist-Led Tele-Consultation to Review Patients with Chronic 
Obstructive Pulmonary Disease. 
Keywords: Chronic Obstructive Pulmonary Disease; COPD; Tele-consultation; 
Telemedicine; Pharmacist interventions; Community pharmacist; Community 
pharmacy; Distance-selling pharmacy; COPD control; Feasibility study.  
Introduction: A feasibility study was conducted with patients randomised to 
intervention arm or treatment as usual, in a community pharmacy-based chronic 
obstructive pulmonary disease (COPD) clinic. The study aimed to establish 
further work required to proceed to a definitive trial to test the impact of 
pharmacist interventions via Tele-Consultations (TC) amongst patients with 
COPD. The objectives were to determine feasibility of the rate of patient 
recruitment, retention, acceptability of TC, practicalities and completeness of 
data collection for outcome measures used to assess COPD control and 
management.  
Methods: Conducted in a single pharmacy by one specialist respiratory 
pharmacist (SRP) (community pharmacist with qualification in respiratory 
therapy). Patients were recruited from the pharmacy customer base and local 
advertisements. Participants were >35 years, with clinician diagnosed COPD 
and able to communicate in English. Participants were randomised (1:1) to 
receive an in-person consultation (IPC) or TC after spirometry, oximetry, and 
BMI measurements in-person. Consultations comprised of COPD review, 
education and medication optimisation - communicated to prescriber via postal 
mail. After 6-months, all participants were reassessed in-person.  
Results: Forty-eight patients from 16 GP practices were recruited over 4-
months; 41 (85%) completed the study. At follow-up, 29% of participants in the 
TC group declared a preference for IPC. Collection of data on all outcomes were 
completed with no adverse events.  
Conclusion: The recruitment target was met by employing additional strategies 
and achieved a satisfactory retention rate. Acceptability of the process of 
conducting TCs and the completeness of data collection was confirmed. Further 
studies should pilot a multi-centred approach with more pharmacists and 
employing an integrated approach with GPs, in preparation for a definitive study.   
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SAMA  Short Acting Muscarinic Antagonist 
SCR  Summary Care Record 
SD  Standard Deviation 
SRP  Specialist Respiratory Pharmacist 
SGRQ St George’s Respiratory Questionnaire 
TC  Tele-Consultation  
TH  Turbohaler 
VAS  Visual Analogue Scale 
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1. Executive Summary 
1.1 Introduction 
Chronic obstructive pulmonary disease (COPD) is a long-term condition with 
significant worldwide public health importance. COPD is associated with a 
chronic innate inflammatory response that results from continuous exposure to 
inhaled noxious particles resulting in dyspnoea, chronic sputum production and 
chronic cough [Global initiative for Chronic Obstructive Lung Disease (GOLD), 
2017]. These symptoms often cause anxiety, insecurity, immobility and social 
isolation, all of which are related to a lack of control and vulnerability (Mathar et 
al., 2015). COPD is a major cause of chronic morbidity and mortality worldwide. 
It is predicted to become the third leading cause of death by 2030, which is owed 
to the persisting prevalence of smoking and ageing of the global population 
(Kontis et al., 2017; Roversi et al., 2017). In the UK, COPD is regarded as one 
of the most expensive diseases to treat and it accounts for more time off work 
than any other condition (Keehan et al., 2017). 
 
It is essential to explore various approaches to managing COPD, given its impact 
on Health-Related Quality of Life (HR-QoL) and the considerable drain on 
healthcare systems (GOLD, 2017). Ideally, these approaches should comprise 
of interventions that retard the progressive nature of the disease, achieve a 
better quality of life (QoL) and have significant cost savings (GOLD, 2017). 
Additionally, immobility and social isolation are important factors which need to 
be addressed if we wish to provide accessible healthcare to patients with COPD. 
The use of assistive technology to offer consultations via remote 
telecommunication or tele-consultations (TC) is seen as one possible solution to 
circumvent accessibility issues and the feeling of isolation when individuals 
suffering with COPD are at home (Mathar et al., 2015). 
 
The term “Tele-Consultation” refers to an interactive audio and video 
telecommunications system that allows real-time, face-to-face communication 
between the patient and the healthcare professional (HCP), separated 
geographically (Deldar et al., 2016; Sood et al., 2007). This electronic 
communication medium is being seen as a means to revolutionise the way 
healthcare is provided, by supporting the management of chronic illnesses at a 
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time where there are increasing expectations for patient-centred care, 
particularly given the substantial challenges faced when serving people with 
limited mobility or people in remote areas (Glied and Jackson, 2017; Sood et al., 
2007). It is against this backdrop that interest in TC has captured policy interest 
within the respiratory health domain, and is already drawing a substantial amount 
of investment worldwide, particularly from the USA Veterans Health 
Administration, who are the world’s largest public funded user of TC services 
(Daniel and Sulmasy, 2015). However, the European Union remains uncertain 
regarding the acceptability, efficacy, and safety of its adoption (McLean et al., 
2011). Thus, careful deliberation is required particularly in the UK, where general 
practices are contractually obliged to offer patients a physical examination, if 
deemed appropriate. 
 
Many insurers emphasise that telephone consultations are not a replacement for 
an In-Person Consultation (IPC) where examination is indicated and thus co-
location of patient and practitioner is usually necessary (McLean et al., 2010). 
This is in contrast to community pharmacists, who although often required to 
assess patients’ symptoms as part of their provision of pharmaceutical care, are 
rarely involved in physical examinations, such as chest palpation. Thus, it seems 
feasible for pharmacists, who may otherwise only access these patients via 
telephone or a rare domiciliary visit, to use TCs when advising immobile patients. 
In principle, TCs offer the visual advantage over telephone communication and 
save time and costs of travel that domiciliary visits inevitably incur. Thus, quality 
research is required to comprehensively understand the practicalities as well as 
any implications of using TCs in a community pharmacy setting. 
 
The community pharmacy sector is experiencing considerable financial pressure 
with the government cutting more than £320 million off the community pharmacy 
budget in England, inevitability leading to closures of pharmacies across the 
country (Department of Health, 2016). The profession has the challenge of 
remaining sustainable and relevant by enhancing and expanding their clinical 
services in a bid to contribute to improving the care of patients, helping people 
stay healthy and helping the NHS become financially sustainable, all of which 
are national priorities within the NHS. Community pharmacists have long been 
clinically underutilised and feel they have the ability to do more to alleviate the 
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crisis faced by general practices’ incapacity to provide effective support to 
patients managing long-term conditions. Indeed, the current provision of clinical 
pharmaceutical services, which largely focuses on adherence, restricts 
pharmacists from fully optimising patients’ medication (Foot et al., 2017). 
 
Previous studies implementing a COPD service within community pharmacy 
have demonstrated favourable financial and clinical benefits to patients 
(Tommelein et al., 2014; van Boven et al., 2016; Wright et al., 2015). Since a 
proportion of inaccessible COPD patients can only be reached by a community 
pharmacist via telephone or an uncommon domiciliary visit, the feasibility study 
will focus on the rate of patient recruitment, retention, acceptability of TC and 
practicalities and completion of  data collection for outcome measures used to 
assess COPD control and management. Accessing remote patients in this way 
may help reduce patients’ anxiety and insecurity associated with COPD (Mathar 
et al., 2015). 
 
1.2 Aim 
A feasibility study was conducted with patients randomised to the intervention, a 
tele-consultation, or  a conventional  in-person consultation, in a community 
pharmacy-based COPD clinic. The study aimed to establish further work 
required to proceed to a definitive trial to test the impact of pharmacist 
interventions via TC amongst patients with COPD. 
 
1.3 Objectives 
The objectives were to determine the rate of patient recruitment, retention, 
acceptability of TC and the practicalities and completeness of data collection for 
outcome measures used to assess COPD control and management.  
 
1.4 Methods 
The feasibility study was a six-month, prospective, randomised-controlled, open-
label trial conducted in a single community pharmacy by one pharmacist who 
had previously worked in secondary care as a SRP. Patients were recruited from 
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the pharmacy customer base and local advertisements. Often, 30-50 participants 
is sufficient for a feasibility study; this study aimed to retain 20 participants per 
group at follow-up and in keeping with similar studies, allowed for a projected 
20% attrition rate, therefore, 48 participants (24 per group) was the sample size 
required. 
 
The inclusion criteria comprised of participants with clinician-diagnosed COPD 
who were over the age of 35 and able to communicate in English. Since all 
participants were assessed within the pharmacy’s consultation room at baseline 
(pre-clinic (PC)) and at 6-months, they needed to be able to access the 
pharmacy. Patients were excluded if they were not responsible for taking their 
own medications or if they were experiencing or recovering from an 
exacerbation. 
 
Participants were  randomly allocated to the IPC or TC arm of the study. In the 
TC arm, the consultation took place via Skype™ or other alternative video chat 
applications the patient was accustomed to. In such cases, the pharmacist was 
located in their consultation room and the patient based at their abode (after their 
PC). In the IPC arm, consultations were conducted within the community 
pharmacy consultation room where the patient and pharmacist met in person. 
Both groups received a COPD medication review from a SRP, comprising 
education on COPD and medication, adherence, inhaler technique, as well as 
appropriateness of current inhaler/s. Data collection also included acceptability 
of TC, HR-QoL and cost. All patient information subsequent to baseline was 
shared with a second pharmacist who documented their recommendations to 
substantiate whether a community pharmacist without specialist training in 
respiratory medicine would make the same recommendations. The second 
pharmacist was blinded to the patient’s allocated group. Participants in both the 
IPC and TC groups were followed up after six months in-person by the 
investigating pharmacist. 
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1.5 Results 
1.5.1 Recruitment 
Forty-eight patients were recruited from 16 GP practices over a 4-month period 
from September to December 2016; 25 (52%) from the pharmacy’s customer 
base and the remaining 23 (48%) through advertisements in several local 
newspapers. The sample consisted of 25 (52%) males and 23 (48%) females. 
One (2.1%) was a never smoker, 28 (58.3%) were ex-smokers and 19 (39.6%) 
were current smokers. Participants had a mean COPD Assessment Test (CAT) 
score of 25. 
 
1.5.2  Retention 
Forty-one participants completed the 6-month follow up consultations which took 
place between March and June 2017; 21 from the IPC group and 20 from the TC 
group (85% retention).  
 
1.5.3 Acceptability  
The process of randomising patients proved acceptable to patients. All 
participants completed the acceptability questionnaire. It was determined that 
41.7% of participants in the IPC group would prefer IPC over TCs. This was 
significantly lower in the TC group (29.2%) after having experienced its 
convenience during the study.  
 
1.5.4 Practicalities of TC 
Ten-participants (42%) in the TC group did not have a facility to access Skype™, 
so a tablet device was either delivered to their home or given to them after the 
PC. This was later collected by the pharmacy driver.  
 
On average, the estimated set-up time required for a TC, was an additional 10-
minutes per participant, which included how to use the Skype™ application. 
During the TCs, the transmission was interrupted on 3 separate occasions 
(12.5%). During one of the 3 interruptions, the TC had to be rescheduled. 
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1.5.5  Outcome Measures and Data Collection 
Completeness of data collection for outcome measures is summarised in Table 
1 below. There were no adverse events. It took one-month to analyse the data.  
 
Table 1: Completeness of data collection for outcome measures 
Outcome 
measure 
Assessment tool 
 
Completion rate 
 IPC TC 
COPD control CAT 100% 100% 
Lung function Spirometry  100% 100% 
Exacerbations  Patient disclosed information 
Checked PMR for recue medication 
100% 100% 
Hospital 
admissions 
Patient disclosed information 
 
100% 100% 
 HR-QoL European Quality of Life Five-
Dimension Questionnaire  
(EQ-5D-5L) 
100% 100% 
COPD 
management 
ABCD assessment tool 100% 100% 
Adherence MARS 100% 100% 
Inhaler 
technique 
Checklists (see Section 9.14) 100% 100% 
 
 
There were 185 recommendations made in total, 83 of which required a 
prescriber to make the intervention. Of these, 24% were acted upon by the 
prescriber. Inhaler technique was successfully carried out during TC, however, 
there were two instances during TC where the patient was out of view of the 
camera and were asked to re-demonstrate. The outcome measures were 
successfully administered in both groups and their completeness was checked 
during the consultation.  
 
  
7 
Lung function was measured using spirometry, which from a practical 
perspective, had to be conducted in-person (during PC) on all patients, as the 
pharmacist needed to instruct the patient on the use of this piece of equipment. 
The number of exacerbations and hospital admissions were based on patient 
recall, which may not have been accurate.  
 
In both groups, the number of participants visiting a pharmacy increased during 
the study period, however, the number of General Practitioner (GP) visits 
decreased. The costs increased when comparing the period 6-months prior to 
the study with the study period (by ~£25 per participant). However, the study 
would have projected to cost £966.20 (16.2%) or £925.80 (15.5%) more if 
domiciliary visits took place ahead of the IPCs or TCs, respectively. 
 
1.6 Conclusion 
COPD is a significant cause of morbidity and mortality and also represents a 
high economic and social burden internationally. Since patients with COPD can 
become housebound, they are less likely to have their medication reviewed by 
their pharmacist. This feasibility study conducted from a single pharmacy with a 
SRP, identified constraints with reliance on the pharmacy’s customer-base  to 
recruit a sufficient sample size, but demonstrated that this could be 
supplemented via local advertisements. The study achieved a satisfactory 
retention rate and confirmed acceptability of the process of conducting TCs and 
the completeness of data collection. Although, lost transmission and the patient 
being out of view of the camera were practical barriers to the success of TC. 
 
1.7 Recommendations 
In order to determine the feasibility of a full scale, multi-centre RCT to determine 
whether TC is non-inferior to IPC, further studies should first pilot a small scale, 
multi-centred approach with more pharmacists involved and with a more 
integrated approach with GPs. Studies should also be directed towards exploring 
whether a SRP, within the community pharmacy setting, can have a greater 
impact on outcomes by independently prescribing with read-write access to 
patients’ notes, which would be a substantial improvement on having to rely on 
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patient recall. A training program may be required to validate pharmacists 
wishing to conduct such clinics. 
 
Essentially, this research study highlighted a number of key matters that could 
support the management of patients with COPD. These consist of TCs, 
medicines optimisation and patient education. Prospective studies should 
include an additional arm, which compares usual care (not exposing patients to 
pharmacy clinics) to the IPC and TC groups, in order to verify the significance of 
pharmacy clinics. The IPC arm should be conducted at the patient’s abode rather 
than the pharmacy consultation room.  
 
Qualitative studies are sparse in this domain and future research can be used to 
explore how TC affects the users’ identities, experiences, expectations, 
motivations and capabilities to influence interaction. Thus, the researcher may 
gain breadth and depth of understanding and corroboration, whilst offsetting the 
weaknesses inherent to using either quantitative or qualitative study designs 
independently.   
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2. Introduction 
This chapter begins with an overview of the debilitating condition COPD and its 
associated Acute Exacerbations (AE-COPD). It describes how the condition can 
cause patients symptoms of anxiety and distress, which can eventually lead to 
immobility and social isolation, thus reducing access to medication reviews. As 
a result, housebound patients tend to gain contact with their HCP mainly via the 
customary telephone or domiciliary routes, and so these modes of consultation 
are considered. This chapter will describe the unsustainable nature of the NHS, 
both in terms of cost and quality of care. It presents a case for the role of TCs 
and their theoretical advantages over telephone and domiciliary visits to access 
those inaccessible patients. This is then followed by the challenges faced by 
general practice in supporting an ageing population and a justification is made 
for the use of pharmacists in optimising patients’ medication from their 
community pharmacy. Consequently, a service redesign proposal is made 
involving COPD medication reviews from a community pharmacy setting via TC 
in a bid to tackle these problems. Finally, a summary of the thesis structure is 
presented.    
 
2.1 Overview of COPD 
COPD is a systemic and heterogeneous disease that is characterised by airflow 
obstruction which is not fully reversible and is slowly progressive; it is a common, 
preventable and treatable condition that is associated with a chronic innate 
inflammatory response, a consequence from exposure to inhaled noxious 
particles (GOLD, 2017).  
 
The principal environmental factor that predisposes to the development and 
progression of COPD is exposure to cigarette smoke (either active smoking or 
passive smoking); however, continuous exposure to air pollution, occupational 
dust and chemicals are important risk factors for some populations (Thomsen et 
al., 2013). The principal genetic factor that predisposes to COPD is severe α1-
antitrypsin deficiency; other genetic determinants are influential in the 
pathogenesis of this condition but are unproven (Kim and Lee, 2015).  
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The chronic airflow limitation is caused by small airways disease (e.g., 
obstructive bronchiolitis) and parenchymal destruction (emphysema), the 
proportions of which vary from person to person. Pathological alterations result 
from an inflammatory response, which may induce destruction of lung 
parenchyma and disrupt normal repair and defence mechanisms (GOLD, 2017). 
These changes impair expiratory flow, which consequentially causes both 
resting and dynamic hyperinflation of the lungs (Bateman et al., 2014). The 
characteristic symptoms of COPD comprise of dyspnoea, chronic cough and 
chronic sputum production, all of which lead to poor QoL, restricted activity and 
typically worsen over time (GOLD, 2017).  
 
2.1.1 Prevalence 
Most national data show that < 6% of the adult population have been informed 
that they have COPD, however, this is a likely reflection of the widespread under-
recognition and under-diagnosis of COPD (Halbert et al., 2006; Quach et al., 
2015). In the UK, it is estimated that there are 3 million people suffering from 
COPD, of which only approximately 900,000 people have been diagnosed 
[National Institute for Health and Clinical Excellence (NICE), 2010]. This high 
prevalence and high mortality make management of this condition an important 
area to study.  
 
2.1.2 The impact of COPD on patients and healthcare 
systems 
COPD is a leading cause of morbidity and mortality worldwide that causes an 
economic and social burden that is both substantial and increasing (Lozano et 
al., 2012; Vos et al., 2012). Estimates suggest that this multifactorial condition is 
the fourth highest cause of mortality globally, killing more than 3 million people 
annually (Rabe and Watz, 2017) and its prevalence is expected to rise given the 
continued occurrence of smoking and aging (GOLD, 2017). HCPs have a crucial 
role in regularly addressing any behavioural risk factors (i.e., smoking, exercise 
and diet).  
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As the disease progresses, patients experience significant disability as a result 
of their symptoms, particularly dyspnoea, which causes distress and isolation 
(Farquhar et al., 2017). It is essential that these less accessible or housebound 
patients still have frequent medication reviews by their HCP, as this can reduce 
symptoms, and the risk and severity of exacerbations, in addition to improving 
exercise tolerance and health status (GOLD, 2017). Furthermore, with the 
addition of new recently-approved inhaled medications for the treatment of 
COPD and the new international GOLD guidelines (2017) advising new 
approaches to therapy, there is no longer a ‘one size fits all’ management 
pathway for individuals with COPD (Wedzicha et al., 2016). The evidence 
supporting these new medications is not widely known or understood by many 
HCPs in primary care and thus can lead to prescribing issues, such as doubling 
up on the same drug class (Anderson, 2016). Also, new types of inhaler devices 
are being made available, and the appropriate inhaled techniques must be 
correctly demonstrated to the patient. As a result, many COPD patients will 
require a medication review by their general practice.  
 
Given the widely known capacity issues faced by general practice in the UK 
(Maynard, 2017), any unmet need in managing COPD could be achieved 
through an expanded role for clinical pharmacists based in a community 
pharmacy setting. This also fits in with a principle of the ‘Five Year Forward View 
of community pharmacy’ (Royal Pharmaceutical Society, 2014), which suggests 
providing additional services to support patients and the public to better manage 
their own long-term conditions. Any prospective role must involve providing 
patients with self-management education, a national priority within the NHS and 
a concept which underpins the “Chronic Care Model” within the framework of the 
NHS. The aim of this model is to motivate, engage and coach patients to 
positively adapt health behaviour(s) and develop skills to better manage disease 
(Effing et al., 2016).  
 
2.1.3 Economic and social burden  
In 2015, COPD was the fifth leading cause of Disability-Adjusted Life Years 
(DALY) lost across the world, causing 2.6% of global DALYs (GOLD, 2017). This 
condition directly costs the NHS £1.3 million per 100,000 people per year and is 
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largely attributed to the expense of managing COPD and its associated hospital 
admissions (NICE, 2011). It is also worth noting that, in the UK, COPD accounts 
for more time off work than in any other condition (Keehan et al., 2017). If 
patients can be better supported with managing their COPD, there is potential 
for huge cost savings to be made.  
 
Governments, particularly of lower income countries, have to manage the 
increasing health needs of their populations, often in rural areas (Wiseman et al., 
2016). Given the substantial burden both globally and domestically, various 
approaches to managing this essential public health issue must be researched 
(GOLD, 2017). It is thought that technology can be used in extending speciality 
services to patients in underserved areas to facilitate disease management and 
help tackle this mounting concern (Bashshur et al., 2014; Bradford et al., 2015; 
Tabak et al., 2014). 
 
2.1.4 Diagnosis 
Early diagnosis and treatment are essential to lowering morbidity. The diagnosis 
can be deduced using a multidimensional assessment, based on the medical 
history, symptoms (such as dyspnoea, chronic productive cough and chest 
tightness), signs (such as wheeze, peripheral oedema and cachexia), and 
investigations, including spirometry. It is important to note that spirometry alone 
is not indicative of the overall severity of the disease, since patients have 
different disease phenotypes and may have significant differences in age, 
symptoms, comorbidities (including both medical and psychiatric disorders) and 
predicted mortality (GOLD, 2017; Hanania et al., 2011; Miller et al., 2013).  
 
Diagnosis of COPD in primary care may be improved by increasing access to 
community respiratory services and investing in training of HCPs about COPD 
and the use of spirometry (Haroon et al., 2015). Various case-finding initiatives 
have proven effective; for example, Wright, Twigg and Thorley (2015) 
demonstrated that community pharmacists can, through targeted screening, 
identify one patient with moderate severity COPD in every two patients 
screened. This, however, was not a controlled trial.    
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2.1.5 Assessment 
The objectives of COPD assessment are to establish the extent of airflow 
limitation, its impact on the patient’s health status and the risk of future events 
(such as exacerbations or hospital admissions), with the purpose of guiding 
therapy. To achieve these objectives, the following must be independently 
assessed: 
 
• Patient’s symptoms and their severity (see Table 2) 
- Modified MRC dyspnoea scale (mMRC)  
- COPD Assessment Test (CAT)  
• Exacerbation history and future risk  
• Presence of co-morbidities (e.g. cardiovascular disease) 
• Additional investigations  
- Pulse oximetry (evaluate a patient’s need for supplemental 
oxygen therapy) 
- Physical activity (six-minute walk test) 
 
 
Table 2: The presence and severity of spirometric abnormalities 
 
FEV1: Forced Expiratory Volume in one second, FVC: Forced Vital Capacity 
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2.1.6 Prevention and maintenance therapy  
The GOLD (2017) guideline directs a collaborative worldwide effort of HCPs to 
increase the awareness of COPD and improve the prevention and management 
of this disease state. If properly managed, some symptoms can be ameliorated, 
but there are no medications that have been proven to modify the long-term 
decline in lung function at present (Burge et al., 2000; Tashkin et al., 2008). A 
multifaceted approach to managing the condition is required, and includes 
interventions for smoking cessation (van Eerd et al., 2016), education (Effing et 
al., 2016), pulmonary rehabilitation (Puhan et al., 2005) and pharmacological 
therapy (GOLD, 2017).   
 
Smokers should at all times be encouraged to abstain from smoking and offered 
Nicotine Replacement Therapy, pharmacotherapy (bupropion) or psychosocial 
interventions (e.g. counselling, self-help materials, and behavioural therapy), 
which the evidence suggests would increase the long-term abstinence rates and 
cost effectiveness (Christenhusz et al., 2012; Stead et al., 2016). Smoking 
cessation is a unique intervention which affects the outcome in patients at all 
stages of COPD, and has proven to retard the progression of the disease by 
preventing further deterioration of lung function (Cahill et al., 2013). E-cigarettes 
are a relatively recent form of Nicotine Replacement Therapy whose efficacy 
remains controversial and their safety profile has yet to be defined (Malas et al., 
2016). Halpern et al. (2015) illustrated that incentive programs were more 
effective than usual care in increasing smoking cessation rates. Peletidi, 
Nabhani-Gebara and Kayyali (2016) indicated that pharmacy-led smoking 
cessation services have a higher success rate compared to self-quitting and 
demonstrated value for money. However, they concede that they are not 
routinely offered and the training for HCPs is inadequate.  
 
The evidence indicates that yearly Influenza vaccine should be offered to all 
COPD patients and a once only pneumococcal vaccine should be offered to all 
patients ≥ 65 years of age (Bonten et al., 2015; Wang et al., 2007). Likewise, all 
patients who suffer dyspnoea when walking at their own pace on level ground 
should be offered Pulmonary Rehabilitation (Vogiatzis et al., 2016). Yet, many 
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patients are not referred to these programmes and/or are not aware of the extent 
to which they may improve their symptoms, functional status and QoL.  
 
2.1.6.1 Pharmacological therapy for stable COPD 
Selecting the appropriate pharmacological treatment of COPD can decrease 
symptoms, lower the frequency and severity of exacerbations as well as improve 
health status and exercise tolerance. In order to guide therapy, it is essential to 
determine the disease severity, with due consideration given to the factors that 
may influence the development and progression of COPD. These include age, 
gender, socioeconomic status, genetic profile, lung growth and development, 
exposure to pollutants, asthma/bronchial hyperactivity, infections and chronic 
bronchitis (GOLD, 2017). The preference of medication within each group 
depends on the availability, favourable clinical response, and cost of medication 
balanced against side effects (GOLD, 2017). The groups of medications 
regularly used to treat COPD are discussed in detail below. 
    
2.1.6.1.1  Bronchodilators 
The bronchodilators, β2-agonists and muscarinic antagonists, cause smooth 
muscle relaxation by stimulating adenylyl cyclase activity and inhibiting the 
action of acetylcholine on airway muscarinic (M3) receptors respectively (de 
Miguel-Díez and Jiménez-García, 2014), which increase Forced Expiratory 
Volume in the first second (FEV1). This reduces dynamic hyperinflation and 
improves exercise tolerance both at rest and on exertion, improving patient 
confidence in carrying out activities and thus increasing their mobility (Aaron et 
al., 2007).  
 
Bronchodilators play an essential role in the pharmacological management of 
COPD, usually following a stepwise approach, in which short-acting β2-agonists 
(SABA) e.g. salbutamol sulphate, and short-acting muscarinic antagonists 
(SAMA) e.g. ipratropium bromide, are used initially to control symptoms (GOLD, 
2017). There are no studies that differentiate between the effectiveness of a 
SABA and SAMA in terms of improvement on FEV1. Patients who suffer 
persistent symptoms are recommended a long-acting β2-agonist (LABA), a long-
acting muscarinic antagonist (LAMA) or both (Wedzicha et al., 2016). The LABA 
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and LAMA treatments are preferred over their short-acting alternatives (SABA 
and SAMA) due to fewer AE-COPD and fewer hospital admissions (Cheyne et 
al., 2015). Furthermore, LAMA (tiotropium) showed superiority in prolonging time 
to first exacerbation when compared to LABA (salmeterol) (Vogelmeier et al., 
2011). However, this study was limited by having a significantly higher 
discontinuation of salmeterol than tiotropium.  
 
2.1.6.1.2  Combination bronchodilator therapy (LAMA-LABA) 
The LABA-LAMA combination has demonstrated superior efficacy compared to 
their individual components (Karner and Cates, 2012). Recently, several of the 
LABA-LAMA combinations have been developed for maintenance therapy of 
COPD, including; 
 
• Glycopyrronium/Formoterol (Bevespi) 
• Umeclidinium/Vilanterol (Anoro Ellipta) 
• Aclidinium/Formoterol (Duaklir Genuair) 
• Tiotropium/Olodaterol (Stiolto) 
 
The FLAME trial, conducted by Wedzicha and team (2016) substantiated claims 
that a LABA-LAMA (Indactarol-Glycopyrronium) combination was more effective 
than the Inhaled Corticosteroid - LABA (ICS-LABA) (Fluticasone-Salmeterol) 
combination in preventing COPD exacerbations in patients of all severities who 
had a history of exacerbation during the previous year; this was regardless of 
the subgroup having an elevated blood eosinophil count (e.g. ≥ 2%). The LABA-
LAMA combination also demonstrated superiority to lung function and health 
status outcomes (Singh et al., 2015). There were no significant differences in 
adverse events and deaths between the two groups, however as expected, the 
incidence of pneumonia was 1.6% higher in the LABA-ICS group (P=0.02). The 
SPARK study (Wedzicha et al., 2013, p. 20) also showed LABA-LAMA 
significantly reduced the rate of exacerbations versus LAMA alone. Thus, since 
the FLAME (Wedzicha et al., 2016) and SPARK (Wedzicha et al., 2013) studies 
contradict other studies (Pascoe et al., 2015; Pavord et al., 2016; Siddiqui et al., 
2015), GOLD (2017) advise the use of either a LABA-ICS or a LABA-LAMA 
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combination ahead of LAMA monotherapy for patients at risk of exacerbations, 
as first line therapy.  
 
2.1.6.1.3 Phosphodiesterase inhibitors 
The oral xanthine derivative, theophylline, may act as a non-selective 
phosphodiesterase inhibitor and may be added to a treatment regimen for its 
bronchodilator effect, however, it is comparatively less effective and its narrow 
therapeutic window makes it less tolerable (Matera et al., 2017). There is 
contradictory evidence regarding its effects on exacerbation rates (Cosío et al., 
2016). 
 
The drug roflumilast, a phosphodiesterase-4 inhibitor, has been shown to reduce 
moderate to severe AE-COPD rates in patients with severe COPD, chronic 
bronchitis and with a previous history of AE-COPD (Calverley et al., 2011; 
Martinez et al., 2015). It demonstrated significant improvements in FEV1 with 
what seemed a tolerable side effect profile. Treatment with roflumilast should be 
commenced by a specialist in respiratory medicine and only used in patients with 
severe COPD (NICE, 2017). 
 
2.1.6.1.4  Anti-inflammatory agents 
2.1.6.1.4.1 ICS in combination with LABA (ICS+LABA) 
Existing evidence suggests that combination ICS therapy in COPD reduces the 
rate of exacerbation and possibly reduces the decline in lung function and the 
rate of decline in QoL (Yang et al., 2012). Thus, for patients with FEV1 < 50% 
predicted and who are considered at high risk of exacerbations, a LABA+ICS 
combination can be used (Kew et al., 2014), however, this must be weighed up 
against the increased risk of oropharyngeal candidiasis and pneumonia, which 
is associated with the ICS element.  
 
In patients with a history and/or findings suggestive of Asthma-COPD Overlap 
Syndrome (ACOS), initial therapy with LABA-ICS may be first choice (GOLD, 
2017). It is important to note that ICS is not recommended as a standalone agent 
in the treatment of COPD, as its effect is significantly enhanced when combined 
  
18 
with a LABA (Vestbo et al., 2016). It is also worth indicating that ICS-LABA is 
overprescribed in patients with mild to moderate COPD when there is a low 
exacerbation risk (Drivenes et al., 2014). Thus, new international guidelines 
(GOLD, 2017) are advocating greater caution with the use of steroid inhalers, 
which requires the need to review many patients’ COPD medication regimens.  
 
2.1.6.1.4.2  Triple inhaled therapy (LABA-LAMA-ICS) 
Patients with persistent symptoms who develop further exacerbations on ICS-
LABA or LABA-LAMA are recommended triple therapy with LABA-LAMA-ICS 
(GOLD, 2017). Evidence suggests the lack of effect of adding ICS to LABA-
LAMA on the frequency of exacerbations (Aaron et al., 2007). However, adding 
a LAMA to LABA-ICS improves lung function and patient reported outcomes 
(Siler et al., 2016; Singh et al., 2016). An inhaler containing all three components 
(LABA-LAMA-ICS), known as Trimbow, has recently been formulated to 
simplify treatment regimens.  
 
2.1.6.1.4.3  Withdrawal of ICS 
The WISDOM trial (Withdrawal of Inhaled Steroids During Optimised 
bronchodilator Management in COPD) found that stepwise withdrawal of ICS is 
non-inferior to the continuation of ICS, with respect to the risk of moderate or 
severe exacerbations but is inferior regarding symptoms and lung function 
(Magnussen et al., 2014). It is important to note, however, that the results of this 
trial apply only to patients with severe but stable COPD who were receiving 
combination therapy (LABA-LAMA-ICS) and thus may not be generalisable to 
other groups. The WISDOM trial suggests that the addition of ICS therapy only 
achieves an initial phase of clinical stability in individuals with stable COPD. In 
view of this, the possibility that certain patient populations may not benefit from 
the addition of ICS should be seriously considered (Brusselle et al., 2015). In 
addition, there are currently no studies published assessing the long-term role 
of ICS for the treatment of stable COPD (Magnussen et al., 2014). It is essential 
that future well-designed randomised controlled trials (RCT) investigate whether 
the addition of ICS provides any therapeutic advantage to LABA-LAMA (Tan et 
al., 2016).  
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2.1.6.1.5  Prophylactic antibiotics 
An unconventional approach to preventing AE-COPD is the continuous use of a 
macrolide (e.g. erythromycin, azithromycin and clarithromycin), which has been 
shown to significantly reduce the frequency of exacerbations amongst patients 
(Herath and Poole, 2013; Uzun et al., 2014), yet their optimal duration and dosing 
remains unclear (Ni et al., 2015). Azithromycin use was related to impaired 
hearing and increased incidence of bacterial resistance (Albert et al., 2011). The 
impact of pulsed antibiotic therapy remains dubious and warrants further quality-
controlled studies (GOLD, 2017).  
 
2.1.6.1.6  Mucolytic agents  
Mucolytics, such as carbocisteine or N-acetylcysteine, are thought to work by 
loosening sputum in order to make it easier to cough it up. There is moderate 
confidence that treatment with mucolytics may cause a small reduction in AE-
COPD and a small, positive effect on QoL (Poole et al., 2015). 
 
2.1.6.1.7  β-Blockers 
Against popular belief, there are numerous studies that have shown there to be 
a decrease in mortality in patients suffering from AE-COPD who are taking β-
blockers. This is perhaps caused by dual cardiopulmonary protective properties 
(Rutten et al., 2010; Short et al., 2011). In spite of this, further larger high-quality 
studies are required to authenticate this finding.  
 
2.1.6.1.8  Benzodiazepines  
Dyspnoea is one of the main symptoms of COPD. The evidence suggests that 
opioids may relieve dyspnoea at rest and on exertion but not exercise capacity 
in severe COPD (Ekström et al., 2015). There is however no evidence which 
supports or opposes the use of benzodiazepines for the relief of dyspnoea in 
COPD (Simon et al., 2016). Thus, Simon et al. (2016) suggests using 
benzodiazepines as a second- or third-line treatment when opioids and non-
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pharmacological techniques have failed. These findings require further 
exploration in prospective well-designed trials.  
 
2.1.6.1.9 Patients’ ability to use inhaler devices 
As inhaled therapies form the backbone of the therapeutic management of 
COPD, it is critical that patients are able to use their inhaler(s) (Laube et al., 
2011; Yawn et al., 2012). The identification of patients’ attitudes to inhalers 
should also be explored to ensure that there are no obvious barriers to the 
initiation and use of prescribed therapy (Braido et al., 2016). It is then essential 
that patients are counselled about the correct use of their inhaler(s). Usmani et 
al. (2018) advocate that those patients at higher risk of errors are provided with 
additional specifically-tailored in-depth support with their inhaler use in order to 
ensure that they are confident with the correct technique. Poor inhaler technique 
not only causes a marked reduction in therapeutic effect but also wastes NHS 
resources. This is particularly noteworthy, since three of the five most expensive 
treatments in primary care are inhalers (Mak et al., 2012).   
 
Although patients’ inhaler technique is not always well understood by HCPs, the 
conveniently positioned community pharmacists have grasped opportunities to 
focus on this issue (Hesso et al., 2016; van Boven et al., 2016). Having an all-
inclusive NHS necessitates that housebound patients are not to be disregarded 
(Hampson and Ottey, 2015). Tatari (2016) has shown that inhaler technique can 
be successfully demonstrated by a community pharmacist via the video 
communication software application, Skype™. In principle, this medium would 
seem to be more suitable for the housebound patient than to arrange a pharmacy 
visit, or for the pharmacist to conduct domiciliary visits, which can be time-
intensive and costly.  
 
2.1.6.2 Pulmonary rehabilitation 
Pulmonary rehabilitation is defined as a comprehensive intervention that 
includes exercise training, education and self-management strategies aimed at 
behaviour change designed to improve the physical and psychological condition 
of patients with chronic respiratory disease. It also encourages and promotes 
long-term adherence to health-enhancing behaviours (Spruit et al., 2013). 
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Pulmonary rehabilitation usually involves a range of HCPs as part of an 
integrated patient management plan, with optimum benefits being achieved after 
six to eight weeks (Vogiatzis et al., 2016). The service must recognise the role 
pharmacists can play in supporting patients with their medicines and 
refer/signpost patients to a pharmacy when medication related-advice is 
required.  
 
2.1.6.3 Patient education and self-management  
The shift towards the personalisation and personal responsibility for healthcare 
has gathered recent pace, whereby patients are offered supported self-care in 
order to maintain their health and independence (Huygens et al., 2016). The aim 
is for the patient to understand how to use the item(s) they have been given and 
ensuring the patient is well informed on when and how to seek further advice. 
Patients must be advised to go to their local pharmacy when they require 
support, advice and resources on staying healthy and independent, with the aim 
of improving outcomes by supporting a more aware and informed community 
(Wright et al., 2015).  
 
Providing a personalised self-management plan to COPD sufferers and 
improving education enables patients to be guided by their medical regimens, 
health behaviour and offers emotional support to better control their COPD 
(Bourbeau and Palen, 2009). These strategies are associated with improved 
dyspnoea, HR-QoL and decreases in admissions (Zwerink et al., 2014). Several 
studies combined self-management plans with access to web-based call centres 
and domiciliary care from doctors and nurses, which demonstrated lower 
readmissions caused by AE-COPD when given to patients at discharge (Casas, 
2006). However, it is difficult to substantiate clear advice regarding the most 
effective self-management plan since the diverse studies demonstrate 
heterogeneity among interventions, study populations, follow-up time and 
outcome measures.  
 
2.1.6.4 Integrated disease management programme  
In the COPD demographic, there is substantial variation in symptoms, exercise 
tolerance and QoL, which poses a particular challenge to medical care. An 
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Integrated Disease Management program offers COPD sufferers access to a 
range of HCPs (e.g. doctors, nurses, physiotherapists and pharmacists) who 
collaborate together to provide efficient and evidence-based care (e.g. 
medication review, pulmonary rehabilitation, self-management and education). 
The evidence indicates that Integrated Disease Management interventions not 
only improve disease-specific QoL and exercise capacity after 12-months, but 
also decrease admissions related to AE-COPD and inpatient stay by 3 days, 
without effecting mortality (Kruis et al., 2013).  
 
2.1.7 Acute exacerbations of COPD  
GOLD (2017) defines AE-COPD as an acute event characterised by worsening 
of the patient’s respiratory symptoms that is beyond normal day-to-day variations 
and which leads to a change in medication. They are classified as mild (treated 
with SABA/SAMA), moderate (treated with SABA/SAMA plus antibiotics and/or 
oral corticosteroids (OCS)) or severe (requires hospitalisation or an A&E visit). 
Frequent AE-COPD are associated with an accelerated decline in FEV1 (Vestbo 
et al., 2011), poorer health status, worsening HR-QoL, increased hospital 
admissions and mortality (Chhabra and Dash, 2014; Wedzicha et al., 2013). The 
ECLIPSE study established that there is a high-risk period for recurrent AE-
COPD in the 8-week period after the initial AE-COPD (Hurst et al., 2009). For 
HCPs charged with managing individuals with COPD, it is vital to note that they 
recognise the following conditions may mimic or aggravate an AE-COPD (Roca 
et al., 2013); 
 
• Pneumonia 
• Pulmonary embolism 
• Congestive heart failure 
• Cardiac arrhythmia 
• Pneumothorax 
• Pleural effusion 
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2.1.7.1 Aetiology of AE-COPD 
It is estimated that 70-80% of COPD exacerbations are triggered by bacterial 
infections (most commonly by Haemophilus influenza, Streptococcus 
pneumonia,  Moraxella catarrhalis) or viral infections (human rhinovirus is most 
common), and the remaining 20-30% arise from exposure to environmental 
pollution or have an unknown aetiology (Buss and Hurst, 2015; Sapey, 2006; 
Sethi and Murphy, 2008). Generally, viral infections precipitate more 
hospitalisations, especially during winter (GOLD, 2017). 
 
2.1.7.2 Burden of AE-COPD 
AE-COPD is a significant prognostic factor and imposes the largest proportion 
of the total COPD burden on the NHS (GOLD, 2017). It accounts for the second 
largest cause of unplanned admissions and the cost to the NHS is estimated to 
be £15, £95 and £1960 per patient for mild, moderate and severe exacerbations, 
respectively (NICE, costing report, 2011). Hence, a key intervention is to lower 
the frequency of exacerbations, not only to reduce the decline in lung function 
and disease progression, but also to reduce costs (Mak et al., 2012).  
 
2.1.7.3 Estimating risk of AE-COPD 
Recent studies have focused on stratifying patients according to their risk of AE-
COPD, due to its detrimental nature in COPD (Collins et al., 2015; Guerra et al., 
2017). This personalised approach is especially favourable when deciding on 
their medicines regimen, such as including an ICS component, which reduces 
exacerbations but are associated with risk, such as pneumonia (Calverley et al., 
2011; Dransfield et al., 2013; Singh and Loke, 2010) and osteoporotic fractures 
(Loke et al., 2011). However, the evidence would appear to suggest that there is 
uncertainty as to which model best forecasts exacerbations in patients with 
COPD (Guerra et al., 2017).   
 
The ECLIPSE study (Hurst et al., 2009) demonstrated that AE-COPD were more 
frequent and more severe with increased severity of the underlying disease. 
However, Hurst and colleagues (2009) concluded that past history of AE-COPD 
was the most accurate predictor of exacerbations. Another prospective predictor 
of exacerbations includes health status, presence of gastro-oesophageal reflux, 
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increased numbers of white blood cells, and finally, airway and blood levels of 
eosinophils and their associated sensitivity to corticosteroids (Pascoe et al., 
2015). Thus, there is an increasing body of evidence that indicate the factors 
involved in determining the risk of AE-COPD, which can be used to inform 
decisions about treatment choices to help reduce AE-COPD.  
 
2.1.7.4 Management strategies of AE-COPD 
The aim of managing an AE-COPD is to minimise its impact and prevent the 
development of subsequent exacerbations. Generally, AE-COPD can be 
managed in an outpatient setting, however, the more severe exacerbations will 
necessitate inpatient treatment. If and when an AE-COPD occurs, prompt 
treatment is warranted to ensure faster recovery, minimisation of lung damage 
as well as reduced frequency of hospital admissions (Donaldson et al., 2015; 
Vollenweider et al., 2012).  
 
One such mechanism for certain patients who are at risk of having an AE-COPD 
is to keep a ‘rescue pack’ at home. This consists of a SABA/SAMA, OCS 
(Walters et al., 2014) and an antibiotic as part of a self-management strategy. It 
must be noted that there are no significant differences in FEV1 improvement 
between the correct usage of a metered dose inhaler (MDI) and nebulisers 
(Turner et al., 1997). In the outpatient setting, the antibiotic used is usually 
empirical and not based on sputum cultures. The evidence supports antibiotic 
use in AE-COPD when clinical signs are suggestive of a bacterial infection e.g. 
purulent sputum production (Ram et al., 2006) or biomarkers at the time when 
patients present to the GP or A&E (Vollenweider et al., 2012). The role of inhaled 
antibiotics for treatment and prevention of COPD remains contentious (Dal 
Negro et al., 2008), however, studies are ongoing regarding this modality. There 
is high quality evidence that demonstrates OCS (e.g. prednisolone) reduce 
recovery time and treatment failures when used to treat AE-COPD (Niewoehner 
et al., 1999; Walters et al., 2014).  
 
The use of rescue packs must be regularly monitored, and patients are advised 
to inform their surgery if they have taken the course in order for a replacement 
to be obtained. Regrettably, COPD sufferers fail to report their AE-COPD to their 
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GP (Mackay et al., 2014). A self-management plan can help inform patients to 
recognise episodes of AE-COPD in order to seek advice early in the course of 
an exacerbation. Commonly, a telephone consultation occurs at the onset of an 
AE-COPD where patients discuss their symptoms with their GP/respiratory 
nurse specialist (RNS). Crucially, there is a role in the utilisation of tele-
consultations (TCs) where the patient and practitioner have a visual 
communication advantage over telephone consultations (Mathar et al., 2015).  
 
2.2 Telemedicine 
Telemedicine (TM) involves the remote exchange of data between a patient and 
HCPs as part of the patient’s diagnosis and healthcare management (McLean 
et al., 2011) to improve a patient’s clinical health status (Wootton, 2012). Within 
the twenty-first century, there has been growing interest in the application of TM 
to support the management of chronic conditions such as COPD (Botsis and 
Hartvigsen, 2008; Wootton, 2012). NHS England (2013) endorses these 
fundamental changes to how care is delivered to facilitate the preservation of the 
NHS’s core values, such as free at the point of use service. They advocate 
finding alternative solutions to effect change, such as harnessing technology to 
improve productivity as part of the patient’s diagnosis and healthcare 
management. 
 
TM consists of both asynchronous and synchronous communication modalities. 
The asynchronous methods allow patient data to be forwarded periodically to 
their HCP, who responds by email or telephone, for example in-home patient 
monitoring (McLean et al., 2011), whereas the synchronous methods enable 
real-time communication between patient and HCPs, for example, telephone or 
TCs. There is also the capability to conduct pulmonary rehabilitation remotely 
(Bolton et al., 2011).  
 
2.2.1 Asynchronous technologies 
Asynchronous technology is an automated communications process by which 
measures and other data are collected at remote or inaccessible points and 
transmitted to receiving equipment for monitoring/self-monitoring; these include 
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lung function, oxygen saturation, Body Mass Index (BMI) and pulse (Davies et 
al., 2000; Hersh et al., 2001; Himes and Weitzman, 2016). It is imperative that 
encryption software is utilised to protect the confidentiality of data transfer 
(Moreno et al., 2009).  
 
There are a growing number of telemonitoring services available for COPD 
patients (Casas, 2006; Dale et al., 2003; Jacobs and Criner, 2016; Mair and 
Whitten, 2000; McLean et al., 2011; Polisena et al., 2010; Trappenburg et al., 
2008), the majority of which have demonstrated a decrease in costs and rates 
of admissions. However, these studies recruited low numbers of patients 
(Ambrosino et al., 2017). Furthermore, several studies have demonstrated 
insignificant or negative effects (Barlow et al., 2007; Udsen et al., 2017). Thus, 
its impact on clinical outcomes and cost-effectiveness remains debateable.   
 
2.2.2 Synchronous technologies 
Synchronous technologies facilitate TCs between the HCP and the patient via a 
video conference device rather than meeting in person (Goldstein and O’Hoski, 
2014). Although these video communication software applications e.g. Skype™, 
are routinely used in business and by many organisations around the world, their 
efficacy between patient-HCP interactions still needs to be scrutinised. It may be 
used to aid patients to better understand their condition, as well as a mechanism 
to deliver the key messages to empower patients to take ownership of their 
health (Himes and Weitzman, 2016). 
 
Raza and colleagues (2009) consider TM to be a feasible and acceptable model 
in pulmonary conditions in underserved rural areas where a nurse is present at 
a satellite site to provide clinical information, such as pulse oximetry. Raza et al. 
(2009) claimed that TCs are reliable and established that waiting times were 
equivalent to the traditional in-person waiting times. As well as saving time and 
transport costs, the authors corroborated that TC is more favourable to the 
environment due to lower emissions from transport vehicles. However, currently 
this modality is not accessible to everyone as a computer or phone with a camera 
facility is needed, along with access to the internet. Other disadvantages include 
missing vital signs, keeping abreast of healthcare laws, reimbursement policies, 
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privacy protection rules and the time required to train staff and patients in using 
IT equipment.  
 
2.2.3 The public’s access to TM 
In 2006, 57% of households in Great Britain had internet availability; this rose to 
84% in 2014 and 90% in 2017 (Office for National Statistics, 2017). In 2011, 36% 
of adults accessed the internet using a mobile phone or smartphone, which rose 
to 73% in 2017. In 2007, telephoning or video calls over the internet via a 
webcam constituted 8% and rose to 37% in 2015. Given this increasing 
availability, and the development of technologies, it seems inevitable that TM will 
continue to gain policy interest (Currell et al., 2010). The utilisation of this 
technology as a consultation mechanism will become increasingly familiar as the 
population becomes more Information and Communication Technology savvy. It 
is for these reasons that introducing TCs to practice and changing behaviours 
should be considered a gradual process.  
 
2.2.4 Tele-Consultation 
TC falls under the umbrella term ‘TM’. Swendeman and Rotheram-Borus (2010), 
portray that at a basic level TM includes medical record keeping, data 
processing, and phone or email consultation, while TC is considered more 
advanced.  
 
Many insurers emphasise that telephone consultations are not a replacement for 
an IPC and examination (McLean et al., 2010). In the UK, general practices are 
contractually obliged to offer patients a physical examination if deemed 
appropriate, and thus, co-location of patient and practitioner is usually 
necessary. Pharmacists, their primary care counterparts, may visually observe 
patients, however, they are rarely involved in physical examination since their 
expertise lies in supporting and guiding patients in relation to their medication 
ahead of diagnosis, and thus, TCs may be a suitable alternative to advise 
patients. Also, the Royal Pharmaceutical Society established a Commission on 
Future Models of Care Delivered through Pharmacy (2014) where they advised 
that pharmacists must provide direct patient care in the location that is most 
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convenient for the patient. However, it seems rational to consider the use of TCs 
when advising remote patients, who may only access their pharmacist via 
telephone or a rare domiciliary visit.  
 
Although it is common practice for HCPs to undertake domiciliary visits, the 
impact of conducting remote consultations could potentially result in substantial 
efficiency savings, especially in terms of saving time for the HCP. Moreover, TCs 
have the necessary visual element that serves as a significant advantage over 
the more conventional telephone consultations. It is necessary to have a 
comprehensive understanding of the practicalities as well as any implications of 
TCs.   
 
In order to use free software applications for TCs, one must have access to a 
Smartphone, laptop, computer or tablet with a camera facility. Patients must 
have access to the internet, which is most commonly via wireless (WiFi) 
connectivity. There are currently no trials with community pharmacists 
conducting TCs. TCs could provide convenience to housebound patients, with 
the pharmacist residing in their consultation room and the patient at home. 
Confidentiality would be assured from the pharmacist’s consultation room, 
however, it would be up to the patient to ensure privacy at home and whether 
they would like a carer or family member present.  
 
2.2.5 Patients’ Attitudes to and Experiences of  TM 
A systematic review conducted by Paré, Jaana and Sicotte (2007) found that 
many patients saw TM as a positive development in healthcare; they felt safer 
and experienced “freedom”, in contrast to being “under surveillance” during their 
hospital stay (Bernocchi et al., 2012; Mair and Whitten, 2000; Ure et al., 2012). 
They felt that TM was convenient and improved the accessibility of healthcare 
(Fairbrother et al., 2012). However, when assessing the suitability of technology, 
it is important to be mindful of the potential reverse effect; that it can socially 
isolate vulnerable groups. An overwhelming majority of patients reported interest 
in using TM devices, but again however, caution is urged as many studies lacked 
sufficient depth. Mort, Finch and May (2009) found that the patients’ role shifted 
from being passive to becoming increasingly active in self-managing their 
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condition when using TM. However, this positive conception must not detract 
from the requirement of having an IPC in certain circumstances.   
 
2.2.6 Effectiveness of TM 
There are a number of studies that claim the effectiveness of TM by improving 
patient experiences, clinical indicators and QoL (Gregersen et al., 2016; McLean 
et al., 2011; Vitacca et al., 2009). TM promises more efficient use of healthcare 
resources by lowering the need for secondary care, however, it must be 
stressed, once again, that there is a need for large, RCTs (Hynes et al., 2012; 
Steventon et al., 2012).  
 
A study by Finkelstein et al. (2006) has demonstrated that using 
videoconferencing technology to create virtual visits between a nurse and 
patients suffering with COPD and congestive heart failure at home can improve 
patient outcomes, and is more cost effective than nurse home visits. However, it 
is not clear whether this effect was ascribed to the technology itself (Everett et 
al., 2011). Also, patients with relatively mild COPD or a high baseline self-
efficacy are thought to benefit less from a management plan involving frequent 
testing and reporting, perhaps due to their patients not considering their 
symptoms significant enough to involve a HCP (Polisena et al., 2010). 
Consequently, given the inconclusive evidence, it is imperative that future 
studies are methodologically sound and sufficiently powered before introducing 
TCs as part of the solution.  
 
2.2.7 Limitations of TM 
The use of TM can involve costly reorganisation of services and training for staff 
and patients, which will inevitably pose disruption to the services (Pinnock et al., 
2013; Rosenbek Minet et al., 2015). Policy makers however claim that this 
investment should be offset by lower long-term costs. Furthermore, there is a 
fear that it encourages overtreatment of patients as well as an overreliance on 
technology (Ure et al., 2012).  
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A significant limitation is the “digital divide” with patients who possess the 
required facilities and those without. There is also unease that vulnerable 
populations are Information and Communication Technology illiterate, thus its 
use must be as user-friendly as possible, whilst protecting against breaches in 
confidentiality i.e. using encryption software (McLean and Sheikh, 2009). Age 
and cognitive function are pertinent when judging the suitability of TM for the 
COPD population, as this can affect their ability to use the technology (McKinstry 
et al., 2009; McLean et al., 2011). That said, there are studies that suggest that 
patients report that the equipment is easy to use (Bernocchi et al., 2012; De San 
Miguel et al., 2013; Roberts et al., 2012), perhaps due to the training they 
received at the time of instillation. 
 
2.2.8 The future for TM 
The Department of Health (2016) and the worldwide health industry are 
considering TM to be a beneficial tool to support evolving services, and in 
particular, to support patients with chronic conditions in the community. More 
specifically, it has been advocated that TM can address the burden of COPD by 
improving accessibility and efficiency, but would involve an element of service 
redesign (McLean and Sheikh, 2009). Furthermore, Jacobs and Criner (2016) 
believe that TM has the potential to lower the burden placed on general practice 
and A&E. It is fundamental for governments and policy makers to demonstrate 
efficaciousness and financial prudency for any suitably alternative solutions. 
Thus, it is imperative to analyse the evidence and also conduct a well-designed 
study that is relevant to both national and international frontline leaders, in 
addition to clinicians, patient groups and local communities. 
 
2.3 Management of COPD in primary care  
2.3.1 General practice crisis 
It is well known that there is a recruitment and retention crisis in general practice, 
which is undermining the system’s capacity to provide effective support for 
patients managing long-term conditions. The UK government’s answer to this is 
to recruit 5,000 extra GPs in the next five years (NHS England - General Practice 
Forward View, 2016). However, given that medicines management forms an 
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integral part of long-term conditions, pharmacists, renowned for their expertise 
in medicines, could be more effectively deployed to optimise patients’ 
medication, which should concurrently contribute to lightening the burden placed 
on general practice and potentially A&E. Thus, the NHS will employ a total of 
2,000 co-funded practice clinical pharmacists. However, this resource is only a 
fraction (~15%) of the ~30,000 community pharmacist workforce who are 
conveniently positioned and armed with the skill set necessary to significantly 
lower the traffic into general practices.  
 
2.3.2 Community pharmacy 
Community pharmacy contributes uniquely to the NHS and is an invaluable 
resource in the struggle against health inequalities (Public Health England, 
2017b). As a core provider of essential healthcare and public health services, 
pharmacy businesses provide substantial value to the wider health and care 
system, however, their involvement is still underutilised. Community Pharmacy 
Forward View [Pharmaceutical Services Negotiating Committee (PSNC), 2016] 
has stated that community pharmacists have a central role to play in finding 
solutions that can secure the best possible future for the NHS and the public’s 
health. They invite and challenge community pharmacy owners and leaders to 
demonstrate their potential and to find new ways of supporting a high performing 
and affordable NHS, despite financial pressures (~15% reduction in income) 
from austerity cuts which threaten pharmacy businesses (Connelly, 2016). In the 
midst of the unprecedented strain on both resources and demand, community 
pharmacy must adapt to the continually evolving NHS and utilise the professional 
knowledge and expertise of their community pharmacists and their associated 
teams to remain sustainable in order to continue their longevity. Over recent 
years, the steadily expanding pharmaceutical services have become more 
clinically focused, in contrast to the more conventional services involving the 
dispensing process. At present, community pharmacists in the main, have not 
fulfilled their potential as being a profession that is underpinned by the 
‘medicines optimisation’ policy. However, any further expansion in clinical 
service provision would warrant further pharmacist training in order to certify their 
competence, particularly if they have become deskilled from not utilising their 
clinical skills for a significant period of time. Any expansion in service provision 
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must complement the existing services (e.g. smoking cessation or influenza 
vaccinations) as the profession heads towards a more clinically focused route, 
especially amongst the COPD population (Mehuys et al., 2010). 
 
Despite community pharmacy being relatively new to providing clinical services, 
the most significant barrier to its success is having the facility to gain read-write 
access to patients’ notes (Royal Pharmaceutical Society, 2015). Such a facility 
would improve the safety of patients and could launch many other possibilities 
within this sector. Unlike their general practice and hospital counterparts, 
community pharmacists have no pathway to manage such chronic conditions, 
prescribe, directly refer patients to other services or gain access to a clinical 
support network via the NHS. A particular advantage to allowing community 
pharmacists more clinical involvement is that they have contact with those 
individuals who may not regularly use other health services, and thus would have 
the capacity to offer more than the customary conveyance of health messages, 
self-care and opportunistic advice. Additionally, the extent of involvement and 
accountability, as well as when to refer, must be unambiguous within protocols 
and guidelines, with an audit trail of interventions clearly documented.  
 
Moreover, accessibility of patients’ notes from a pharmacy will drive the NHS’s 
expectation of developing more integrated primary care networks that are 
efficient and effective (Murray, 2014). This will also require pharmacy owners 
and leaders to work in partnership with patients, general practices, local 
government commissioners, Department of Health, NHS England and other 
NHS bodies. Given the isolated nature of community pharmacy, community 
pharmacists should also be connected with fellow pharmacists from general 
practice and within secondary care.   
 
2.3.2.1 Community pharmacy services provision 
Currently, there are 5 advanced services commissioned within the NHS 
Community Pharmacy Contractual Framework; they consist of the following:  
 
1. Medicines Use Reviews (MUR),  
2. New Medicines Services (NMS),  
  
33 
3. Flu vaccination,  
4. Stoma Appliance Customisation,  
5. Appliance Use Reviews.  
 
MUR and NMS are the services that are relevant to this study.  
 
2.3.2.1.1 Medicines Use Review  
MURs are structured adherence-centred reviews involving patients experiencing 
polypharmacy, particularly those receiving medicines for long-term conditions, to 
help them manage their medicines more effectively. Adherence is defined as the 
extent to which a person’s behaviour – taking medication and executing lifestyle 
changes – corresponds to recommendations agreed with a HCP. Each 
pharmacy gets paid £28 per MUR and can conduct a maximum of 400 MURs 
per financial year. At least 70% of MURs must involve patients with one of the 
following: 
 
1. Taking high risk medicines 
2. Recently discharged from hospital (within 2 weeks of discharge) 
3. With respiratory disease 
4. At risk or diagnosed with cardiovascular disease and regularly prescribed 
≥ 4 medicines.  
 
2.3.2.1.2 New Medicines Service  
NMS provides support for patients with chronic conditions who are newly 
prescribed a medicine to help improve adherence. The following are four 
conditions and therapy fields which are applicable to this service: 
 
1. Asthma and COPD, 
2. Type II diabetes, 
3. Antiplatelet or anticoagulation therapy, 
4. Hypertension.  
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For each of these conditions or treatments, there is a list of medicines that have 
been agreed as being suitable for a NMS. A NMS can be conducted if the patient 
is newly prescribed one of the medicines from the list, subject to confirming it is 
used to treat one of the above conditions.  
 
2.3.2.1.3 Limitations of the MUR and the NMS  
From a clinical standpoint, community pharmacists offer a more limited and 
undemanding clinical service when compared to their general practice and 
secondary care pharmacist colleagues, which is to be expected given the limited 
resources at their disposal. The restrictive nature of the MUR and NMS services 
do not fully draw on the pharmacists’ clinical skills, and consequently, lead to 
regular referrals being made, even if the pharmacist is able to deal with the issue 
directly.  
 
The NHS must ensure that maximal value is acquired from NHS outlay on 
medicines, whilst improving patient outcomes (Murray, 2014). This can be 
brought about by radically redesigning and expanding pharmacy services to 
capitalise on using pharmacists’ expertise, premises and resources more 
efficiently. Consequently, such a change would lower the demand for more 
specialist or higher cost services, and thus, the costs of managing long-term 
conditions would be better controlled. However, the IT infrastructure would need 
to be reformed to enable pharmacists’ access to medical records with a 
mechanism in place to add notes, prescribe and refer to other HCPs. Moreover, 
any prospective model should take into account the imminent advances in 
personalised or tailored medicine which will undoubtedly become an integral part 
of a pharmacist’s armoury.  
 
Another significant limitation of MURs and the NMS is that remuneration is 
quantitative and does not incentivise quality. Thus, patients perceived to have 
less medication issues may be consciously or subconsciously selected to have 
an MUR or NMS, ahead of those patients thought to require a considerably 
longer duration of consultation. This is becoming increasingly likely given the 
financial constraints on contractors whose primary objective is the number of 
MURs and NMSs, ahead of focusing on patient outcomes, in order to secure 
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payment. This adds pressure onto pharmacists to meet pre-determined targets, 
rather than servicing those patients based on clinical need - a core principle of 
the NHS. Going forward, it may be more appropriate to incentivise patient 
outcomes ahead of any quantitative processes. However, since multiple HCPs 
are involved in the care of individual patients, the challenge would be finding out 
which HCP contributes to the patient’s outcome measure. A possible solution to 
this would be to create interdisciplinary teams working closely together for the 
betterment of patient care.  
 
2.3.2.1.4 The practicalities of MUR and NMS 
There is evidence that MURs and the NMS improve adherence and patient 
safety post-discharge, however, these do not translate into reduced hospital 
admissions, perhaps due to hospital admissions being too insensitive a measure 
to demonstrate the service’s effectiveness (Elliott et al., 2014). 
 
Both these services offer the opportunity for pharmacists to advise patients, in 
person, about their medicines. However, unlike the MUR service, the NMS 
consultation is permitted to take place via telephone. This inconsistency between 
the two services may be due to visual communication not being considered a 
requirement for an effective NMS to take place. Car and Sheikh (2003) refer to 
the clinician’s apprehension with regards to their risk of missing vital signs during 
telephone consultations. Thus, it is understandable that this method is used 
more as a last resort in general practice, as visual communication and physically 
examining patients are fundamental to their role.  
 
According to the MUR guidance by the PSNC (2013), MURs must be provided 
at the pharmacy premises unless prior approval from NHS England is sought to 
conduct the service at the patient’s home or via telephone [Direction 4(6)], where 
harder-to-reach patients, such as the immobile, would then become accessible. 
The process can be somewhat burdensome for pharmacists who would need to 
seek NHS England’s approval each and every time this service is to be 
conducted to the inaccessible, which creates a barrier, resulting in delays in 
accessing the patient. Consequently, this has a deterring effect on pharmacists 
wishing to provide this service to those unable to attend the pharmacy premises, 
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many of whom will have a real need for it (Tatari, 2016) (see Appendix 16 in 
Section 9.19). 
 
Domiciliary MURs may prove to be an inefficient use of pharmacists’ time when 
travelling to and from patients’ houses. Also, the maximum period during which 
the pharmacist may be absent from the pharmacy premises is two hours per day, 
unless of course there is a second pharmacist at the premises site. In summary, 
telephone medication reviews lack the visual communication between patient 
and HCP, whereas domiciliary medication reviews are potentially time-intensive 
and will be an added expenditure to the contractor/NHS. Consequently, in certain 
circumstances, it may be more appropriate to deliver MURs/medication review 
services via TCs in housebound individuals with COPD (Tatari, 2016).   
 
2.3.2.2 Conducting COPD Clinics 
In this study, COPD clinic, will refer to a community pharmacy-based, clinical 
medication review, that is specific to COPD patients. Blenkinsopp and Lowe 
(2011) suggested that a clinical medication review should: 
 
• Check the requirement of all the patient’s medicines (Are they 
helping or causing harm/risk to the patient?) 
• Check the patient is happy to continue the medicines 
• Check whether they require additional medicine/s for their 
condition/s.  
 
As discussed earlier, MURs primarily focus on improving adherence by 
discussing the patient’s use of medicines and aim to improve their knowledge 
about their purpose. However, conducting clinical medication reviews will offer a 
more structured evaluation of a patient’s medicines. The boundary between 
MUR and clinical medication review, however, is not clear cut (Blenkinsopp et 
al., 2012). Based on offering a more comprehensive support service to the 
COPD population, conducting COPD clinics would be more suitable (Wright et 
al., 2015), especially since MURs and NMSs are not specific to COPD and MURs 
are only limited to one consultation per year.  
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Few trials to date have conducted any kind of COPD service in a community 
pharmacy setting. Carrying out a COPD service offers greater freedom to 
clinically review patients’ medication regimen and offers greater potential to 
impact outcomes (Jarab et al., 2012). However, the inconvenience of not having 
the infrastructure in place to access medical notes to comprehensively conduct 
such a service could pose a risk to the patient, especially if general practice is 
not involved. To avoid any risk in the interim, recommendations can be made to 
the patient’s GP or HCP charged with managing their COPD, who can use their 
discretion about whether to implement these recommended interventions.   
 
Over and above addressing adherence concerns, a community pharmacy clinic 
could entail measuring patients’ spirometry, oximetry, BMI and symptoms, as 
well as assessing the appropriateness of the patient’s inhaler device (using an 
In-Check DIAL). The clinic would involve providing a personalised self-
management plan and improving patient education with the intent that the patient 
will be better informed on managing their condition. The COPD clinic should form 
part of an Integrated Disease Management program with various HCPs 
collaborating together and signposting where appropriate.  
 
Like MURs, if the patient has sufficient inspiratory force to activate their inhaler 
then their inhaler technique can be checked. If there is a more appropriate inhaler 
or medication regimen based on efficacy and cost, this can be relayed back to 
the patient’s general practice via postal mail. 
 
2.3.2.3 Suitability of community pharmacists to conduct COPD 
clinics 
The accessibility of community pharmacists is essential to counsel and answer 
questions that patients may have regarding therapeutic options for COPD. At a 
very basic level, all pharmacists should check whether patients are adherent to 
their medication and have correct inhaler technique (Babu et al., 2014). With 
validated training to support any additional knowledge and skills required to 
deliver a COPD service, pharmacists will be able to optimise patients’ medication 
(Wright et al., 2015). Thus, COPD clinics carried out by a community pharmacist 
may be the solution to reducing exposure to risk factors, impact on patient’s 
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health status and lowering their risk of future events (such as exacerbations, 
hospital admissions or death).  
 
2.3.2.4 Conducting clinics at Drugs4Delivery pharmacy 
Drugs4Delivery pharmacy is a distance-selling internet pharmacy. In 2016, there 
were 11,688 community pharmacies; of these, only 266 (~2.3%) were distance-
selling pharmacies (NHS Digital, 2016). Distance-selling internet pharmacies are 
proscribed to offer essential services e.g. dispensing, at the pharmacy premises. 
Essential services can, however, be carried out by delivering to the patients’ 
abode. In contrast, MURs and NMSs can be provided at the pharmacy premises. 
Generally, it is challenging to attract patients to the premises of a distance-selling 
internet pharmacy for the sake of clinical services, such as MUR/NMS, especially 
since their medication is delivered to their home. By contrast, a traditional 
pharmacy will opportunistically offer such services while the patient is waiting for 
their medication(s) to be dispensed. Thus, inviting patients to Drugs4Delivery 
pharmacy for COPD clinics could potentially pose a challenge. Offering COPD 
clinics within a distance-selling internet pharmacy has not been realised in any 
trial or study before. 
 
2.4 Housebound patients 
The majority of community pharmacies offer a service whereby they order 
patients’ prescriptions, collect them from the surgery and deliver the medication 
to the patients’ homes. As well as providing convenience to the patient, this 
service also tends to lock patients into using a particular pharmacy, as it 
minimises the likelihood of their prescription being dispensed at an alternative 
chemist. Hence, it makes good business sense to increase the percentage of 
patients using this ‘order, collection and delivery’ service. The drawback is that 
these patients are less exposed to the clinical pharmacy services on offer within 
the pharmacy. Also, of those receiving a delivery service, there is usually a 
fraction of patients who are unable to access the pharmacy due to their health 
conditions.  
 
The National Health Executive estimates that 1.6 million people access a 
pharmacy every day and that 90% of the population live within walking distance 
  
39 
of a pharmacy (“Community Pharmacy Forward View,” PSNC, 2016). This 
accessibility is a fundamental component of the primary care sector, especially 
since patients do not require an appointment when wishing to consult a 
pharmacist. However, there are a proportion of patients that are incapable of 
accessing their pharmacy and the associated services. It is clearly inequitable 
not to cater for these patients and restrict clinical services only to patients that 
are able to physically access the pharmacy, which would be in complete contrast 
to having an all-inclusive NHS and ‘meeting the needs of everyone’. Therefore, 
for inclusivity purposes, it would be beneficial to devise a more pragmatic 
solution to access this seemingly disadvantaged proportion of patients who are 
unable to access clinical services. This inaccessible demographic may 
potentially require more support from a pharmacist, as they are likely to have 
polypharmacy which can be confusing, especially given that their medication-
related advice is unlikely to be explained and/or reviewed by their pharmacist in-
person.  
 
In principle, remote check-ups with a visual element provide an accommodating 
and efficient way of maintaining contact with patients. However, it is uncertain 
whether conducting check-ups in this way is just as effective as having them in-
person or whether they may create unexpected negative consequences (Kew 
and Cates, 2016). Therefore, a future challenge is to find out whether TCs can 
provide the solution to efficiently forge communication channels with 
housebound patients without compromising patient safety.   
 
2.5 Summary  
Given the substantial burden of COPD both globally and domestically, GOLD 
guidelines (2017) advocate that various approaches to managing this essential 
public health issue must be researched. Since individuals with COPD can 
become housebound, they are less likely to have their medication reviewed. This 
introduction discussed how TCs can be used to improve patients’ accessibility in 
order to facilitate disease management and help tackle this mounting concern. 
More specifically, this chapter focused on the key considerations required to 
manage COPD and how the NHS could potentially utilise community 
pharmacists to optimise patients’ medicines, but that further research is required. 
  
40 
Using TC technology seems a plausible solution in principle, particularly since 
pharmacists are rarely required to physically examine patients. Research is 
needed to determine the impact of pharmacist interventions utilising TC in a co-
ordinated approach comprising complex interventions from a SRP, within a 
community pharmacy-based COPD clinic.  
 
It is important to test the feasibility of such a large-scale study, therefore the 
research presented in this thesis is a feasibility study to determine the rate of 
patient recruitment and retention, acceptability of TC and the practicalities and 
completeness of data collection for outcome measures used to assess COPD 
control and management. This feasibility study incorporates a community 
pharmacy-based COPD clinic conducted via audio and visual communication 
software applications, such as Skype™, in order to allow inaccessible patients, 
access to their pharmacist. The COPD clinics will consist of a clinical medication 
review that will help optimise medication and provide education and a self-
management plan for the patient to manage their condition more effectively.  
 
2.6 Aim 
A feasibility study was conducted with patients randomised to intervention or 
treatment as usual, in a community pharmacy-based COPD clinic. The study 
aimed  to establish further work required to proceed to a definitive trial to test the 
impact of pharmacist interventions via TC amongst patients with COPD.  
 
2.7 Objectives 
The objectives were to determine feasibility of the rate of patient recruitment, 
retention, acceptability of TC and practicalities and completeness of data 
collection for outcome measures used to assess COPD control and 
management.  
 
2.8 Summary of thesis structure  
Following this introduction, the thesis begins with a review of the literature 
(Chapter 3), where two key areas are appraised; how pharmacists contribute to 
the management of COPD and how HCPs have utilised TCs when managing 
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patients with COPD. Chapter 4 presents the methods and experimental 
procedures, which were guided by a previous proof of concept study, and the 
plan for statistical analysis. This is followed by the results section in Chapter 5, 
which presents findings about the rate of recruitment, retention, the acceptability 
of TC to patients and preliminary findings about the practicalities of providing the 
COPD review service via TC and IPC and completeness of data collection. Data 
collected for the IPC and TC groups included baseline characteristics, prescribed 
inhalers, inhaler technique, number of interventions made, adherence, number 
of NMS conducted, COPD control, adverse effects, HR-QoL and cost. The 
findings in relation to the current literature, as well as the limitations of the study, 
have been examined and discussed in Chapter Error! Reference source not 
found.. Finally, conclusions and recommendations for future research are 
considered in Chapter 7.     
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3. Review of literature 
3.1 Introduction 
In order to situate this new way of working, the literature review will serve to 
appraise two key areas; how pharmacists contribute to the management of 
COPD, and how HCPs in general have utilised TCs within their practice when 
caring for patients with COPD. In essence, this literature review will underpin, 
synthesise and stimulate this feasibility study. Also, throughout the design of a 
research project, it is essential to continue to forge links with the body of 
knowledge in the respective field, which is integral to finding its positioning 
among the literature. 
 
3.2 Literature review methods  
The method used to review the literature is based on the principles proposed by 
the Cochrane Collaboration for Systemic Reviews of Interventions (Higgins et 
al., 2011), as this resource is internationally recognised as the highest standard 
in evidence to inform healthcare decisions, with a view to minimising bias. 
Although these principles were adhered to, since this literature review forms part 
of a doctorate award, resources were limited and therefore the review was 
carried out independently.  
 
The literature search aimed to identify as many items as possible within the two 
key areas for this literature review. The aim was to refine the research questions, 
as well as draw on the literature to justify the choice of approach and 
methodology to be adopted.  
 
Searches of MEDLINE, HMIC, PsycINFO, CINAHL, and OVID were performed 
from database inception to the end of 2017. The search terms were restricted to 
the English language due to the lack of funding for translation facilities. 
Reference lists of obtained articles were manually explored to unearth additional 
studies that fit the eligibility criteria.  
 
The Cochrane Handbook for Systemic Reviews (Higgins et al., 2011) was 
utilised to assess the risk of bias for studies that met the inclusion criteria. The 
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seven features of interest were; sequence generation, sequence concealment, 
blinding of personnel, blinding of outcome, incomplete outcome data, selective 
outcome reporting and other bias sources. The risk of bias was categorised as 
‘low’, ‘unclear’ or ‘high’ risk.  
 
3.2.1 The effects of pharmacist interventions on COPD cases 
It is essential to evaluate the literature for pharmacist-led COPD management, 
thus a literature review was carried out to identify research that measured the 
effects of all pharmacist involvement in managing COPD. 
 
On the 2nd January 2016, 9th January 2016 and 14th December 2017 a 
comprehensive search strategy was conducted using the electronic healthcare 
databases MEDLINE, PsycINFO, CINAHL and OVID. The following search 
terms were used: (CONSULTATION* OR CLINIC OR MEDICINE* REVIEW* OR 
INTERVENTION OR COUNSELLING) AND (CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE OR EMPHYSEMA OR CHRONIC BRONCHITIS OR 
CHRONIC OBSTRUCTIVE AIRWAYS DISEASE OR CHRONIC 
OBSTRUCTIVE LUNG DISEASE) AND (PHARMACISTS OR PHARMACY OR 
PHARMACY SERVICES) AND (PRIMARY CARE OR COMMUNITY OR 
OUTPATIENT). 
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3.2.1.1 Study selection for the effects of pharmacist 
interventions on COPD control 
Studies were included if they met the following criteria (see Table 3).  
Table 3: Summarises the inclusion criteria and its rationale for pharmacist 
interventions on COPD control 
Model Inclusion criteria Rationale 
 
P 
 
Patient, 
population 
or problem 
 
Clinician-diagnosed COPD 
patients within primary or 
outpatient care. No exclusions 
were made on sex or ethnicity. 
 
 
The search is not only specific to the community pharmacy 
sector in order to increase number of studies reviewed.  
 
I 
 
Intervention 
 
≥ 2 quantitative interventions 
were carried out by a 
pharmacist  
 
 
COPD is a complex and chronic condition managed by a 
variety of interventions.  
 
C 
 
Control or 
comparison  
 
Usual care or pre-test post-test  
 
Although pre-test post-test studies are uncontrolled, these 
were included to broaden the number of studies assessed. 
Also, although RCTs are the gold standard for assessing the 
effectiveness of interventions, quasi-experimental studies 
were included in order to increase the number of included 
studies.  
 
 
O 
 
Outcome 
 
Objective measurable 
outcomes  
 
This is required in order to differentiate any statistical 
significance. These include QoL, admissions, 
exacerbations, symptom control, inhaler technique, 
adherence and cost effectiveness.  
 
RCT: Randomised Controlled Trials; QoL: Quality of Life.  
 
Studies were excluded if: 
• they recruited participants with AE-COPD,  
• community pharmacy or outpatients were not involved,  
• it was a service evaluation only,  
• it was a single intervention only,  
• COPD interventions were not differentiated from other long-term 
conditions outside of respiratory diseases. 
• There was no medication review 
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3.2.1.2 Results 
Table 3 illustrates the characteristics of the included studies. These searches 
yielded a total of 420 documents, which were then filtered down to 128 after 
screening titles as well as removing duplicates. Of these 128 articles, 95 were 
from MEDLINE, 31 were from CINAHL and only 1 was from OVID and 
PsychINFO.  
 
After screening the identified studies using titles and abstracts, 15 full text 
articles were obtained and judged for their eligibility, of which, 6 were deemed to 
meet the eligibility criteria (see Figure 1). The six studies that satisfied the 
eligibility criteria took place in both primary care and outpatient departments. 
They studied the impact of a pharmacist on COPD control, however, none 
utilised TC. Figure 1 illustrates those articles that satisfied the inclusion criteria 
using the Preferred Reporting Items for Systemic reviews and Meta-Analysis 
(PRISMA) Consort diagram (Moher et al., 2009).   
 
 
 
Records identified via 
database searching 
(n=420)  
 
Records excluded after 
screening titles ± abstracts 
(n=284)  
 
Records isolated for 
screening (n=136)  
 
Duplicate records 
excluded (n=8) 
 
Records after duplicates 
removed (n=128)  
 
Records excluded after 
screening of abstracts 
(n=113) 
 
Full text articles reviewed 
for eligibility (n=15)  
 
Full text articles did not 
meet inclusion criteria 
(n=9) 
 
Articles meet the eligibility 
criteria for quantitative 
synthesis (n=6) 
 
Figure 1: PRISMA Consort diagram of literature review selection on the 
effects of pharmacists on the management of COPD patients    
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3.2.1.3 Excluded studies 
Nine studies failed to meet the literature review inclusion criteria when the full 
text was reviewed for the following reasons: community pharmacy or outpatients 
not involved (Hsu et al., 2015; Liddy et al., 2008); service evaluation only 
(Mehuys et al., 2010; Verma et al., 2012); single intervention only (Hämmerlein 
et al., 2011; Toy et al., 2011); COPD interventions were not differentiated from 
other long-term conditions outside of respiratory diseases (Beauchesne et al., 
2012; Luder et al., 2015; Twigg et al., 2015). 
 
3.2.1.4 Included studies 
Six articles met the inclusion criteria for quantitative synthesis. Four of the 
studies were carried out in Europe (Khdour et al., 2009; Tommelein et al., 2014; 
van Boven et al., 2016; Wright et al., 2015), one was carried out in the United 
States (Weinberger et al., 2002) and the other was carried out in Jordan (Jarab 
et al., 2012). All studies focused on patients with COPD, however, one, 
(Weinberger et al., 2002) also included patients with asthma. The number of 
participants ranged from 88 to 1113. The follow-up period for the studies ranged 
from 3-months to 12-months. Three studies had a follow-up period of 12-months 
(Khdour et al., 2009; J F M van Boven et al., 2014; Weinberger et al., 2002), two 
studies had a follow-up period of 6-months (Jarab et al., 2012; Wright et al., 
2015) and only one (Tommelein et al., 2014) study had a 3-month follow-up.  
 
All six studies included patient education, smoking cessation, adherence and 
inhaler technique as interventions. Healthcare utilisation was documented in all 
included studies, however, only Wright et al. (2015) and van Boven et al. (2016) 
evaluated the cost implications. See the tables reviewing community pharmacist 
interventions on COPD control (Table 5) and their characteristics (Table 4) for 
further information.  
 
3.2.1.5 Primary outcomes 
Inhalation technique and adherence were primary outcomes for two studies 
(Tommelein et al., 2014; Wright et al., 2015). Khdour et al. (2009) used St 
George’s Respiratory Questionnaire (SGRQ), as well as a COPD knowledge 
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questionnaire, which are validated assessment tools.   The study by van Boven 
et al. (2016) also employed the COPD knowledge questionnaire. 
 
In terms of participants’ QoL, Weinberger et al. (2002) used asthma and COPD 
specific measures based on Juniper et al. (1992) and Guyatt et al. (1987). 
Khdour et al. (2009) and Jarab et al. (2012) used SGRQ, while the 3 other 
studies employed the EuroQol five-dimension questionnaire (EQ-5D). All of 
which are validated assessment tools.  
 
Khdour et al. (2009) was the only included study that did not detail the health 
status or severity of symptoms of their participants. Tommelein et al. (2014) and 
Wright et al. (2015) used the CAT, van Boven et al. (2016) documented Clinical 
COPD Questionnaire (CCQ), whereas Weinberger et al. (2002) and Jarab et al. 
(2012) used Peak Expiratory Flow Rate (PEFR) and FEV1, respectively, which 
are all validated assessment tools. CAT and CCQ have comparable 
psychometric properties and are easier to use compared with the rather 
excessive SGRQ (Tsiligianni et al., 2012).  
 
3.2.1.6 Effects of interventions 
See table reviewing community pharmacist interventions on COPD control 
(Table 5) and their characteristics (Table 4) for further information. 
 
Three studies that used HR-QoL as a primary outcome failed to demonstrate 
statistical significance of a positive outcome (Jarab et al., 2012; Khdour et al., 
2009; Weinberger et al., 2002). The remaining three studies used HR-QoL as a 
secondary endpoint but also failed to establish any statistical significance 
(Tommelein et al., 2014; van Boven et al., 2016; Wright et al., 2015). Regarding 
health resource utilisation, three of the six included studies demonstrated a 
significant reduction in hospitalisations (Jarab et al., 2012; Khdour et al., 2009; 
Tommelein et al., 2014) and one study demonstrated a significant reduction in 
A&E admissions (Khdour et al., 2009).  
 
Two of the six studies failed to achieve statistical significant in improvements in 
adherence (van Boven et al., 2016; Weinberger et al., 2002). Potential 
  
48 
contributory factors for this lack of significance in the van Boven et al. (2016) 
study were the small sample size (N = 88) and that only 25% of interventions 
were carried out by a pharmacist; whereas Weinberger et al. (2002) found that 
drop outs had higher than average mMRC dyspnoea score (See Appendix 10 in 
Section 9.11), were less educated and had lower HR-QoL, which could have 
contributed to a lower attrition bias. Weinberger et al. (2002) argued that had 
these patients not dropped out of the study, they would have benefitted from the 
programme. Another study found that patients who missed their appointments 
were often those who required more assistance in adhering to their medication 
(Osterberg and Blaschke, 2005).  
 
Although all studies provided counselling on inhaler technique, only two of the 
six studies actually noted significant improvements in technique as a 
consequence (Tommelein et al., 2014; Wright et al., 2015). It is worth noting, 
however, that the direct comparison of inhaler technique over a range of studies 
is challenged by the fact that a range of different methods and inhalation devices 
were used. One study that was excluded from the literature review, on the 
grounds that it only tested a single intervention, showed particularly favourable 
improvements in inhaler technique (Hämmerlein et al., 2011). 
 
In summary, all included studies demonstrated the ability for pharmacists to 
produce favourable healthcare outcomes, and as such, they advocated the 
provision of a pharmacist-led COPD support service. In particular, a targeted 
approach was shown to provide the greatest impact (van Boven et al., 2016). 
These findings substantiate the recommendations from the Department of 
Health (2016), who advocate that community pharmacists can contribute to 
supporting patient adherence and improve prescribing quality, which translates 
to reduced hospital admissions. There is, however, a clear shortfall in sufficiently 
powered and well-designed RCTs in this field with rigorous cost-effectiveness 
built in. 
 
Such interventions conducted via TCs could offer an alternative mechanism to 
access the service and could be highly amenable, particularly for dyspnoeic or 
immobile patients (Haynes et al., 2008). There are clinicians who are 
apprehensive about the risk of missing vital signs when using telephone 
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consultations (Car and Sheikh, 2003), however, this risk would be lessened via 
TCs, given the added visual facility.  
 
3.2.1.7 Risk of bias 
The Cochrane Handbook for Systemic Reviews (Higgins et al., 2011) was 
utilised to assess the risk of bias for each of the six studies that met the inclusion 
criteria. The risk of bias will be categorised as ‘low’, ‘unclear’ or ‘high’ risk (see 
Table 4).  
 
All studies demonstrated high attrition rates, which rendered the studies 
insufficiently powered, which may have diluted any effect of the interventions. 
Although the recruitment samples fell short of the standard 80% power required, 
the studies by Jarab et al. (2012) and Khdour et al. (2009) can otherwise be 
considered fairly robust studies. Caution must be exercised with the van Boven 
et al. (2016) and Wright et al. (2015) studies as they were not RCTs, but rather 
were pre-test post-test studies. Their lack of control group for comparison 
sacrifices external validity, and as such, these two studies are classed as less 
reliable than the other included studies. The Weinberger et al. (2002) study had 
a particularly high attrition rate, which may have diluted the results of an 
otherwise robust study.  
 
Blinding of participants (performance bias) was regarded as ‘high risk’ in all but 
one study (Tommelein et al., 2014). Due to the complex nature of the 
intervention, it was not possible to blind patients, which could have contaminated 
the control group. However, Tommelein et al. (2014) took measures to minimise 
detection bias by having an independent investigator blinded to group allocation. 
Blinding of participants has less of an impact if objective assessment measures 
are used. The objective, primary outcome measures were PEFR (Weinberger et 
al., 2002), FEV1 (Jarab et al., 2012) and inhaler technique checklist (Tommelein 
et al., 2014; Wright et al., 2015).  
 
The study by Tommelein et al. (2014) was the shortest in duration (3 months), 
which may not have allowed sufficient time for the intervention to take effect on 
COPD control. However, it can still be considered a well-controlled trial.  
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A limitation of half of the studies was that follow-up occurred at different times of 
year (Jarab et al., 2012; Tommelein et al., 2014; Wright et al., 2015). The 
significance of which is that there is a higher incidence of exacerbations in winter, 
which has important consequences for patients in terms of increased morbidity 
and mortality. This seasonality increases both GP consultations and hospital 
admissions (Donaldson and Wedzicha, 2014). This problem was eliminated in 
the 12-month studies (Khdour et al., 2009; van Boven et al., 2016; Weinberger 
et al., 2002). All 6 studies were deemed ‘low risk’ in terms of selective reporting 
(reporting bias). 
 
A further shortcoming of all but one (Wright et al., 2015) of the included studies 
was that, although several NHS resources were accounted for, there is a wider 
range of health services that the patient may have used and thus should have 
been enquired about. Furthermore, unlike the studies that took place in the 
outpatient clinics (Jarab et al., 2012; Khdour et al., 2009), a drawback for the 
community pharmacy-based studies (Tommelein et al., 2014; van Boven et al., 
2016; Weinberger et al., 2002; Wright et al., 2015) was that the patients’ self-
reporting of their resource utilisation was not measured against what was 
documented in their medical records. Contamination bias was more likely in 
participants using the same community pharmacy, where patients from the 
intervention and control group were more likely to interact.  
 
These six studies were heterogeneous with regards to the risk of bias, and this 
is clearly illustrated in Table 6 and Figure 2. 
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Table 4: Characteristics of included studies; effect of community 
pharmacist interventions on COPD control 
 
 
PI: Pharmacist Intervention; CG: Control Group; FEV1: Forced Expiratory Volume in 1 
second; PR: Pulmonary Rehabilitation; HR-QoL- Health-Related Quality of Life.  
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PI: Pharmacist Intervention; CG: Control Group; FEV1: Forced Expiratory Volume in 1 
second; PR: Pulmonary Rehabilitation; HR-QoL- Health-Related Quality of Life.  
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PI: Pharmacist Intervention; CG: Control Group; FEV1: Forced Expiratory Volume in 1 
second; PR: Pulmonary Rehabilitation; HR-QoL- Health-Related Quality of Life; CAT: 
COPD Assessment Test; MRA: Medication Refill Assessment; mMRC: Modified MRC 
dyspnoea scale; EQ-5D: EuroQol Five-Dimension Questionnaire.  
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CCQ: Clinical COPD Questionnaire; EQ-5D: EuroQol Five-Dimension Questionnaire; 
EQ-5D-VAS: EuroQoL Five-Dimension Visual Analogue Score; SABA: Short-Acting 
Beta-Agonist; SAMA: Short-Acting Muscarinic Antagonist; ICS: Inhaled Corticosteroid; 
QoL: Quality of Life; mMRC: Modified Medical Research Council dyspnoea scale.  
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PEFR: Peak Expiratory Flow Rare; CG: Control Group; PCP: Pharmaceutical Care 
Program; UC: Usual Care; HR-QoL- Health-Related Quality of Life; PFR: Peak Flow 
Rate.  
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CAT: COPD Assessment Test; EQ-5D: EuroQol Five-Dimension Questionnaire; 
mMRC: Modified Medical Research Council dyspnoea scale; PMR: Patient Medication 
Record; QALY: Quality-Adjusted Life-Years.  
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Table 5: Review of the included studies involving the effect of community 
pharmacist interventions on COPD control.  
 
 
PMR: Patient Medication Record; HR-QoL- Health-Related Quality of Life; CG: Control 
Group; PI: Pharmacist Intervention; CCQ: Clinical COPD Questionnaire; QoL: Quality 
of Life; mMRC: Modified Medical Research Council dyspnoea scale; EQ-5D: EuroQol 
Five-Dimension Questionnaire; PCP: Pharmaceutical Care Program; PEFR: Peak 
Expiratory Flow Rare’ CAT; COPD Assessment Test. 
 
  
58 
Table 6: Risk of bias summary: review of each risk of bias item presented 
across included studies (n=6) 
 Sequence 
generation 
(selection 
bias) 
Allocation 
sequence 
concealment 
(selection 
bias) 
Blinding of 
participants & 
personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment 
(detection 
bias) 
Incomplete 
outcome data 
(attrition bias) 
Selective 
reporting 
(reporting 
bias) 
Other sources 
of bias 
Jarab et al., 
2012 
+ + - + - + + 
Khdour et al., 
2009 
+ + - + - + + 
Tommelein et 
al., 2014 
+ + + - - + + 
van Boven et 
al., 2015 
- - ? - - + + 
Weinberger et 
al., 2002 
+ + - - - + + 
Wright et al., 
2015 
? - - - ? + + 
 
Key: (-  = low risk); (? = Unclear risk); (+ = High risk) 
 
 
 
Figure 2: Risk of bias graph: review each risk of bias item presented across 
included studies (n=6) for the effect of community pharmacist 
interventions on COPD control.  
 
The seven features of bias are sequence generation, sequence concealment, blinding 
of personnel, blinding of outcome, incomplete outcome data, selective outcome 
reporting and other bias sources. 
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3.2.2 The effects of  TCs in COPD management 
It is essential to evaluate the literature for TC use in COPD management, thus a 
literature review was carried out to identify research that measured the effects of 
HCPs involvement when using TC, in managing COPD. 
 
On the 9th January 2016, 16th January 2016 and 14th December 2017, literature 
searches were conducted using the electronic healthcare databases MEDLINE, 
HMIC, and CINAHL. The following search statements were used: 
(TELECONFERENC* OR VIDEOCONFERENC* OR TELE-CONSULTATION 
OR REMOTE CONSULTATION) AND (CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE OR EMPHYSEMA OR CHRONIC BRONCHITIS OR 
CHRONIC OBSTRUCTIVE AIRWAYS DISEASE OR CHRONIC 
OBSTRUCTIVE LUNG DISEASE).  
 
3.2.2.1 Study selection for utilising TCs in COPD management 
It is obligatory to scrutinise the literature for the use of a TC facility in COPD 
management, as this will test whether this intervention actually works. Again, 
using the P.I.C.O. model (Patient, Intervention, Control, Outcome) to structure 
the eligibility criteria, studies were included having met the following criteria 
(Table 7). 
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Table 7: Summarises the inclusion criteria and its rationale for tele-
consultations on COPD control 
 
Model Inclusion criteria Rationale 
 
P 
 
Patient, 
population 
or problem 
 
Clinician-diagnosed COPD 
within primary, secondary or 
intermediate care setting. No 
exclusions were made on sex 
or ethnicity.  
 
 
Not specific to pharmacy in order to broaden review 
material 
 
I 
 
Intervention 
 
Medication review by any HCP 
via tele-consultations 
 
 
To find out whether other healthcare professionals have 
carried out similar, tailored interventions via tele-
consultations.  
 
 
C 
 
Control or 
comparison  
 
Usual care or pre-test post-
test  
 
Although pre-test post-test studies are uncontrolled these 
were included to broaden the number of studies assessed. 
Also, although RCT are the gold standard for assessing the 
effectiveness of interventions, quasi-experimental studies 
were included in order to increase the number of included 
studies.  
 
 
O 
 
Outcome 
 
Objective measurable 
outcomes  
 
In order to differentiate any statistical significance. These 
include QoL, admissions, exacerbations, mortality. Other 
outcomes of interest were FEV1, symptom control, inhaler 
technique, adherence and cost-effectiveness. 
 
RCT: Randomised Controlled Trials; QoL: Quality of Life; FEV1: Forced Expiratory 
Volume in 1 second.  
 
Studies were excluded if: 
• there was no medication review  
• it was a study protocol only 
• they lacked reporting an inclusion and exclusion criteria 
• the results of COPD intervention were not differentiated from other 
conditions. 
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3.2.2.2 Results 
These searches retrieved a total of 143 documents, which were then filtered 
down to 24 after checking article titles. After removing the duplicates 19 articles 
remained. Of these 19 articles, 14 were from MEDLINE, 4 were from CINAHL 
and only 1 was from HMIC. After reviewing the 19 abstracts using titles and 
abstracts, 9 documents were selected for their relevance and their full text was 
reviewed. Of these 9 studies, only 3 fulfilled the inclusion criteria. Figure 3 
illustrates those articles that satisfied the inclusion criteria using the PRISMA 
Consort diagram (Moher et al., 2009).  
 
The included studies were conducted in secondary care (Schou et al., 2013; 
Sorknaes et al., 2011) and primary care (Udsen et al., 2017), all without any 
pharmacist involvement (see Table 9). Table 8 illustrates the characteristics of 
the included studies. 
 
Records identified via 
database searching 
(n=143) 
 
Records excluded after 
screening titles ± or 
abstracts (n=121) 
 
Records isolated for 
screening (n=24) 
 
Duplicate records 
excluded (n=5) 
 
Records after duplicates 
removed (n=19) 
 
Records excluded after 
screening of abstracts 
(n=10) 
 
Full text articles reviewed 
for eligibility (n=9) 
 
Full text articles did not 
meet inclusion criteria 
(n=6) 
 
Articles meet the eligibility 
criteria for quantitative 
synthesis (n=3) 
 
Figure 3: Consort diagram of literature review selection on the effects of 
healthcare professionals’ management of COPD via TC. 
 
The seven features of bias are sequence generation, sequence concealment, blinding 
of personnel, blinding of outcome, incomplete outcome data, selective outcome 
reporting and other bias sources. 
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3.2.2.3 Excluded studies 
Ten studies failed to meet the literature review inclusion criteria for the following 
reasons: no medication review (Mathar et al., 2015; Rosenbek Minet et al., 2015; 
Steventon et al., 2012; Strachan et al., 2012; Tabak et al., 2014; Vitacca et al., 
2009); study protocol only (Jakobsen et al., 2013; Udsen et al., 2014); lack of 
reporting of inclusion and exclusion criteria (Dichmann Sorknaes, 2016); and the 
results of COPD intervention were not differentiated from other conditions.  
 
3.2.2.4 Included studies 
All three studies were carried out in Denmark and focused solely on patients with 
COPD.  Studies by Sorknaes et al. (2011) and Schou et al. (2013) were 
conducted in secondary care and Udsen et al. (2017) conducted their study in 
primary care. The number of participants ranged from 44 (Schou et al., 2013) to 
1225 (Udsen et al., 2017), and the study duration ranged from 28 days (Sorknaes 
et al., 2011) to 12 months (Udsen et al., 2017). Sorknaes et al. (2011) included 
interventions on clinical observations, measured oxygen saturations and lung 
function, and educated on exacerbation prevention and medicines usage, 
however, the specific details were not provided.  In contrast, Schou et al. (2013) 
directed their interventions towards HR-QoL, daily activity, anxiety, depression 
and cognitive decline. The trial by Udsen et al. (2017) primarily focused on costs 
per QALY gained and was the only study to evaluate cost-effectiveness. 
 
This literature search exposes the limited number of quantitative trials where 
HCPs provided personalised feedback on COPD over a distance. There were 
no published studies resided in the primary or intermediate care setting, focusing 
specifically on medication reviews, nor did they document the effects of any 
medication review. None of the studies involved pharmacies or pharmacists. 
Since governments are enthusiastic that TM can help support the growing 
burden of COPD, rigorous cost-effectiveness assessments focusing on 
medication reviews must be implicated in the proposed research (as was 
conducted in Wright et al., 2015), given the urgency of reducing healthcare costs. 
Table 9 summarises the effect of HCPs on COPD control via TCs and their 
characteristics reviewed in Table 8, for more detailed information. 
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3.2.2.5 Primary outcomes 
All three included studies had different primary and secondary outcomes. 
Sorknaes et al. (2011) investigated the number of early readmissions from AE-
COPD, Schou et al. (2013) determined HR-QoL and Udsen et al. (2017) 
researched cost-effectiveness of tele-healthcare. 
 
Sorknaes et al. (2011) determined readmission from AE-COPD as having more 
dyspnoea, more cough and/or more sputum production and requiring increased 
medication. Schou et al. (2013) determined HR-QoL using SGRQ which, 
although time intensive and complex, is considered a reliable questionnaire. For 
Udsen et al. (2017), the primary outcome measure for the cost-effectiveness 
analysis was the total cost per QALY gained measured.  
 
3.2.2.6 Effects of interventions 
See table reviewing community pharmacist interventions on COPD control 
(Table 9 and Table 10) and their characteristics (Table 8) for further information. 
 
The study by Sorknaes et al. (2011) demonstrated that offering nurse TC to 
patients suffering from COPD helped to lower the early readmission of patients 
with AE-COPD. Although the study mentioned that the nurse advised patients 
on how to use their medicines, they failed to report the medication advice offered, 
or elaborate on the other interventions made. From a qualitative perspective, TC 
was reported to have high patient and nurse satisfaction. In essence, this is a 
fairly unreliable study (due to the high risk of selection, detection and reporting 
bias, as well as short study duration) which may otherwise have captured policy 
interest.  
 
The study by Schou et al. (2013) was considered more robust than that by 
Sorknaes et al. (2011) due to its randomised design. Although, the findings 
showed FEV1 had improved after 6 weeks in both arms, there was no significant 
difference in HR-QoL or other self-reporting outcomes in AE-COPD via TCs at 
the 3-month endpoint. This study was considered high risk of performance, 
detection and attrition bias, as well as having a short study duration.  
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The study by Udsen et al. (2017) was arguably considered more robust than the 
Schou et al. (2013) study as it had a lower risk of performance and detection 
bias. However, it did have a higher risk of reporting and other bias than the Schou 
et al. (2013) study. Udsen et al. (2017) found that TC was unlikely to be a cost-
effective addition to usual care if offered to all patients with COPD. However, the 
notable limitations were the low number of participants (61%) who completed 
registrations of all cost categories and outcomes, and the lack of training for HCP 
using TCs.  
 
3.2.2.7 Risk of bias 
Again, the Cochrane Handbook for Systemic Reviews (Higgins et al., 2011) was 
utilised to assess the risk of bias for each of the studies that met the inclusion 
criteria. The seven features of interest were sequence generation, sequence 
concealment, blinding of personnel, blinding of outcome, incomplete outcome 
data, selective outcome reporting and other bias sources. An assessment of the 
validity of the included studies is reviewed in Table 8, where the risk of bias is 
categorised as ‘low’, ‘unclear’ or ‘high’ risk. These studies were heterogeneous 
with regards to risk of bias, and this is clearly illustrated in Table 9, Table 10 and 
Figure 4. 
 
Unlike the other two studies, that by Schou et al. (2013) was insufficiently 
powered (n = 44), which may have diluted the validity of their results. However, 
it demonstrated a high degree of internal validity in terms of patient selection and 
patient availability at follow-up. A limitation of the Udsen et al. (2017) study was 
the use of single-level multiple imputation with clustering as a fixed effect. Using 
an imputation effect that accounts for clustering as a random effect is superior 
to single-level imputation (Gomes et al., 2013), however, a barrier to the adoption 
of multiple imputation is that conventional statistical software does not have this 
function available (Udsen et al., 2017). Furthermore, including clustering as a 
fixed effect could overestimate the uncertainty of the estimates (Andridge, 2011).  
 
Sorknaes et al. (2011) was the only study that lacked randomisation between 
the intervention and control group, which would have introduced a high risk of 
bias. Blinding of participants (performance bias) was regarded as ‘high risk’ in 
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both Sorknaes et al. (2011) and Udsen et al. (2017), however, detection bias 
was only determined to be high risk in the Udsen et al. (2017) study. 
Contamination bias was possible with participants in the Sorknaes et al. (2011) 
study as they used the same hospital, where patients from the intervention and 
control group were more likely to interact. This was not the case for the other two 
multi-centre studies. Due to the complex nature of these interventions it was not 
possible to blind patients, which potentially could have contaminated the control 
group. However, blinding of participants has less of an impact if objective 
assessment measures were used. The objective, primary outcome measures 
were hospital readmissions (Sorknaes et al., 2011), HR-QoL (Schou et al., 2013) 
and cost-effectiveness analysis (Udsen et al., 2017).  
 
The Sorknaes et al. (2011) study was the shortest in duration of all of the 
included studies (28 days), and together with Schou et al. (2013), may have been 
significantly affected by the variation in exacerbation risk, depending on the time 
of year. This was not an issue with Udsen et al. (2017), as this was a 12-month 
study. The same can be said for determining health service utilisation, where 
only the Udsen et al. (2017) study recorded patients’ utilisation of other 
healthcare services during the study duration.  
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Table 8: Characteristics of included studies: effect of healthcare 
professionals on the management of COPD sufferers via teleconsultations 
 
 
TC: Tele-Consultation; CG: Control Group; ECOPD: Exacerbation of COPD; PI: 
Pharmacist Intervention.  
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TC: Tele-Consultation; CG: Control Group; mMRC: Modified MRC dyspnoea scale; 
CAT: COPD Assessment Test; SpO2: Peripheral capillary oxygen saturation; QALY: 
Quality-Adjusted Life-Years.  ECOPD: exacerbations of COPD.  
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TC: Tele-Consultation; CG: Control Group; FEV1: Forced Expiratory Volume in 1 
second. 
 
  
  
69 
Table 9: Review of the included studies involving the effect of tele-
consultations on COPD control 
 
 
TC: Tele-Consultation; CG: Control Group; ECOPD: Exacerbation of COPD; QALY: 
Quality-Adjusted Life-Years; HR-QoL: Health-related quality-of-life; FEV1: Forced 
Expiratory Volume in 1 second.  
 
 
 
Table 10: Risk of bias summary: a review of each risk of bias item 
presented across the included studies (n=3) 
 
 Sequence 
generation 
(selection 
bias) 
Allocation 
sequence 
concealment 
(selection 
bias) 
Blinding of 
participants & 
personnel 
(performance 
bias) 
Blinding of 
outcome 
assessment 
(detection 
bias) 
Incomplete 
outcome data 
(attrition bias) 
Selective 
reporting 
(reporting 
bias) 
Other sources 
of bias 
Sorknaes et 
al., 2011 
+ - - + ? + ? 
Udsen et al., 
2017 
+ - - - + + ? 
Schou et al., 
2013 
- - + + + - - 
 
Key: (-  = low risk); (? = Unclear risk); (+ = High risk) 
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Figure 4: Risk of bias graph: review each risk of bias item presented across 
included studies (n=3) involving the effect of Tele-consultations on COPD 
control. 
 
The seven features of bias are sequence generation, sequence concealment, blinding 
of personnel, blinding of outcome, incomplete outcome data, selective outcome 
reporting and other bias sources. 
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3.3 Summary 
This chapter has laid a foundation for this current feasibility study by analysing 
two key areas; how pharmacists contribute to the management of COPD, and 
how HCPs in general have utilised TCs within their practice when caring for 
patients with COPD. 
 
The literature search only identified 6 studies that focused on pharmacists 
managing COPD. These studies demonstrated measurable benefits in having 
pharmacist involvement, however, there were clear limitations in the design of 
these studies. There is clearly a gap in the literature for robust studies within this 
field. This research study was the first to carry out a feasibility study of a COPD 
medicines management service from a distance-selling internet pharmacy that 
monitors spirometry, oximetry and inhaler technique.  
 
There were only three studies that met the inclusion criteria for the systematic 
review of the use of TCs within a HCP’s practice when managing patients with 
COPD. This research study sought to add to this domain by exploring the 
feasibility of reviewing patients with COPD using TCs with the patient at home 
and the pharmacist residing in the consultation room of their community 
pharmacy. It was also the first to compare COPD TCs to IPCs, which will be 
further discussed in the next chapter.  
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4. Methodology and Methods 
This chapter will begin by philosophically reflecting on the methodological 
approach to addressing the research questions and will then consider a range 
of research methods to inform the study design. The methodological options will 
be appraised in order to ensure the most appropriate method is applied to 
achieve specific research objectives. It will then detail the methods that were 
actually used for conducting this research study, including data collection 
methods, outcome measures and analysis plan.  
 
4.1 Methodology  
A positivist paradigm to studying social phenomena gives importance to 
research methods focusing on quantitative analysis. Thus, this study sought to 
synthesise data quantitatively in order to uncover the outcome measures (Table 
11).  
 
Since the essence of the social phenomena is objective in nature, it gives 
importance to research methods focusing on the broad categories of survey, 
observational, and experimental (Chilisa, 2011). The relative strengths and 
weaknesses of each of these research designs will be discussed in relation to 
achieving the aims and objectives of this feasibility study, namely, to establish 
further work required to proceed to a definitive trial to test the impact of 
pharmacist interventions via TC amongst patients with COPD. The objectives 
were to determine feasibility of the rate of patient recruitment, retention, 
acceptability of TC and practicalities and completeness of data collection for 
outcome measures used to assess COPD control and management. 
 
Survey methods were not applicable to this research since this descriptive 
approach does not test the hypothesis (Clancy, 2002). 
 
With observational studies, the investigator does not control the treatment but 
attempts to make justifiable comparisons between those naturally exposed or 
unexposed to a factor of interest (Clancy, 2002). Case-control, cohort and cross-
sectional studies are collectively referred to as observational studies. Often 
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these studies are the only viable method of studying various problems, for 
example, instances where a RCT might be unethical (Mann, 2003). 
 
Case-controlled studies compare groups retrospectively and seek to identify 
possible predictors of outcome, such as in rare outcomes or diseases. These 
studies are comparatively more cost-efficient than the cohort and cross-sectional 
studies, however, this method is limited by the difficulties in identifying controls 
that are appropriately matched, and generally require large numbers of 
participants to account for selection bias (Mann, 2003). A case-controlled study 
was thought to be inappropriate for this study as this research study aims to test 
the effect of an active intervention rather than investigating possible causes of 
an outcome relevant to COPD.  
 
Cohort studies measure events in chronological order and can be used to 
differentiate between cause and effect. For example, they can be used to study 
epidemiology, aetiology and prognosis (Mann, 2003). This study could 
potentially use two cohorts, however, this does not enable the effects of the 
active interventions stated in the aims and objectives of this research study to 
be investigated. Rather, an experimental design was considered more suitable 
without being ethically problematic.  
 
Cross-sectional studies are used to establish prevalence and causation, which 
is essential to the clinician as it influences the likelihood of any particular 
diagnosis and the predictive value of any investigation (Mann, 2003). Cross-
sectional studies are clearly distinct from case-controlled and cohort studies, 
where reference to either exposure and/or outcome is made. Although cross-
sectional studies are relatively quick and easy to conduct, they do not allow 
distinction between cause and effect, and therefore, this method was 
inappropriate for this study.  
 
With experimental studies, the investigator makes some change to the study 
population and collects data on the outcomes of that change, for example, 
studying new treatments (Clancy, 2002). RCTs are the gold standard in clinical 
contexts, where participants are allocated at random to receive either the control 
or experimental group in order to minimise bias between the two groups, 
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examples of which were in the literature review (Chapter 3), such as the study 
by Tommelein et al., (2014). Although RCTs are generally time-intensive and 
financially expensive, the design uniquely allows the yielding of causal results, 
and has the potential to enable powerful statistical manipulation of data (Bowling, 
2002).  
 
Experimental study design is the preferred choice for this feasibility study as it 
generates data and test the study methods and procedures for a potential, large-
scale RCT. Prior to conducting a large, costlier RCT, it is good practice to carry 
out a feasibility study to determine whether it is a strong candidate for further 
evaluation (Craig et al., 2006). Definitive trials are powered sufficiently to be able 
to evaluate and quantify the overall effects of TC (the intervention) compared to 
IPC (the control group) on COPD control. Since there are multiple interventions 
that influence COPD control (see Section 2.1.6), patients require different 
interventions to address their personalised needs. It is however, important to 
minimise potential contamination between the two groups. Another concern is 
the increased time and money necessary to implement a RCT, especially given 
the limited funds for this study.   
 
There is a lack of agreement in the literature about the use of the terms ‘pilot’ 
and feasibility’ in relation to studies conducted to inform the design of a main 
study (Eldridge et al., 2016). Both terms include testing procedures for their 
acceptability, estimating the likely rates of recruitment and retention of subjects, 
and the calculation of appropriate sample sizes; and are explicitly recommended, 
particularly in relation to identifying problems that might occur in an ensuing RCT 
of a complex intervention (Craig et al., 2008). The Medical Research Council 
states that a feasibility assessment can be an implied activity within pilot studies 
(Craig et al., 2008). 
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4.2 Study design  
4.2.1 Interventions 
A prospective rather than a retrospective data collection design was chosen, as 
this ensures that data can be collected for all outcomes investigated, which 
would not have otherwise been the case in customary practice. Prospective 
studies also have the benefit of having fewer sources of bias in general.  
 
This research study used complex interventions to assess the effect of a 
community pharmacist’s interventions in COPD. Complex interventions are 
interventions that contain several interacting components, but they have other 
characteristics that evaluators should take into account, for example, the number 
of interacting components within the experimental and control interventions 
(Craig et al., 2008). This poses issues pertaining to the difficulty standardising 
the design and delivery of the interventions (Rifkin, 2007), the organisational and 
logistical difficulty of applying experimental methods to service (Ogilvie et al., 
2006), and the length and complexity of the causal chains linking intervention to 
outcome (Victora, Habicht and Bryce, 2004). The MRC framework is designed 
to aid researchers to choose and implement appropriate methods, given the 
state of existing knowledge and the nature of their target intervention (Craig et 
al., 2008).  
 
There are a variety of interventions that are widely regarded as variables for the 
management of COPD within the literature review (see Chapter 3); these include 
advice on trigger avoidance, adherence, inhaler technique, education on COPD 
and education on medication. Moreover, considering that each participant may 
require different aspects of their condition to be addressed, interventions were 
expected to differ between participants. For instance, one patient may require 
an alternative device as their inspiratory force was inadequate, whereas another 
might not require the ICS component of their inhaled medication.  
 
This study was randomised to assess whether this was acceptable to patients, 
even though this is not a requirement in a feasibility study (Craig et al., 2008). In 
future definitive studies involving such complex interventions, it will be 
appropriate to select a randomised method for allocation of participants to the 
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study arm, as this significantly lowers the risk of bias within the research study. 
Also, a key outcome of future studies could be to appreciate whether the complex 
interventions had a favourable influence on COPD control under real-life 
circumstances in order to determine whether a community pharmacy-based 
COPD clinic is beneficial. Accordingly, a pragmatic research study was chosen 
ahead of a clinical explanatory study, since a pragmatic RCT assesses whether 
it would work in everyday practice, whereas an explanatory RCT investigates 
whether it would work in ideal circumstances (Roland and Torgerson, 1998). 
 
In this research study, it was not possible to blind the investigating pharmacist 
from knowing which participants had been assigned to the IPC group and which 
had been allocated to the TC group, as the investigating pharmacist was 
responsible for every stage of the study process, including recruitment, 
randomisation and conducting the consultations at both baseline and follow-up. 
It was also not possible to blind the participants, nor is it a requirement in a 
feasibility study, thus making the design an open (non-blind) study. Had the 
financial resources been less restrictive, a SRP would have been recruited 
independent of the investigator to conduct the consultations. Without blinding, 
there is a risk of expectation influencing findings, especially if there was 
subjectivity in assessment, leading to biased results (Day and Altman, 2000). 
This is not challenging the integrity of the investigator or patients, but bias 
associated with knowing the variable is often subconscious (Lijmer et al., 1999). 
To mitigate against this bias, objective rather than subjective measurements 
were used.  
 
Given that future, large scale studies are likely to be open, this interventional 
research study was designed in the same way to test the feasibility of this method 
of allocation within the community pharmacy setting. The group allocation for 
each participant was not revealed until the participant had irrevocably been 
entered into the study, to avoid selection bias and to improve the credibility of 
any future definitive study’s conclusions. However, this also posed a challenge, 
since the investigating pharmacist was solely tasked with recruiting relevant 
participants into the study. To mitigate these risks, allocation was by random 
number creation (See Section 4.2.3). Consequently, a prospective, randomised, 
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open study was the research method of choice with measures put in place to 
minimise bias.  
 
4.2.2 Study setting 
Various study settings were considered for this research. These included 
community pharmacy, walk-in centres, general practice, and respiratory 
outpatient clinic within secondary care.  
 
The setting should ideally be as convenient as possible for the participants, thus 
ruling out secondary care, as this setting is generally less convenient for patients 
to attend (when compared to community pharmacies, walk-in centres and 
general practices, which are more accessible). However, conducting this study 
in an outpatient clinic within secondary care has many advantages, such as 
access to clinical records and easy access to many other specialist HCPs, in 
order to consult them or refer to them. Walk-in centres and general practices are 
also considered accessible locations with access to clinical records. However, 
section 0 builds on the argument of locating the study within a community 
pharmacy setting, in order to utilise their resources. 
 
Community pharmacy is considered a convenient and accessible location for 
patients in the community, and depending on its location, will serve its 
surrounding population. A local population is unlikely to reflect the COPD 
population in the UK as a whole, since there are natural geographic variations in 
demographic factors such as age and socio-economic status (Gershon et al., 
2012). A distance-selling internet pharmacy, on the other hand, will service a 
much wider community (usually nationwide), and thus reflects the overall COPD 
population more closely, including their associated age and socio-economic 
statuses. Since this study requires all patients to access the premises at both 
baseline and at the 6-month follow-up period, the patients living further away 
from the distance-selling internet pharmacy may feel inconvenienced by the 
distance. Ultimately, it was decided to conduct this study at Drugs4Delivery 
pharmacy, a distance-selling internet pharmacy within Grimsby, as TCs were 
thought to be most pertinent to this type of pharmacy.  
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Grimsby is a large town and seaport in Lincolnshire that is physically linked to, 
and forms, a conurbation with the adjoining town of Cleethorpes. Grimsby hosted 
the largest fishing fleet in the world by the mid-20th Century. The fishing industry 
declined dramatically in the early 21st Century after the North Atlantic Treaty 
Organisation (NATO) granted Iceland a 370-kilometre Icelandic exclusive fishery 
zone. As a result, Britain lost access to rich areas, with thousands of jobs lost. 
Also, following the challenges of a post-industrial economy, the town has areas 
that are amongst the most deprived in the country, with the prevalence of 
claiming any benefits over 25% higher than the national average. The main 
sectors of the Grimsby economy are ports and logistics, food processing, 
chemicals and process industries. 
 
Generally, community pharmacies cater to their neighbourhood, with the majority 
of their patients coming from one or two nearby surgeries. However, since a 
distance-selling internet pharmacy must cater to patients across the UK, they 
are more likely to represent the overall COPD demographic than a traditional 
local pharmacy would. That said, Drugs4Delivery pharmacy has only ~10% of 
their patients residing outside the Lincolnshire County. The health of people in 
North East Lincolnshire is generally worse than the England average; For 
example, COPD prevalence is 2.4% compared to the national average of 1.87% 
(NHS Digital, 2017). In this region, the rate of smoking related deaths is 354 per 
100,000 population, which represents 333 deaths per year (Public Health 
England, 2017a). 
 
The consultation was conducted by a SRP (also the researcher) within 
Drugs4Delivery pharmacy’s consultation room, with the patient either present in-
person or via tele-communication, depending on the group they had been 
randomly allocated to. At the 6-month follow-up period, the same SRP offered 
an in-person consultation to both groups, in order to collect data to distinguish 
whether there had been a significant difference between the IPC and TC groups.  
 
A six-month study duration was considered appropriate, based on the studies in 
the literature review (Chapter 3), which ranged from 28-days to 12 months. A 3-
month study duration may not be a sufficient timeframe to detect potential 
changes in patients’ COPD control, however, a 6-month duration was chosen, 
  
79 
given the researcher’s time constraint to carry out the study. Also, from a 
practical perspective, a six-month duration is a realistic interval to re-assess 
patients’ COPD control. Any shorter may possibly affect patient recruitment and 
attrition rate as it could be potentially onerous on both the patient and 
pharmacist. Also, a longer duration allows the interventions a chance to impact 
their health and detect any differences in interventions and thus should be 
considered for the next stage of study development to go ahead, if indicated.    
 
In a community pharmacy setting, an obvious drawback is not having access to 
patient records. Instead, this study relied on the information gained from the 
patient as well as their PMR.  
 
4.2.3 Randomisation 
The Random Allocation Process is crucial to the RCT. It consists of generating 
an unpredictable random sequence, choosing individuals entirely by chance, 
with no regard to the will of researchers or patients’ condition and preference, 
and with the view to control all known and unknown prognostic factors that may 
affect results across the two groups. It then implements this sequence in a way 
that conceals the treatments until patients have been formally assigned to their 
groups (Dettori, 2010). This avoids selection bias by concealing the allocation 
sequence from those assigning participants to the two groups, until the moment 
of assignment, in order to prevent researchers from influencing which patients 
are assigned to a given group (Kim and Shin, 2014). Nevertheless, unless 
studies are undertaken in a rigorous manner, biases can be introduced that 
negate the effect of random allocation (Hahn et al., 2005). 
 
Using a random allocation method could result in a random imbalance in patient 
number in each group. To account for this, a random permuted block 
randomisation list was used to allocate equal numbers of participants to each 
group. A block size of 4 was used to reduce the likelihood of inferring the next 
treatment assignment, since this contains six unique permutations of group 
order, making prediction of the next randomization assignment much more 
difficult.  
 
  
80 
Stratified randomisation sampling involves the division of a population into strata, 
whereas the minimisation method allocates patients to the group that best 
maintains balance in stratifying factors (Kahan and Morris, 2012). Both stratified 
and minimisation methods were inappropriate for this research study.  
 
4.2.4 Study population 
The inclusion criteria comprised of participants aged > 35 years old; this includes 
the vast majority of COPD patients (Cavaillès et al., 2013) with clinician-
diagnosed COPD. For research into COPD, it is fundamental that the diagnosis 
of airway obstruction, which traditionally hinges on a FEV1/FVC ratio below a 
threshold, can be accurately established (Celli et al., 2015). A clear limitation of 
this study was that the diagnosis was largely based on the patient informing the 
pharmacist of whether they had a diagnosis of COPD, a limitation also reflected 
in real life consultations in a community pharmacy setting. This posed a 
particular challenge in this study since patients may suffer from asthma, ACOS 
or other similar conditions, which the patient may confuse with COPD, not to 
mention co-morbidities which the patient may be unaware of. Participants were 
encouraged to bring any recent healthcare documents, such as their discharge 
summary. Also, patient symptoms, history of exposure to risk factors and 
spirometry were used at baseline to confirm COPD.  
 
Participants of all severities were included, from mild to severe in spectrum. All 
participants were required to access the pharmacy for a PC consultation and 6-
month follow-up consultation. The study was limited to patients who were able 
to communicate in English due to the lack of funding for translation facilities. 
Patients were excluded if they failed to meet the inclusion criteria, failed to 
provide written consent or were not responsible for taking their own medication/s. 
Finally, patients were also excluded if they could not access the internet using a 
tablet provided by Drugs4Delivery pharmacy. No patient was assessed during 
an exacerbation or during their recovery from an exacerbation.  
 
A variety of methods were reflected on to inform the final approach used to recruit 
patients. These included selecting individuals with COPD from Drugs4Delivery 
pharmacy, advertising in local newspapers and referrals from general practice 
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and secondary care. To increase the recruitment pool, all patients, regardless of 
their geographic location, were invited to take part in the study. The recruitment 
strategy was first to recruit individuals using Drugs4Delivery pharmacy, as this 
offered an accessible cohort of COPD patients. Thus, this study uses a 
convenience sample method, which is a non-probability sampling technique, 
where participants are selected due to their convenient accessibility and 
proximity to the researcher. This method seemed an uncomplicated approach to 
identify potential participants for the study, as the setting of the consultations 
took place in a local community pharmacy. Bowling (2002) argues that this form 
of recruitment helps with recruitment, monitoring and in reducing attrition rates. 
However, only patients with COPD were recruited, which required the application 
of purposive sampling technique before recruiting and randomising participants.  
 
The study targeted patients with a diagnosis of COPD, using Drugs4Delivery 
pharmacy, and were eligible to take part in the study. The Drugs4Delivery 
pharmacy database provided a practical and convenient way to access patients 
that use inhaled devices, which was convenient given the limited resources and 
time-frame of the study. A notable advantage of Drugs4Delivery pharmacy is that 
it has a relatively even spread of patients across the Grimsby, Cleethorpes and 
Immingham region, and is non-reliant on any particular surgery. Thus, the 
sampling was a fair representation of the Lincolnshire area (but not the UK as a 
whole).  
 
From Drugs4Delivery’s PMRs, the lead investigator identified all patients on 
inhalers who were 35 years of age or over. These patients were then contacted, 
and if they had been informed of a COPD diagnosis, they were invited to take 
part in the study. Since the pharmacist already worked at Drugs4Delivery 
pharmacy for several years and these patients regularly used Drugs4Delivery 
pharmacy, the pharmacist was already familiar with them and their medication 
history, which resulted in less time required for consultation. The pharmacist 
ensured that Drugs4Delivery patients were not treated any differently to other 
patients by not making any assumptions and adhering to the standard questions 
by following the COPD consultation format (See Appendix 6 and 7 in Section 0 
and 9.7). Thus, this method may offer greater advantage over other recruitment 
methods, as there was familiarity with patients’ medication and medication-
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taking behaviour. However, if the patient was known to the pharmacist, 
acquiescence bias may result. This is where participants have a tendency to 
agree with all the questions or to indicate a positive connotation (Rammstedt et 
al., 2017). This can be minimised by the use of objective measures of COPD 
control. Furthermore, a negative effect may occur when the participant believes 
that the community pharmacist may not have the requisite expertise to advise 
and manage their COPD, which may directly influence recruitment and 
adherence to the advice offered. 
 
Another method of recruitment was via promoting this research to all the local 
general practice surgeries in the Grimsby, Cleethorpes and Immingham area. 
The study was promoted by sending a letter out to each and every GP and RNS 
in the locality, explaining the details of the study. Participant information leaflets 
were also posted out to the surgeries for those GPs/RNSs wishing to refer 
suitable candidates. This recruitment technique was in keeping with the majority 
of the community pharmacy-based studies included in the literature review 
(Tommelein et al., 2014; van Boven et al., 2016; Weinberger et al., 2002; Wright 
et al., 2015). Two respiratory consultants in the Diana, Princess of Wales 
Hospital in Grimsby, were also informed of this feasibility study by mail.    
 
Since the total study population was not achieved via these methods, advertising 
in several local newspapers was used to recruit the remainder of the participants. 
These participants were assessed using the eligibility criteria and if included, 
were randomised appropriately. Advertising in the local newspapers was an 
additional recruitment mechanism that was free of charge as the intended 
purpose of the article was to enable research, as opposed to promoting a 
business, for example. From the proof of concept study carried out in 2014 
(Tatari, 2016), it was expected that two patients would be recruited per day. It 
was estimated that forty-eight patients should take twenty-four days to recruit 
(see Section 4.2.8).  
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4.2.5 Ethical considerations 
The study proposal for this research was reviewed firstly by The University of 
Bradford Ethics Committee, and then formally by the South Central – Berkshire 
Research Ethics Sub-Committee, who gave a favourable ethical opinion on 15th 
July 2016 (See Appendix 1 in Section 9.1).  
 
Several ethical issues were identified in the study, primarily due to the perceived 
risks associated with altering existing clinical practice. However, this study aimed 
to supplement existing practice rather than replacing the GP or a RNS 
consultation. Essentially, this study sought to optimise patients’ medication, and 
any recommendations made were referred to the patient’s GP. Clinical equipoise 
is then a necessary condition for the ethical justification of conducting RCTs due 
to the genuine uncertainty in the literature regarding the merits of both IPC and 
TC.  
 
It was imperative that TCs were conducted while the pharmacist was in the 
pharmacy consultation room and the patient, who was transmitted on screen, 
was able to talk at normal speaking volumes without being overheard by any 
other person (Direction 4(5)(a)) (PSNC, 2013). Patients were prompted to decide 
as to whether they wanted to talk in private, or be accompanied by another 
person, e.g. their carer.  
 
A letter from the pharmacist introducing and explaining the study was posted to 
patients who were potentially eligible to partake in the study (See Appendix 2 in 
Section 9.2). Information regarding the study was clear and honest in order to 
enable the patient to make an informed decision on their potential involvement 
(See Appendix 3 in Section 9.3). Participants were only considered for the trial 
once they had provided written informed consent (See Appendix 4 in Section 
9.4). 
 
All patient data were stored securely and confidentially within the Drugs4Delivery 
pharmacy. For identification, a list of patients, their code and their allocated 
group was kept separately. This will be destroyed 1 year following the study end 
date. Also, any written publications will have patient data anonymised.  
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Table 11: The assessment tools used to assess the outcome measures 
 
Outcome measure Assessment tool Rationale/Notes 
Primary  
- COPD control 
 
CAT  
 
Used by both Tommelein et al. (2014) and 
Wright et al. (2015). A valid and reliable 
questionnaire with worldwide relevance 
(Tsiligianni et al., 2012). 
Secondary  
- HR-QoL 
 
EQ-5D-5L 
 
Although not specific to any medical condition, 
it is a validated tool used in COPD (Lin et al., 
2014). An improvement on the less sensitive 
EQ-5D-3L questionnaire which has more of a 
ceiling effect.  
- Adherence 
 
Patient reported (MARS) and from 
PMR information.  
Establish whether non-adherence is intentional 
or unintentional (Cochrane et al., 1999). 
- Lung function FEV1 and FEV1/FVC (using 
spirometry) 
Helps to monitor disease progression 
- Shortness of 
breath 
mMRC dyspnoea test Assesses a patient’s level of dyspnoea and 
tends to be stable over time.  
- Medication 
changes 
Using the ABCD Assessment Tool   To determine the risk of interventions made and 
their likelihood of recurrence. 
- Inhalation 
technique 
Based on checklists from other 
studies (Basheti et al., 2005; 
Erickson et al., 2000; Lenney et al., 
2000). The In-Check DIAL flow meter 
will test inspiratory flow rate for 
different devices.  
No certified checklist available. In-Check DIAL 
measures patient’s inspiratory flow and 
compares this against flow ranges for each 
inhaler type. The measurement indicates 
whether the patient needs to inhale with more 
or less effort in order to achieve optimum 
inspiratory flow for their inhaler device. 
Pharmacist will counsel and demonstrate. 
- Exacerbations Patient will provide this information. 
Confirm this with checking their PMR 
for COPD rescue medications.  
An indicator of COPD control. 
- Acceptability of 
TC 
See bar chart in Figure 7  A similar questionnaire will be carried out for 
IPC.  
- A & E visits  Patient to disclose information Must be a COPD-related visit 
- Hospital 
admissions 
Patient to disclose information Must be a COPD-related admission 
- Resource 
utilisation 
Including primary & secondary care 
use, medication use (using the latest 
Drug Tariff) lost productivity and total 
societal costs.  
Costs (Wright et al., 2015): 
- Intervention costs ~ consultation costs + training + equipment 
- Other NHS costs ~ sum of all resources used 
- Societal costs ~ lost productivity + NHS costs 
- Cost associated with COPD support service ~ 
 6-month follow-up cost – 6-month pre-intervention cost 
 
CAT: COPD Assessment Test; HR-QoL: Health-Related Quality of Life; EQ-5D-5L: five-
level version of the EuroQol five-dimensional questionnaire; Medication Adherence 
Report Scale: MARS; FEV1: forced expiratory volume in one second; FEV1/FVC, ratio 
of forced expiratory volume in one second against the forced vital capacity; mMRC: 
modified Medical Research Council dyspnoea score. 
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4.2.6 Measures of COPD control and quality of life 
Choosing between the available disease specific instruments that measure 
health status, such as Chronic Respiratory Questionnaire (CRQ), SGRQ, and 
CAT, must be driven by study purpose and research questions in combination 
with the domains of the instrument (Weldam et al., 2014). It is essential that this 
information is frequently gathered in a clinical setting. Although CRQ and SGRQ 
have been extensively validated and used in research studies, they are time-
intensive and complex (Jones et al., 1992). The need for help with the completion 
of SGRQ was especially seen in patients with low education level, which is more 
prevalent in individuals with COPD (Ringbaek et al., 2012). Thus, Jones et al. 
(2009) devised the CAT, a more appropriate shorter, simpler and convenient 
health status measurement for use in routine practice. Thus, based on these 
practical advantages, CAT was chosen to measure health status. CAT was also 
more commonly used in the included studies (see section 0). 
 
The CAT is composed of eight questions, each with a semantic six-point 
differential scale, providing a score out of 40, indicating the impact of the disease. 
It is completed by the patient and the result is immediately available after 
summating the scores on individual questions. Scores of 0-10, 11-20, 21-30 and 
31-40 represent mild, moderate, severe or very severe in clinical impact, 
respectively (Dodd et al., 2011). The CAT has similar discriminative properties 
to SGRQ, since the reliability and score distribution of both instruments is 
identical; however, multiple regression analyses demonstrated that physiological 
measures may not be important for the CAT, unlike dyspnoea and psychological 
factors which significantly contributed to both CAT and SGRQ scores (Morishita-
Katsu et al., 2016). 
 
The generic measure of health EQ-5D-5L is less able to discriminate among 
different levels of severity of COPD and correlates less with clinical measures of 
COPD than with the disease-specific instruments, such as CAT. EQ-5D-5L 
captures additional information on HR-QoL than CAT and incorporates more of 
a broad aspect of health. For these reasons, both the disease-specific (CAT) and 
generic measure (EQ-5D-5L) are useful to capture complementary information 
that may be advantageous to integrate into a study (Pickard et al., 2011).  
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It was vital that the outcome measures investigated (Table 11) such as COPD 
symptoms and control, were meaningful and pertinent to the healthcare arena. 
It was also important to enable the comparison with similar interventional studies 
addressed in the literature review. It was essential to ensure that validated 
measures of COPD control and QoL in patients were used to evaluate the impact 
of pharmacist interventions. The EQ-5D-5L utility index is a valid and responsive 
measure of health status. Although it is limited by ceiling effects and lack of 
responsiveness, these effects appear to be significantly less than EQ-5D-3L 
(Pickard et al., 2011). Given the value of EQ-5D-5L in health economic analysis, 
inclusion in clinical studies involving COPD would provide useful additional cost-
effectiveness data of interest (Nolan et al., 2016). Also, CAT is a useful marker 
in clinical trials that evaluate COPD control and track changes in patients’ overall 
health status (Paap et al., 2016). 
 
The outcome measures used in this research study e.g. CAT, are 
interchangeably proposed by GOLD (2017) for assessing symptoms in patients 
with COPD (Casanova et al., 2015). Also, the same outcome measures are used 
in comparable studies in the literature review (see Chapter 3).    
 
4.2.7 Measures of Adherence 
Adherence can be labelled as objective or subjective (Jimmy and Jose, 2011). 
Objective measures include pill counts and biochemical measures, whereas 
subjective measures involve those requiring a patient’s evaluation of their 
medication-taking behaviour (Velligan et al., 2007). Although objective measures 
should be used to validate and correlate subjective ones, they are costly and 
difficult to perform, e.g. measurement of a drug or its metabolite in body fluids 
(Lam and Fresco, 2015). 
 
An ideal medication adherence measure should present low cost, be user-
friendly, highly reliable, flexible and practical (Vermeire et al., 2001). However, 
there is no single method that performs well on all criteria, since each measure 
has its own limitations.  
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A patient’s GP record or their PMR can be used as an indicator as to whether or 
not the patient is adhering to their medication. However, this may not be an 
entirely accurate measure of patient adherence (Lam and Fresco, 2015) and, 
since not all participants were using the Drugs4Delivery pharmacy service, it 
would not be possible to establish all participants’ prescription frequency via the 
PMR. Even those using Drugs4Delivery could be using other pharmacies also. 
Furthermore, obtaining their GP records would prove onerous and potentially 
difficult. 
  
Based on these reasons, a subjective approach using questionnaires was 
employed in this study. Where possible, these were validated against objective 
PMR or GP records. Patients or their carer, were encouraged to complete the 
self-reported questionnaires, although low literacy levels could be a barrier 
(Nguyen et al., 2014). The three questionnaires that were considered were Brief 
Medication Questionnaire, Morisky Medication Adherence Scale (MMAS-8) (See 
appendix 12 in Section 9.13) and Medication Adherence Report Scale (MARS) 
(See appendix 11 in Section 9.12) (Lam and Fresco, 2015). The scales that were 
considered covered questions on adherence, medication-taking behaviours and 
barriers to adherence. 
 
The Brief Medication Questionnaire assesses how individuals have taken each 
of their medications in the preceding week, drug efficacy, bothersome features 
and remembering difficulties (Lam and Fresco, 2015). Although this is popular 
among HCPs, it is time-consuming in comparison to MMAS-8 and MARS (Lavsa 
et al., 2011). MMAS-8 has high validity and reliability amongst patients with 
chronic conditions (Morisky et al., 2008). MARS also offers high validity and 
reliability and consists of ten non-threatening questions to support patients to 
openly indicate their medication adherence. The MARS questionnaire covers 
adherence, medication-taking behaviours and barriers to adherence. MARS was 
selected to assess patients’ medication adherence in this study, as it is reliable, 
user-friendly in this setting and is used in many of the included studies within the 
literature review (see Chapter 3). However, acquiescence bias may occur in 
subjective methods such as these, and the patient must be encouraged to be 
open and honest.   
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4.2.8 Sample size 
Calculation of the exact sample size is a critical part of research design. In a 
feasibility study, however, the sample size is often a pragmatic balance between 
information needs and resources (Eldridge et al., 2016). Typically, up to 40 
patients are recruited for a feasibility study (Craig et al., 2008). Thus, this 
feasibility study had a recruitment target of 20 participants per group. In keeping 
with similar studies, this study allowed for a projected 20% attrition rate. 
Therefore, 48 participants (24 per group) was the sample size required. 
 
 
4.2.9 Acceptability  
The acceptability of TCs was measured based on whether the participants were 
willing to undergo another TC in future, without actually signing up to it, which 
was a subjective measure using an interpretivist approach; where one seeks to 
gain insights into the beliefs and theories that inform research. To mitigate 
against participants feeling they have an obligation to answer yes to whether 
they were willing to undergo a future TC, participants were given an anonymised 
feedback form, to complete and return.  
 
All patients recruited into the study either had access to tele-communication 
facilities at home or were lent a tablet device from Drugs4Delivery for the TC to 
take place. TC equipment comprised of a computer, tablet or smartphone with a 
camera facility, along with access to the internet. All participants were monitored 
on their ease of use of the TC equipment within the demographic investigated. If 
required, family members could help the patient gain access to the TC 
application or the investigating pharmacist could help set this facility up, as was 
the case in the proof of concept study (Tatari, 2016).  
 
In cases where the participant did not have a device from which to transmit TC, 
a tablet was lent to them after their PC, where its use was demonstrated. Once 
the pharmacist initiated a TC, the participant was only required to click on the 
green phone that appeared on the screen. So, the only practical reason 
preventing transmission via TC was having no network coverage nor WiFi. The 
  
89 
tablet device was then collected approximately an hour later by the 
Drugs4Delivery driver. On its return, the tablet device was thoroughly cleaned.   
 
All participants reviewed in the proof of concept study were excluded from this 
study. It was highly unlikely that participants would have previously taken part in 
TCs, as Brant and colleagues (2016) reported none of the 319 general practices 
surveyed used this method. However, the extent to which such technologies are 
actually used at present remains unclear. Thus, no problems were anticipated in 
terms of prior preference for group allocation. Therefore, preference trials were 
not considered, where there are strong preferences in which randomisation were 
refused by the participant or HCP (Torgerson and Sibbald, 1998). Randomised 
consent trials were not considered either (Sedgwick and Hooper, 2014). 
 
4.2.10 Proof of concept study  
A proof of concept study (Tatari, 2016) (see Appendix 16 in Section 8.16) for 
conducting MURs via Skype™, was carried out in order to gauge the patient 
feedback on the appropriateness and feasibility of using the telecommunication 
medium. The MUR was conducted in the pharmacy consultation room with the 
patient transmitted on screen. This was seen as a potential solution to the 
proportion of patients who are unable to visit their community pharmacy and 
consequently deprived of the benefits a MUR service may offer (unless, of 
course, the pharmacist seeks NHS England’s approval for a home visit every 
time they wish to offer the service). To date, the dilemma of being inclusive to all 
patients, especially with regards to mobility, has not been comprehensively 
addressed.  
 
To summarise the one-month proof of concept study carried out in January 2015, 
18 (86%) patients had access to Skype™ through their Smartphone or computer 
(Tatari, 2016). Of the 25 patients contacted via telephone, 17 (68%) gave 
consent and had Skype™ access. Only 3 patients did not respond, representing 
an 88% response rate. There was no significant difference in the quality of MURs 
between Skype™ and the usual in-person pathway. Only 2 of the 17 patients 
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(12%) thought that they would benefit more from IPC than Skype™ and 15 out 
of 17 (88%) patients preferred the Skype™ consultation. 
 
From a positivist perspective, there were clear benefits to the number of tele-
MURs conducted, rather than travelling to patients’ homes, which was thought 
to assist the NHS financially. Three patients (18%) did not know how to install or 
use Skype™, however, this was installed on their behalf and they were trained 
on its application. It was found that, on balance, the benefits of this technology 
were substantial and could act as a supplement when MURs cannot be carried 
out in-person within the pharmacy premises.  
 
This one-month proof of concept study demonstrated that recruitment rates were 
relatively high, since 17 out of 25 patients (68%) took part. However, this did not 
include any COPD patients who, on average, are an older demographic. The 
only stipulation for inclusion was that patients were required to be eligible for a 
MUR.     
 
4.2.11 Researcher 
As the lead researcher was the pharmacist conducting the consultations, this 
may have brought the validity of the study into question, had it been the main 
study designed to assess the effect of the intervention/s, since the researcher 
was fully immersed in the study, rather than being an impartial outsider. 
However, the advantage of this approach was that it was easier to obtain 
information from the patients as the researcher was accustomed to many of the 
patients (Asselin, 2003). In order to quality-assure that the pharmacist 
maintained a consistent approach to both IPCs and TCs, a second pharmacist 
sat in on 4 (16.6%) consultations per group with patient consent. 
 
The only difference between the two groups was in conducting the consultation 
in-person or via tele-communication. There was minimal to no contamination risk 
of one group of participants, interacting and discussing their consultations with 
the other group. Contamination risk occurs when patients of one group 
inadvertently get exposed to the other, thus potentially minimising the difference 
in outcomes between the two groups. Patients in both groups were reviewed in 
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the same consultation room during the PC and at the 6-month follow-up 
appointment, thus, on these occasions, may have been in close proximity to 
each other. However, contamination had not been considered a risk to the study. 
Had contamination been considered a significant risk, a multi-centre design 
could have been used to minimise contamination between participants, although 
this can incur selection bias (Puffer et al., 2003).  
 
4.3 Study methods 
The research study was strategically designed as a pragmatic, six-month, 
prospective, randomised-controlled, open-label, feasibility study where 
participants were randomly allocated to the IPC or TC. The aim was to recruit 48 
participants and randomly assign them to the two groups, using the block 
randomisation technique in a 1:1 ratio after each participant had authorised 
written consent to take part in the study. Participants attended a community 
pharmacy COPD clinic at baseline (see Section 4.3.1). Both groups received 
personalised interventions from the same SRP. Treatment could have been 
discontinued at any point in the study at the pharmacist’s or the patient’s 
discretion. 
 
4.3.1 Study procedures 
The prospective research is encapsulated in 
Figure 5 and Appendix 5 (Table 15) and 6 in Sections 9.5 and 0. All potential 
participants of Drugs4Delivery pharmacy were offered the opportunity to enrol in 
the study on delivery of their repeat prescription. If interest was shown, an 
information form was left with the patient for their consideration. As discussed in 
Section 4.2.2, another method of patient recruitment was through promoting the 
service to general practices and walk-in centres within the locality, who were 
informed that they could refer individuals with COPD to the study. Information on 
the study was provided to general practices via letter which included a letter of 
invitation to patients (Appendix 2 and 3). Only five of the surgeries involved, were 
visited in-person, in order to introduce and provide further information regarding 
the service.  The other surgeries in the locality were not visited due to the time 
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constraints of the investigating pharmacist. The shortfall of patient population 
was made up via advertising in the local newspapers.   
 
The patients’ age, sex and medication history were established from the PMR 
(and/ or summary care record) prior to their arrival. 
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Figure 5: The Study Process 
 
T, Time from baseline; IPC, In-Person Consultation; TC, Tele-Consultation; PMR, 
Patient Medication Record; CAT, COPD Assessment Test; mMRC dyspnoea score, 
modified Medical Research Council dyspnoea score; NMS, New Medicines Service; 
FEV1, forced expiratory volume in one second. 
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4.3.2 Pre-clinic 
From September 2016 through to January 2017, all patients entered a PC. At 
the PC, participants were assessed in-person by the same SRP conducting the 
clinic, in order to obtain the following information; height and weight to calculate 
BMI, appropriateness of current inhaler(s) (using the In-Check DIAL), oximetry 
and spirometry. Values after bronchodilation were used in qualifying pulmonary 
function tests. These measurements can only be carried out in-person and, since 
community pharmacy cannot access patients’ clinical information, all 48 
participants were required to attend the pharmacy to capture this data.  
 
All other information was obtained using a structured protocol once the 
participant was randomised into either the IPC or TC group. This information was 
based on local and international guidelines and consisted of; 
 
• Assessment of COPD 
- Patient history e.g. occupation, pack year smoking history, medication 
history  
- COPD control (CAT score) 
- HR-QoL (EQ-5D-5L) 
- Co-morbidities 
 
• Education 
- COPD pathology 
- Medication 
- Adherence (MARS) 
- Inhaler technique 
- COPD self-management plan 
 
All patients that did not have a self-management plan were provided with one, 
within which there was a section to note changes in symptoms and use of 
medications between visits. Participants were encouraged to document any 
changes within their self-management plan to improve the accuracy of 
monitoring all their exacerbations. Langsetmo et al. (2008) and Schmidt et al. 
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(2014) exposed the underreporting of mild exacerbation events which affected 
patients’ health status.  
 
Participants were also asked to provide additional, objective information 
pertaining to the 6-month period preceding baseline. This included work days 
taken off due to sickness, GP appointments made for COPD assessment and 
management, exacerbations treated by the GP, rescue packs used, hospital 
admissions following an AE-COPD, the number of days spent in hospital 
following AE-COPD and the number of A&E visits.  
 
This retrospective measure obviously relies on the patient’s recall, which may 
not be as accurate as obtaining the information directly from the patient’s GP. 
However, the proof of concept study demonstrated that contacting the GP for 
this information proved too laborious, and there were also many instances where 
the GPs refused to impart these details. Another option considered was for 
patients to record all this information in a patient diary, however, although the 
evidence suggests this is a valuable tool to monitor and accurately record these 
events, it was considered unnecessary. This is because, although it was 
considered less accurate, retrospective measures were considered sufficient 
given that a diary task may not have been adhered to and may have raised 
attrition rates (Llor et al., 2012). 
 
4.3.3 Tele-Consultation 
In the TC arm, the consultation took place via Skype™, a widely used, readily 
available free software application. The pharmacist was located in the 
Drugs4Delivery consultation room with the patient based at their abode. Where 
possible, the patient had the TC on the same day as the PC otherwise it was 
arranged to take place within 72 hours of the PC.  
 
4.3.4 In-Person Consultation 
IPC was conducted at Drugs4Delivery pharmacy, within the consultation room 
situated in Alexandra Dock Business Centre, Fisherman’s Wharf, Grimsby. The 
participant waited 10 minutes between having the PC and the IPC. This 10-
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minute break period may mimic the routine in a general practice where typically, 
a nurse carries out the pre-consultation measurements, which is then passed on 
to the GP for assessment. The GP then discusses the results and treatment 
options with the patient. Also, since there had to be an interruption period 
between the PC and the patient returning home for the TC, a gap was factored 
in between the PC and the IPC to create consistency between the two groups.  
 
4.3.5 Tele-Consultation and In-Person Consultation 
Participants were informed that they would be asked about the number of GP 
appointments for COPD, AE-COPD treated by their GP, rescue packs used, 
hospital admissions following AE-COPD, number of days spent in hospital 
following AE-COPD and A&E visits between baseline and the completion of the 
study at their 6-month follow-up. They were asked to record this prospectively in 
order to help them recall this information. Hence, the before and after data for 
IPC were measured against the before and after data for TC, which is an 
improvement on the uncontrolled studies reviewed in Chapter 3 (van Boven et 
al., 2016; Wright et al., 2015). This information could not be corroborated with 
patient records, since these are not accessible to community pharmacy. The 
pharmacist did not request clinical information from the general practices as this 
proved unsuccessful in the proof of concept study (Tatari, 2016). As a result, all 
participants were encouraged to bring along medical paperwork, such as 
discharge summaries, which occurred in the majority of cases. It is important to 
note that participants’ baseline or follow-up were not assessed within 14 days 
following an exacerbation as this could lead to unrepresentative measures. 
 
In keeping with the six included studies within the literature review, both the IPC 
and TC groups received guidance on their COPD condition and medication, 
which included the importance of adherence. The appropriateness of patient’s 
inhaler device(s) was assessed using the In-Check DIAL meter and if 
inappropriate, an alternative device was suggested to their GP. Also, the 
appropriateness of the medications themselves was assessed by the 
pharmacist, and when necessary, alternatives were recommended to the 
patient’s GP via a postal letter sent within a week of their baseline consultation. 
If the GP agreed to change their medication and/or device, the patient received 
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counselling in the form of a NMS. Adherence was checked with the patient, using 
a validated questionnaire (MARS) and their PMR.   
 
A key element of the study was educating patients how to recognise and respond 
to exacerbations, and in certain cases, suggestions were made to their GP to 
prescribe their patient a rescue pack (Wright et al., 2015). A COPD management 
plan was negotiated with each participant and this was shared with their GP. It 
also involved referring patients to pulmonary rehabilitation, recommending 
influenza and/or pneumococcal vaccinations, as well as encouraging smokers to 
attend smoking cessation clinics. Any adverse events ensuing from this study 
were documented and, if appropriate, reported using the Yellow Card Scheme.  
 
Any information or recommendations that needed to be relayed back to the 
GP/RNS were communicated via postal mail. If the GP adjusted or switched 
medications, the patient would then be eligible for a NMS. If the participant was 
recruited from Drugs4Delivery pharmacy, this was flagged up by the PMR and 
the NMS conducted via telephone. Changes to participants’ medication that were 
recruited from other than Drugs4Delivery pharmacy, could only have a NMS 
conducted from the pharmacy that supplied their medication. Thus, obtaining 
data about whether treatment recommendations were implemented were either 
by the patient themselves or their summary care record.  
 
To prevent the SRP subconsciously favouring one group, especially since there 
can be a degree of subjective interpretation, a second pharmacist (YT) sat in on 
8 (16.6%) consultations (4 per group) to identify whether both groups were 
treated equally. This helps to quality assure the clinics and ensure the reliability 
of the study to the protocol. The second pharmacist also reviewed the data for 
all 48 patients, retrospectively. He was blinded to the patient’s allocated group 
and documented his own recommendations without knowledge of the 
recommendations made by the SRP. The SRP then compared the 
recommendations made to his own. The second pharmacist had a PG clinical 
diploma in community pharmacy and was also an independent prescriber, 
although not a specialist in the field of respiratory medicine. Regardless, the 
GOLD (2017) pocket guide to COPD diagnosis, management and prevention, 
was read in preparation for this task and referred to when reviewing the data.  
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4.3.6 Follow-up 
After a 6-month follow-up period, all participants were assessed in-person 
between March 2017 and June 2017. The BMI, In-Check DIAL, oximetry and 
spirometry measurements were obtained again to determine whether there had 
been any significant difference between the two groups. Other important data 
collected were smoking status, CAT score, HR-QoL, MARS and inhaler 
technique reassessment.  
 
4.4 Consultation skills 
The importance of maintaining the same pharmacist throughout the study is 
paramount when understanding the variability that a HCP can have on patients’ 
experiences. A favourable patient experience is positively associated with 
clinical effectiveness and patient safety, thus HCPs should resist side-lining 
patient experience as too subjective (Doyle et al., 2013; Kerr et al., 2017). 
 
The consultation skills used by the SRP were in keeping with the ‘Consultation 
skills for pharmacy practice’ framework (NHS Health Education England, 2014), 
and supported the provision of patient-centred, high-quality care, involving 
coaching and self-management skills. Patients with effective self-management 
skills make more efficient use of HCPs’ time and have enhanced self-care 
(Adams et al., 2007; Bourbeau and Palen, 2009). More specifically, self-
management interventions in patients with COPD are associated with improved 
HR-QoL, a reduction in the probability of COPD-related hospital admissions and 
improvement in dyspnoea (Zwerink et al., 2014). 
 
The consultation length was planned to be approximately 35 minutes. This was 
mainly allocated to educating and reviewing the suitability of medication. The 
consultation length itself does not directly improve consultation outcome, but 
rather, the content within the consultation affects this (Lemon and Smith, 2014). 
A holistic approach was taken when assessing patients’ adherence to their 
management plan e.g. understanding and respecting the patient’s values. The 
number of patients seen in a day would depend on both patient and pharmacist 
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availability, however, six to eight consultations per day were aimed for in order 
to be able to review and record any results. This was considered appropriate 
given the findings of the QUALICOPC study (Eide et al., 2016), where both short 
and long patient lists were associated with various negative patient experiences 
in a consultation with a GP.   
 
4.5 Data collection 
The purpose of this research was to determine the feasibility of TC, in a 
community pharmacy-based COPD clinic. This study will be used to establish 
further work required to proceed to a definitive trial to test the impact of 
pharmacist interventions via TC amongst patients with COPD. Thus, since this 
research was a prospective, real-life RCT, it was essential that the outcome 
measures investigated were relevant to clinical practice and employed in other 
comparable studies.  
 
The literature review (see Chapter 3) has shown that a number of interventions 
are effective in the management of COPD, including educating patients on their 
medication, adherence, inhaler technique and self-management (Davis et al., 
2016). The majority of the study questionnaires were completed by the patient 
in order to reduce bias (see Table 11 for details of outcome measures). However, 
in order to guarantee that data collection was complete, the pharmacist 
explained what was required of the patient when there was any uncertainty. In 
the TC group, patients were provided with the paperwork after their PC to 
complete when at home. This information was then collected at a later date. The 
research pharmacist ensured collation of all data using separate forms for each 
participant (Refer to Appendix 7 in Section 9.7).  
 
In future studies, this information could be sent to the patient via email, however, 
this would potentially prove more challenging to the less computer-competent 
patients; in this study, it was decided against this idea as the paper method was 
consistent with both groups.  
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4.6 Outcome measures 
Data were collected at baseline and at the six-month follow-up visit. Indirect 
measures of COPD control, such as A&E visits, were collected for the 6-month 
period preceding baseline and during the six-month study duration. A study 
duration of 6-months was considered sufficient for this feasibility study given the 
time constraints of the researcher to undertake the study, as well as taking into 
account the studies in the literature review, which ranged from 28-days to one-
year.  
 
Awareness of the qualities and restrictions of assessing outcome measures of 
COPD is central to the strategy and analysis of relevant research studies. In 
contrast to methods used for monitoring lung function, there is no gold standard 
for measuring symptoms such as health status, physical activity, exercise 
capacity, dyspnoea or AE-COPD. Glaab, et al. (2010) claim that there is no 
single outcome measure for the assessment of treatment response in COPD, 
and Jones, Harding and Berry et al. (2009) suggest that further research is 
required to improve questionnaires assessing outcome measures within primary 
care. 
 
4.6.1 Inhaler technique 
The GOLD (2017) and NICE (2010) guidelines recommend that prior to 
prescribing a new inhaler for patients with COPD, the patient should receive 
training and education in the use of the device. These guidelines suggest that 
inhaler technique should be regularly assessed at each clinic visit, although the 
challenge in many practice situations is the allocation of personnel and time.  
 
Errors in device use impacts the effectiveness of the delivered drug, and thereby 
leads to sub-optimal control of COPD (GOLD, 2017). It is therefore essential to 
comprehend and quantify device-use errors, so that patient interventions can be 
effectively introduced together, with developing a standardised training protocol 
for the individual inhaler devices. Definitions of critical and non-critical errors, as 
well as the number and type of checklist steps, vary widely between devices and 
studies (Chrystyn et al., 2017). A critical error is one that may impact the 
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effectiveness of the delivered drug and thereby lead to sub-optimal control of 
COPD (Lavorini et al., 2008). There is insufficient evidence to be able to assess 
the impact of device errors on clinical outcomes (Chrystyn et al., 2017). 
 
Inhaler technique was determined primarily during the pre-consultation phase, 
as it required the patient to be present in-person in order to use the In-Check-
DIAL. The In-Check DIAL is a hand-held low range inspiratory flow measurement 
device with a dial top used as an inhaler technique training and assessment tool. 
The DIAL can be adjusted to accurately simulate the resistance of popular 
inhaler devices, e.g. MDI and Dry Powder Inhalers (DPI) (which includes 
Turbohaler, Handihaler, and Ellipta), enabling HCPs to train patients to the 
correct inspiratory technique, considering force and flow rate to achieve 
maximum deposition of the medication being inhaled in the lungs. It is accurate 
to +/-10% or 10L/minute (whichever is greater). Following the pre-consultation 
check, the subsequent baseline consultation (IPC or TC), allowed the pharmacist 
to identify patients not attaining sufficient inspiratory force for their inhaler 
device(s).  
 
If patients’ inspiratory force was inadequate for their inhaler, the pharmacist 
would discuss possible alternative devices with the patient. A discussion on 
inhaler preference was considered with the patient in order to improve the 
likelihood of adherence to the treatment (Capstick and Clifton, 2012). Patients’ 
inhaler device history was discussed in order to avoid recommending an inhaler 
device or treatment that was unsuccessfully used in the past. Again, the 
limitation of this method is that it relies on patient recall. However, requesting 
this information from patients’ GPs has proven arduous from the proof of concept 
study carried out (Tatari, 2016). Once all this information was established, with 
their consent, the pharmacist wrote to the patient’s prescriber suggesting a more 
suitable device. 
 
Those that attained sufficient inspiratory force had their inhaler technique 
assessed at the baseline consultation. This was demonstrated using their current 
inhaler device/s via an IPC or TC, depending on the group to which the patient 
was allocated. A customised checklist for each inhaler device was based upon 
checklists adapted from the included studies (see Chapter 3), as well as 
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manufacturer’s instructions (see Appendix 13 – Section 0). If the patient made 
any mistakes, the pharmacist informed and demonstrated the correct technique 
to the patient. The patient was then asked to re-demonstrate this until their 
technique was accurate. Inhaler technique score was calculated as a percentage 
of all the correctly performed steps when using a particular inhaler (Sanchis et 
al., 2016) (See Appendix 13 in Section 0). If the patient could not use their 
inhaler, due to a lack of coordination or dexterity, a spacer device was 
considered. 
 
It was important that all patients, regardless of technique, were asked whether 
their inhaler device was acceptable to them. If a device was unsuitable to the 
patient, an alternative device was suggested to their prescriber with the view to 
aid long-term treatment adherence (Aydemir, 2015). Selecting an inhaler device 
that is tailored to the individual patient’s ability to use a particular type of device 
as well as patient needs and preferences can enhance patients’ confidence 
(Dekhuijzen et al., 2016).  
 
4.6.2 Economic evaluation 
The number of participant visits to their pharmacy, walk-in-centre, general 
practice and hospital were monitored, in both groups. Costs were assigned to 
these visits according to estimates calculated in a previous study by Curtis 
(2013). The total cost of the intervention was estimated by summing up the cost 
of training, equipment and the bi-annual review. The estimated total other NHS 
costs were adapted from the study by Wright et al. (2015), by summing the costs 
associated with each of the self-report items of resource use, not including days 
off sick. The total NHS costs were estimated by summing the intervention cost 
and total other NHS costs (Wright et al., 2015). Assuming there is demonstrably 
equivalent clinical effectiveness between the two groups, this can be presented 
as a cost-minimisation analysis (Curtis, 2013).  
 
4.7 Analysis plan 
For future definitive studies, in order to assess the appropriateness of a particular 
type of statistical analysis, it was vital to appropriately classify the variables as 
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either categorical e.g. nominal or ordinal, or continuous e.g. scale. The nominal 
data (i.e. demographic information, smoking status, whether or not the patient 
has a COPD management plan) can be statistically tested between groups using 
Chi-square test (Campbell, 2007). For non-parametric data, i.e. CAT, lung 
function, number of A&E visits, number of admissions, adherence and inspiratory 
flow rate, the Mann-Whitney U test can be used between groups (Hart, 2001), 
and for statistical analysis within groups, Wilcoxon signed-rank test can be used 
(Hilton, 1996). The data can then be inspected graphically in order to see 
whether the distribution was normal using a probability–probability plot (P-P plot) 
or a Q-Q plot (using quartiles). The Kolmogorov-Smirnov test (K-S test) can be 
used to statistically assess whether the distribution of the data as a whole 
deviated from a comparable normal distribution. 
 
The ability to use an inhaler (before and after counselling) and pharmacist 
interventions can be statistically tested between groups using Chi-square test 
and within groups using Wilcoxon signed-rank test (Table 12). Calculating cost 
(for IPC and TC) was adapted from Wright et al. (2015); the only study in Chapter 
3 that calculated cost-effectiveness of their pharmacy service. 
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Table 12: Statistical tests on the outcome measures  
 
 
CAT: COPD Assessment Test; SpO2: Peripheral capillary oxygen saturation; FEV1: 
forced expiratory volume in one second; FEV1/FVC, ratio of forced expiratory volume in 
one second against the forced vital capacity; EQ-5D-5L: five-level version of the 
EuroQol five-dimensional questionnaire; MARS: Medication Adherence Report Scale; 
NMS: New Medicines Service.  
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4.7.1 Exploratory analysis plan 
In any future main study, it will be crucial to explore the individual effects of each 
component of the consultation on COPD control, whilst being mindful that this 
condition is progressive in nature, and therefore, any estimation will be an under- 
rather than an over-estimation of benefit. Effects on adherence, inhaler 
technique and adjustments to treatment are discussed below. It is also vital to 
consider the seasonal variability of COPD, especially considering that baseline 
measurements took place during autumn and winter (where there are more 
exacerbations), whereas the 6-month follow-up took place during the spring and 
summer months.  
 
4.7.1.1 Effect of medication adherence  
Poor medication adherence has multifactorial causes that need to be identified 
before interventions can be designed to improve adherence (Brown and Bussell, 
2011). The effect of adherence on HR-QoL may be a consequence of the 
effectiveness of treatment and its associated side-effects. HR-QoL may, in turn, 
influence the patterns of patients’ drug use, as an increased HR-QoL may cause 
non-adherence (Ágh et al., 2015). From the evidence base, it is expected that 
adherent patients are more likely to:  
 
- Have better symptom control (and thus COPD control) – measured using 
CAT 
- Have better lung function - measured using FEV1 and FEV1/FVC ratio 
- Suffer fewer exacerbations - fewer OCS courses, A&E visits and hospital 
admissions 
- Have better HR-QoL - measured using EQ-5D-5L 
 
The proof of concept study conducted via Skype™ (Tatari, 2016) demonstrated 
that there was no significant difference in adherence between Skype™ and the 
usual in-person MUR, albeit, the study only took place over a one-month period. 
Thus, it was anticipated that there would not be any significant difference 
between IPC and TC.  
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4.7.1.2 Inhaler technique 
The clinic comprised of evaluating the patient’s inhaler technique (See Appendix 
13 in Section 0). If the inhaler technique was inadequate, the patient received 
guidance on the correct usage of their device(s). If correct technique was 
maintained throughout the duration of the study, then it was envisaged that there 
would be improvements in the following outcome measures: 
 
- Better symptom control (and thus COPD control) – measured using CAT 
- Better lung function - measured using FEV1 and FEV1/FVC ratio 
- Suffer fewer exacerbations - fewer OCS courses, A&E visits and hospital 
admissions 
- Better HR-QoL – measured using EQ-5D-5L 
 
Again, the proof of concept study conducted via Skype™ (Tatari, 2016) 
demonstrated that there was no significant difference in inhaler technique 
between Skype™ and the usual in-person MUR, albeit, the study only took place 
over a one-month duration. It was anticipated that there would not be any 
significant difference between IPC and TC. Furthermore, self-management 
education is anticipated to improve both inhaler technique and medication 
adherence.  
 
4.7.1.3 Adjustments to treatment 
If their inhalers are not conducive to their lung function and symptoms, then 
recommendations were made to offer a more suitable alternative. This may have 
been a case of stepping up or stepping down treatment. It was anticipated that 
optimising treatment would improve all outcomes, such as; 
 
- Better symptom control (and thus COPD control) – measured using CAT 
- Better lung function - measured using FEV1 and FEV1/FVC ratio. 
- Suffer fewer exacerbations - fewer OCS courses, A&E visits and hospital 
admissions 
- Better HR-QoL - measured using EQ-5D-5L 
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If stepping down was indicated, this would reduce any unnecessary side effects 
from the medication, as well as lower the prescribing budget; in the case of ICS, 
this could be anything from reducing the risk of oral candidiasis and pneumonia. 
If the GP decided to implement the change(s) recommended to the patient’s 
treatment regimen, then a NMS was conducted to support the patient in 
understanding how to use the new device/medication. Again, it was anticipated 
that there would not be a significant difference between IPC and TC. 
 
4.8 Study sponsorship 
This independent research study has been self-funded. 
 
4.9 Dissemination of findings 
After the study, opportunities were sought to disseminate the outcomes of the 
research to other pharmacists within the locality. This provided an opportunity 
for other pharmacists to use these ideas within their own practice, or at least help 
them to use similar interventions when counselling their own COPD patients. 
The topics that will be included are self-management, adherence, inhaler 
technique, pharmacological and non-pharmacological interventions.  
 
It is anticipated that the findings will also be disseminated to NHS England, as 
well as locally to the North/East Lincolnshire Care Quality Commission, to 
illustrate the findings of providing a pharmacy-based COPD clinic. A business 
case may be presented to illustrate any potential monetary savings that may 
have been made. 
 
It is expected that the findings of this study will be published in reputable, peer-
reviewed pharmacy, respiratory and TM journals (see Appendix 19 in section 
8.19). The prospective avenues of publication include: 
 
i. The feasibility of conducting TC, in a community pharmacy-based COPD 
clinic.  
ii. Utilising Spirometry, Oximetry and In-check DIAL devices to optimise 
medication for COPD sufferers. 
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iii. The impact of tele-consultation clinics conducted by a pharmacist on 
adherence.   
iv. The impact of tele-consultation clinics conducted by a pharmacist on 
inhaler technique.  
v. Conducting clinics from a Distance-Selling Internet Pharmacy.  
 
The intention will be to present my results at national and international 
conferences, as well as share the findings at local meetings, such as the 
Doncaster and South Humber Local Practice Forum.  
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5.  Results 
5.1 Introduction  
The results will focus on the rate of patient recruitment, retention, acceptability 
of TC and the practicalities and completeness of data collection when conducting 
TC. The outcome measures were collected to show the practicalities of service 
delivery and completeness of data collection. If this feasibility study proceeds to 
a larger trial, this data collection will be used to test the impact of pharmacist 
interventions via TC amongst patients with COPD. Thus, this chapter will also 
present results from between-groups (IPC and TC) comparison as further 
research will have larger numbers to establish whether there are any significant 
differences in these outcome measures, at the 6-month follow-up stage between 
the two groups when controlling the baseline measures.  
 
5.2 Patient Recruitment and Retention 
Forty-eight patients were recruited into the study; 25 were recruited via 
Drugs4Delivery pharmacy and 23 via advertisements in 2 local newspapers 
(Grimsby Telegraph and Cleethorpes Chronicle) in November and December 
2016 (see Figure 6). This study did not manage to generate any recruits via 
referrals from general practices or walk-in centres. 
 
One hundred and seventy-nine COPD patients were identified as using 
Drugs4Delivery pharmacy. Ninety met inclusion criteria for the study, of whom 
25 (27% rate of recruitment) agreed to take part. These patients using 
Drugs4Delivery pharmacy were recruited between September 2016 and 
December 2016. The remaining 23 patients (48%) were recruited by advertising 
in 2 regional papers between November 2016 and December 2016. It took 14 
weeks to complete the recruitment process. Twenty-four patients were randomly 
assigned to the IPC group and 24 to the TC group. Participants were willing to 
be randomised after it was explained that the advice would be the same 
regardless of which group they were randomly allocated. Both the characteristics 
of the patients at baseline and dropout rates were similar in IPC and TC groups 
(Table 16). The mean [Standard Deviation (SD)] age was 61.4 (10.8) years and 
there were only 2 more males than females (52.1% to 47.9%, in the IPC and TC 
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groups, respectively). Only one patient had never smoked (2.1%), 28 (58.3%) 
patients were ex-smokers and 19 (39.6%) were current smokers.  
 
All efforts were made to avoid the loss of participants to follow-up during the 
study. In an attempt to lower the dropout rate, participants’ views on their 
treatment were heard and then advice provided, then a decision was made 
jointly, with participants’ views treated respectfully (Ali Murshid and Mohaidin, 
2017). The clinics were conducted in a professional setup, with a reception area, 
receptionist, and waiting room where all participants were offered a hot or cold 
drink before PC. During the consultation, they were made aware that the 
pharmacist would like to assess them again in 6-months’ time in order to 
determine whether their condition improved, stayed the same or declined. 
 
Forty-one patients were followed up at 6-months  30 days (85% retention); 21 
were from the IPC group and 20 from the TC group, who were reassessed 
between March and June 2017. 
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Figure 6: Patient Enrolment and Outcomes Flow Diagram  
 
IPC, In-person consultation; TC, Tele-consultation 
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5.3 Acceptability of TC 
The process of randomising patients (1:1) into the IPC and TC groups proved 
acceptable to patients, after it was explained that the advice they receive would 
be the same regardless of which group they are allocated. At the end of the 
consultation, all participants in both groups were asked whether they would ‘like’, 
‘not like’ or were ‘impartial’ to using TC in future. The data reflects that 
participants in the TC group were more likely to use TCs compared to 
participants in the IPC group. Participants from both groups felt that they were 
better informed regarding their condition and treatment, and understood their 
options going forward. They felt that any questions they had were discussed 
without feeling limited by time. At follow-up, 29% of participants in the TC group 
declared a preference for IPC.   
 
 
Figure 7: The number of participants within each group who were willing, 
unwilling or impartial to using TC in the future.  
 
IPC, In-Person Consultation; TC, Tele-Consultation. 
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5.4 Practicalities of study implementation 
This feasibility study used a complex intervention therefore the practicalities 
encountered in its implementing will be useful to inform a future definitive study 
(Craig et al., 2008).  
Initial confirmation of diagnosis, was based on participants informing the SRP of 
whether they had been diagnosed with COPD, due to not having access to 
patient records. The study relied on PMR, documents brought in by the patient 
and patient recall. Also, patients’ co-morbidities were based on the patient 
informing the SRP and not always confirmed from their medical records. It was 
found that populating questionnaires, management plans and forms with patient 
information (e.g. date of birth, medication regimen) prior to the consultation, 
allowed more time to be spent with the patient discussing medical issues. The 
pharmacist’s familiarity with the 25 patients using  Drugs4Delivery pharmacy 
enabled further time saving during the consultation.  
 All participants completed the 15 minutes baseline consultation (PC) which 
consisted of using spirometry (lung function), oximetry (oxygen saturation), In-
Check DIAL (inspiratory force) and measuring BMI (measuring the height and 
weight of participant). From a practical perspective, these measurements had to 
be carried out in-person on all 48 patients (in the Drugs4Delivery pharmacy 
consultation room), as this required the use of specialist equipment with 
instruction from the SRP.  
 
In general, patients felt they were better informed regarding their condition and 
treatment, and understood their options going forward. They felt that any 
questions they had were discussed without feeling limited by time. That said, no 
patient fed back that the consultations were too long in duration (PC was 15 
minutes and the clinic itself was 20 to 25 minutes), which otherwise could have 
resulted in their detachment from the study. This may have been helped by 
informing patients of the likely duration of the clinic.  
 
The actual consultations took place with the patient either present in-person 
(IPC) within the pharmacy consultation room, or via tele-communication (TC) 
while the pharmacist was in the consultation room and the patient, was 
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transmitted on screen, from their home, depending on which group they were 
randomly allocated to. After the PC, if the participant was randomly allocated to 
the TC group, they had their TC either on the same day or arranged within 72 
hours of the PC. Ten-participants (42%) in the TC group did not have a facility 
to access Skype™, so a tablet device was either delivered to their home or given 
to them after the PC. The pharmacist then called the patient via Skype™ so that 
the patient only needed to answer the call, in a similar fashion to a phone call. 
This was later collected by the pharmacy driver.  
 
Prior to the TC, patients were asked if they wanted to talk in private, to ensure 
they were not overheard by other household members. There were no issues 
uncovered with regards to privacy. Those in the IPC group, waited for 10-minutes 
(in reception) between having the PC and the IPC. On average, the estimated 
set-up time for a TC, was an additional 10-minutes per participant, which 
included how to use the Skype™ application.  
 
A notable barrier during the TCs, was that the transmission was interrupted on 3 
separate occasions (12.5%). During one of the 3 interruptions, the TC had to be 
rescheduled. At baseline consultation, 13 of the 48 participants (27%) did not 
attend and required re-scheduling. There were no barriers to offering lifestyle 
advice, providing a COPD self-management plan (via postal mail) or optimising 
patient medication via TC. All patients were counselled on their inhaler technique 
via IPC or TC, depending on which group they were allocated. During TC, inhaler 
technique was successfully demonstrated, by being side-on or at an angle to the 
camera (in order to keep an eye on the patient and so that the patient can clearly 
view each step). There were however two instances during TC where the patient 
was out of view of the camera and were asked to re-demonstrate.  
 
Adherence was primarily measured using the validated questionnaire, MARS, 
PMR, summary care records and GP records (See Section 4.2.7 for further 
information). This was successfully administered for 100% of all participants in 
both groups and the completeness of MARS was checked during the 
consultation. The number of exacerbations and hospital admissions were based 
on patient recall, which may not have been accurate.  
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The EQ-5D-5L is a generic, validated preference-based instrument for 
measuring the health utilities of patients in economic evaluations (Payakachat et 
al., 2015). The study showed this measure was feasible and was easily 
administered by the research pharmacist for all participants during both IPC and 
TC. The CAT questionnaire was successfully administered, and complete data 
obtained for all participants in both arms of the study and there were no feasibility 
issues to report. The pharmacist ensured that all data were collected for all 
markers of COPD control. Since information on CAT and exacerbations were 
collected during consultations, this allowed the GOLD assessment tool to be 
completed. This tool was easy to use and enabled all participants’ COPD to be 
classified. In a potential future study, the primary outcome measure is likely to 
measure whether there has been a difference in COPD control between the two 
arms of the study as measured using CAT (see Appendix 9 in section 9.9), Thus, 
the CAT and GOLD assessment tool can be strongly recommended for this 
purpose. 
 
Since this research was a real-life, complex interventional feasibility study, clinics 
ranged from 30 to 50 minutes in duration (median of 35 minutes). This 
consultation duration was required in order to have sufficient time to perform the 
various assessments necessary for this study. The assessments were carried 
out regardless of whether they had recently been carried out elsewhere, since 
community pharmacy does not have the facility to access patients’ notes. 
Approximately 15 to 30 minutes were spent discussing each patient’s treatment 
as well as potential options. In several cases, more time was required to discuss 
patients’ co-morbidities; however, due to the scheduling of the next appointment, 
discussing co-morbidities was often time-constrained.  
 
Not having access to patient records was a drawback. Instead, this study was 
limited to the information gained from the patient, as well as their PMR and SCR. 
Accessing summary care records was useful to view the ordered prescriptions 
of the participants using other pharmacy services. Thus, all 23 patients gave 
consent to accessing these records, which were checked every month. Checking 
patients’ summary care records was a laborious process as it shows the most 
recent items ordered (hence why it was necessary to check this every month), 
however, it does not show whether this was dispensed to the patient (which 
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would require contacting the patient’s pharmacy). Contacting each patient’s 
pharmacy was not feasible for this study due to the time constraints.  
 
All information was obtained using a structured protocol based on the GOLD 
(2017) guidelines. The SRP ensured that all outcome measures were collected 
by checking questionnaires and forms before the end of each consultation. 
Response rates to questionnaires were high and any missing information was 
followed-up by the pharmacist, resulting in a 100% response rate. All data were 
collected within the consultation. It took one-month to analyse the data.  
 
The independent assessment of clinical recommendations made by a second, 
non-specialist pharmacist resulted in 29% and 40% less documented 
suggestions, 55% and 60% of these were acted upon, in the IPC and TC group, 
respectively. However, all recommendations made by the second pharmacist 
were made by the SRP. A similar outcome occurred for interventions not 
requiring a prescriber. More interventions were made by the SRP, however, this 
time more patients from the IPC group implemented these interventions than the 
TC group (SRP - 69%, 59%; second pharmacist – 76%, 70%, respectively).  
 
During the study, if the GP/RNS agreed to change their medication and/or 
device, the patient received counselling in the form of a NMS. This was 
conducted on 10 of the 25 patients from Drugs4Delivery pharmacy. At the 6-
month follow-up patients were reassessed in-person, in the pharmacy 
consultation room. All outcome measures were re-measured, and any 
medication changes were noted.  
  
5.5 Data Collection 
5.5.1 Baseline Characteristics  
Participants’ median CAT score was 25 with an interquartile range (IQR) of 
16.32, which reflects the variation in patients’ condition severities. The CAT 
score for the IPC group was slightly higher (worse) than the TC group (26 vs. 24, 
respectively). The pulmonary function tests were similar between the two groups, 
with an overall mean (SD) post-bronchodilator % predicated FEV1 of 51.9 (13.7). 
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The Visual Analogue Scale (EQ-VAS) had a mode of 50 and a range of 60, with 
negative kurtosis (platykurtic distribution). Participants’ oxygen saturation had a 
median of 97.0%, and was negatively skewed, which indicates that the majority 
of patients were clustered around the higher values of oxygen saturation.    
 
In relation to exacerbations in the previous 6-months, participants reported a 
mean (SD) of 1.35 (1.10) of the number of oral steroid courses taken. 79.2% of 
patients reported having one or more GP visits in the previous 6-months (with a 
mode of 1), approximately half of which were attributable to their COPD (see 
Figure 33). Furthermore, 22.9% of participants were admitted to hospital in the 
previous 6-months. Only 10 (20.8%) participants were in possession of a rescue 
pack and just 3 (6.3%) had a self-management plan. The majority of patients 
were categorised in the GOLD group C quadrant (low symptom severity, high 
exacerbation risk) or D quadrant (high symptom severity, high exacerbation risk) 
(see Figure 19). 
 
 
In terms of treatment regimen, the IPC group had more participants taking 
mucolytic agents than the TC group (11 and 4, respectively). The majority of 
patients were prescribed an ICS, alone or in combination, within their treatment 
regimen (81.3%). More specifically, over half of patients were prescribed LABA-
ICS (54.2%), 10.4% were prescribed ICS alone and 18.8% were prescribed the 
LABA-LAMA-ICS combination. The preferred and relatively new LABA-LAMA 
combination was only prescribed for a minority of patients (10.4%). 22.9% of 
patients were undergoing oxygen therapy and only 6.3% had previously 
undergone surgical interventions. Pulmonary rehabilitation had been attended 
by 33% of participants and had a SD of 0.48.  
 
5.5.2 Interventions 
There were 185 recommendations made in total, 83 of which required a 
prescriber to make the intervention. Of these, 24% were acted upon by the 
prescriber (IPC - 23.8%: TC 24.3%). Each patient received a median of 2 
interventions that required a prescriber, with an IQR of 2. Recommendations for 
switching inhaler device, stopping a medicine and adding a medicine were fewer 
in the IPC arm compared to the TC arm. Furthermore, provision of a COPD self-
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management plan was similar between the two arms (23 IPC versus 22 TC; X2 
0.356, p = 0.551; Fisher’s Exact Test). Patients not possessing a COPD 
management plan at baseline were issued one after their consultation. 
 
Patients in the IPC group received fewer smoking cessation interventions than 
TC (8 versus 11 patients respectively; X2 1.505, p = 0.556; Fisher’s Exact Test). 
Lifestyle advice (exercise, weight management and healthy eating) was given to 
7 patients in the IPC group compared to 9 in the TC group (X2 0.375, p = 0.540; 
Fisher’s Exact Test). The pharmacist’s referrals to pulmonary rehabilitation, GP 
and secondary care were 29.2%, 4.2% and 0% in the IPC arm, respectively, 
compared to 33.3%, 4.2% and 4.2% in the TC arm, respectively. There were 
10.5% more patients who actually went to pulmonary rehabilitation in the TC arm 
compared to the IPC group. No intervention was necessary for 2 patients in the 
IPC group compared to only 1 in the TC group (X2 0.356, p = 1.000; Fisher’s 
Exact Test) (see Appendix 9.8 in section 9.8 for summary table of interventions). 
 
5.5.3 Outcome Measures 
The following between group comparisons are illustrated as this could be used 
to inform future studies or for pooling results in a systematic review. Since not all 
data were normally distributed, the non-parametric tests, Mann-Whitney U and 
Wilcoxon signed-rank, were used to determine whether two independent 
samples or related samples, respectively, were selected from populations having 
the same distributions (Fagerland, 2012).   
 
Figure 26, Figure 27 and Figure 28 in Appendix 16, reflect the improvement in 
patients’ inspiratory flow rate after receiving counselling through both groups. 
Table 18, also in Appendix 16, is supplemental information in order to indicate 
the required inspiratory flow rate for each inhaler. Counselling on the correct 
inspiratory flow rate when using MDIs achieved a reduction (positive indicator) 
in the mean inspiratory flow rate from baseline to follow-up (IPC, 69 down to 25; 
TC, 53 down to 32). A similar effect occurred with the HandiHaler device, where 
the inspiratory force significantly lowered from before counselling was offered at 
baseline to the 6-monthly follow-up (IPC, 51 down to 34; TC, 58 down to 26). 
The opposite effect occurred with the Turbohaler, where the inspiratory force 
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actually increased (positive indicator) from baseline to endpoint (IPC, 51 up to 
66; TC, 46 up to 62).  
 
At the 6-month follow-up, only 3 participants (2 from IPC and 1 from the TC 
group) had an inspiratory force that was too slow, an improvement on baseline 
where there were 5 from IPC and 7 from the TC group (see Figure 27 and Figure 
28, in Appendix 16). These 3 participants were using the Turbohaler and 
Spiromax device, which require a higher than average inspiratory force. All 
patients in both groups demonstrated an inspiratory force that was within the 
correct range for their inhaled devices (see Figure 8). This was also helped by  
switching patients to a more appropriate inhaler device when indicated. 
Furthermore, at follow-up, there were 6 patients (3 from each group), who had 
an inspiratory force that was too fast for using a MDI. There were 12 participants 
at baseline (6 from each group) with fast inspiratory force, which were corrected 
for all participants directly after counselling.  
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Figure 8: The patients’ mean Inspiratory Flow Rate via various inhaler 
devices tested at the 6-month follow-up without subsequent counselling. 
The bars indicate the correct inspiratory flow rate for each device.  
IPC, In-Person Consultation; TC, Tele-Consultation; MDI, pressurised metered dose 
inhaler; Acc, Accuhaler; TH, Turbohaler; EB, Easi-Breathe; EH, Easyhaler; Resp, 
Spiriva respimat; Ell, Ellipta; Spir, Spiromax. 
 
 
 
  
  
121 
Data from the summary care records and/ SCR showed that no participant 
reported less than 25% adherence in either group. There were slight differences 
in mean scores for the MARS questionnaire between participants allocated to 
the two groups at baseline with regards to their medication adherence behaviour 
(See Figure 9 below and Figure 29 and Table 21 in Appendix 16).  
 
 
 
 
Figure 9: A graph showing the frequency of percentage adherence rates to 
participants’ inhaled device/s in the two arms, based on PMR / summary 
care records.   
 
IPC, In-Person Consultation; TC, Tele-Consultation. 
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Baseline, phlegm and ‘poor sleep quality’, which are two indicators (out of eight) 
of CAT score, were higher in the IPC group (negative outcome) than the TC 
group. However, when taking all eight indicators into consideration, there was 
little difference at baseline (Figure 10Error! Reference source not found.). In 
sufficiently powered studies, scores can be used to show any differences 
between study arms, for example, in the feasibility study, when controlling for 
baseline CAT, there was a greater reduction in CAT score in the IPC group by 
0.55 units (95% CI -1.43 to 0.33), although the difference between the two 
groups was not statistically significant (p=0.215). The type of data that compares 
both groups can be illustrated as below (see Figure 10 below and Figure 30 and 
Figure 31 in Appendix 16).   
 
 
Figure 10: The average scores of the 8-items that constitutes the CAT score 
at baseline and endpoint for both groups.  
 
IPC, In-person consultation; TC, tele-consultation; CAT, COPD Assessment Test 
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The mean FEV1 between the IPC and TC groups were similar, Mann-Whitney U 
= -0.747, p=0.459 and Mann-Whitney U = -0.828, p=0.29, respectively. The IPC 
and TC groups were similar at 0-months and 6-months with regards to the mean 
number of steroid courses taken in the previous 6-months compared to the 6-
month study duration; independent samples t-test = 0.130, p=0.897 and 
independent samples t-test = 0.093, p=0.972 (Table 23 in Appendix 16). In the 
IPC arm, 3 participants self-reported that they quit smoking by the 6-month 
follow-up compared to only 2 participants in the TC arm.  
 
 
 
Figure 11: The mean change in lung function (FEV1) when comparing IPC 
and TC groups, over the study duration.  
 
IPC, In-Person Consultation; TC, Tele-Consultation; FEV1, forced expiratory volume in 
one second. 
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There was little difference between IPC and TC groups during the 6-months prior 
to baseline and the 6-month study period with regards to mean steroid courses 
in the previous 6-months compared to the 6-month study period. This was also 
the case for hospital admissions (see Figure 33 in Appendix 16). 
 
 
 
 
 
 
Figure 12: The GOLD (2017) ABCD assessment tool.  
IPC, In-Person Consultation; TC, Tele-Consultation 
 
 
The baseline data for the number of participants falling into each quadrant were 
indicated at the top of each quadrant; the first figure is at baseline and the second 
figure after the arrow is at follow-up. Three participants dropped out from the IPC 
group and four dropped out from the TC group. This tool demonstrated that 
participants in both groups have increased in the B quadrant with a reduction in 
the C quadrant and a slight reduction in the D quadrant (see Figure 12 and Figure 
13).  
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Figure 13: The percentage number of participants in each quadrant for 
both the IPC and TC groups throughout the study duration.  
IPC, In-Person Consultation; TC, Tele-Consultation; 0m, 0-months; 6m, 6-months 
 
 
At baseline (0-months), the effect of pharmacist TCs on HR-QoL, using the EQ-
5D-5L assessment (Lin et al., 2014), was similar to the pharmacy IPC group at 
0-months (Mann-Whitney U 317.0, p=0.911). At the 6-month follow-up, the effect 
of pharmacist TCs on HR-QoL, was also similar to the IPC group at 6-months 
(Mann Whitney U 299.0, p=0.674) (see Table 23 in Appendix 16). However, 
when analysing the mean scores of the components of EQ-5D-5L, the 
component ‘patients carrying out usual activities’ was less in the TC group than 
in the IPC group at the 6-month follow-up (see Figure 34 in Appendix 16). Apart 
from ‘usual activities’ and ‘pain/discomfort’ within the IPC arm of the EQ-5D-5L 
assessment, both groups only slightly improved from baseline to the 6-month 
follow-up (see Figure 34 in Appendix 16). The EQ-VAS results at baseline 
between both arms were similar (see Table 22 in Appendix 16). Both the IPC 
and TC arms decreased over the study duration (mean difference 3.68 and 5.78, 
respectively). 
 
The effects of the New Medicines Service did not reveal any significant effect on 
QoL compared to those that did not have a NMS.  
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5.5.4 Economic evaluation 
The number of pharmacy visits by participants increased during the study period 
by 42.9% and 53.5% in IPC and TC groups, respectively. This is illustrated in a 
histogram, which shows the number of participant visits to a pharmacy, walk-in-
centre, GP and hospital (see Figure 14). The other notable change was the self-
reported 30% and 38.6% decrease in the number of GP visits during the study 
duration in IPC and TC groups, respectively. Costs were assigned to each of 
these visits (See Table 13 and Figure 15), and these costings were estimated 
according to the methods set out by Curtis (2013). The total cost of the 
intervention was estimated by summing up the cost of training, equipment and 
the bi-annual review (see Table 14). The total other NHS costs were estimated 
by summing the costs associated with each of the self-report items of resource 
use, not including days off sick (see Figure 15).  
 
 
 
 
Figure 14: The number of visits made to a pharmacy, walk in centre, 
general practice and hospital within each group 6-months prior to study 
(indicated as “0-months”) and over the duration of the 6-month study 
(indicated as “6-months”).  
 
IPC, In-Person Consultation; TC, Tele-Consultation; 
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In both groups, the number of participants visiting a pharmacy increased during 
the study period, however, the number of GP visits decreased. The costs 
increased when comparing the period 6-months prior to the study with the 6-
month study period. Had the uptake of the recommendations been 100%, this 
would have still resulted in an increase in costs, but this would have been to a 
lesser extent. There was little difference in cost between IPC and TC groups 
(Figure 16 and Figure 17). However, the study would have cost considerably 
more had domiciliary visits taken place ahead of the IPCs or TCs (Figure 16).   
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Table 13: The study costs to the participants and to Drugs4Delivery 
pharmacy.  
 
 
 
*Based on Burns et al. (2016), where the cost of home visits for pharmacists were based 
on averaging other HCPs unit cost/ home visit (conservative estimate). A GP home visit 
costs £69 more than a regular consultation in their surgery, whereas a home visit for a 
Physio or Allied Health Professional costs £24 more.  
 
Table 14: Total cost of interventions  
 
 
* Curtis (2013) 
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Figure 15: Total other NHS costs - Unit costs attached to different 
components of resource use.  
 
*Curtis (2013) 
**Taken from the National Schedule of Reference Costs 
***Based on the Office for National Statistics Annual Survey of Hours and Earnings  
****Estimate based on Schomberg et al. (2011).  
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5.5.4.1 Calculating Costs 
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Figure 16: The total NHS costs on the different consultation methods 6-
months prior to the study and 6-months during the study.  
IPC, In-Person Consultation; TC, Tele-Consultation. 
 
 
  
 
Figure 17: The estimated mean unit cost per participant 6-months prior and 
during the study between the two study arms.  
 
 
 
IPC, In-Person Consultation; TC, Tele-Consultation; 
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Figure 18: The mean cost of medication per participant per month at 
baseline, endpoint and the proportion that were in-line with the pharmacist 
recommendation between the two study arms.   
 
IPC, In-Person Consultation; TC, Tele-Consultation;  
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6. Discussion 
This chapter will begin by recapping the purpose of the study (see Section 6.1), 
followed by a summary of the results in relation to the aims and objectives (see 
Section 6.2). The results will be examined and explained, more broadly, in 
relation to existing research and the importance of this study’s findings, in order 
to assess its contribution within this domain (See Section 6.3). The study itself 
will then be critically appraised and the associated strengths and limitations will 
be discussed (see Section 6.4). Finally, implications and practical applications of 
the study will be made (see Section 6.5).  
 
6.1 Purpose of the Study 
A feasibility study was conducted with patients randomised to intervention or 
treatment as usual, in a community pharmacy-based COPD clinic. This ground-
breaking study aimed to establish further work required to proceed to a definitive 
trial to test the impact of pharmacist interventions via TC amongst patients with 
COPD. The objectives were to determine feasibility of the rate of patient 
recruitment, retention, acceptability of TC and practicalities and completeness of 
data collection for outcome measures used to assess COPD control and 
management.  
 
There are a proportion of inaccessible COPD patients that can only be reached 
via telephone, which lacks the visual communication element, or alternatively a 
domiciliary visit, which is time-consuming. The concept of TC has the potential 
to be used to improve accessibility for these harder-to-reach patients. Accessing 
remote patients in this way may help alleviate patients’ anxiety and insecurities 
associated with COPD (Mathar et al., 2015).  
 
It is essential to explore various approaches to managing COPD, given its impact 
on HR-QoL and the considerable drain on healthcare systems (GOLD, 2017). 
The innovative approach used to deliver services in this study is relevant, given 
the rapidly developing technology and the pressures to ensure high quality of 
care to an aging population. In addition, community pharmacy is recognised as 
a highly valuable but underutilised resource.  
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It is well known that community pharmacy faces turbulent times in England, with 
funding cuts and unpopular reforms. Contractors are having to adapt their 
business plans and increase their operational efficiency in order to survive. Most 
pharmacy businesses can no longer rely on essential services (such as 
dispensing medicines and appliances) to stay afloat, rather, they must diversify 
in order to generate alternative income streams from a range of sources and 
services. In view of this situation, community pharmacy is an untapped resource 
and policymakers should seize the opportunity to invest in these teams to 
achieve health coverage (Cairney and Jones, 2016). 
 
Optimising patients’ medication constitutes the essence of a pharmacist’s 
training both from an undergraduate and postgraduate standpoint. Thus, a 
community pharmacist’s job role should enable them to fully utilise their skillset, 
lest they become clinically deskilled. Since there was a lack of research into the 
effectiveness of community pharmacists providing medicines optimisation 
clinics, and no studies on conducting them via TC, this feasibility study was 
designed to test whether providing community pharmacists with a platform, in 
the form of IPC and TC, to make suggestions/interventions within the ‘medicines 
optimisation’ agenda could be tested in a definitive study to find out whether this 
would impact on patients’ symptoms and their outcomes.  
 
The goal of COPD management is to improve a patient’s functional status and 
HR-QoL by preserving optimal lung function, improving symptoms, and 
preventing the recurrence of exacerbations. This study identified appropriate 
outcome measures and evaluated whether the data could be collected. This was 
in preparation for a future definitive study. Finally, the economic impact of this 
model of service delivery was also determined.  
 
6.2 Summary of results 
The study was conducted in a single pharmacy by one SRP. Participants were 
>35 years with clinician diagnosed COPD and able to communicate in English. 
Participants were willing to be randomised (1:1) to receive an IPC or TC after it 
was explained that the advice they receive would be the same regardless of 
which group they were allocated. It was feasible to measure the patient’s FEV1, 
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inspiratory force, oxygen saturation and BMI during an in-person PC. A sample 
size of 48 participants took 4 months to recruit, with 25 participants recruited 
over 2½ months from the pharmacy customer base (equating to 27% of those 
eligible to enter) and a further 23 recruited from local advertisements over an 
additional 1½ months. The study achieved a satisfactory retention rate; 21 from 
the IPC group and 20 from the TC group (85% retention).  
 
Administering the tools to assess the outcome measures was both practical and 
feasible for TC. Initial response rates to questionnaires were high and any 
missing information was followed-up by the pharmacist to achieve 100%. All 
outcome data were collected within the consultation with no adverse events. It 
took one-month to analyse the data. This study found that 65% of participants 
were willing to use TCs in future, and this was higher in the TC group (71%) after 
participants had experienced this approach. On average, the set-up time 
required for TC, was an additional 10-minutes per participant, which included 
instructions on how to use the Skype™ application. During the TCs, the 
transmission was interrupted on 3 separate occasions (12.5%). During one of 
the 3 interruptions, the TC had to be rescheduled. 
 
Unexpectedly, the total NHS cost of offering this COPD pharmacy clinic was 
estimated as being higher during the 6-month study duration than the 6-months 
prior to the study, for both the IPC and TC groups. Finally, it was found that 
similar recommendations were made by the second community pharmacist, who 
was not a SRP. This result is useful for future, multi-centred studies, where 
pharmacists may not be specialists in respiratory therapy. 
 
6.3 Discussion of results 
This feasibility study was the first of its kind in several aspects and it is important 
to contextualise the findings within the limited body of knowledge in this field. 
The innovative aspects of the study included: reviewing patients with COPD 
using TCs with the patient at home and the pharmacist residing in the 
consultation room of their community pharmacy; comparing COPD TCs to IPCs; 
and carrying out a COPD service from a distance-selling internet pharmacy. 
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In order to situate this new way of working, the two key areas that were focused 
on in the literature review were how pharmacists contribute to the management 
of COPD (Jarab et al., 2012; Khdour et al., 2009; Tommelein et al., 2014; van 
Boven et al., 2016; Weinberger et al., 2002; Wright et al., 2015) and how HCPs, 
in general, have utilised TCs within their practice when caring for patients with 
COPD (Schou et al., 2013; Sorknaes et al., 2011; Udsen et al., 2017). There was 
particular focus on measureable aspects, namely, interventions, COPD control, 
lung function, exacerbations, admissions, inhaler technique, adherence, HR-
QoL, acceptability of TCs and cost.  
 
The headings in this section are organised in a similar sequence to the previous 
chapter (Chapter 5 - Results). The study findings will be rationalised by offering 
insights into the feasibility of conducting a complex intervention involving 
pharmacy COPD clinics in terms of recruitment and retention (see Sections 6.3.1 
and 6.3.2), acceptability of TCs (seen Section 6.3.3), practicalities of study 
implementation (see Section Error! Reference source not found.) and data 
collection (see Section Error! Reference source not found.) and explained 
more broadly, in relation to existing research. The importance of the findings will 
be discussed in order to assess their contribution within this domain.  
 
6.3.1 Patient Recruitment  
Given that this was a feasibility study, the sample size is often a pragmatic 
balance between information needs and resources (Eldridge et al., 2016). 
Typically, up to 40 patients are recruited for a feasibility study (Craig et al., 2008). 
 
Recruitment of Drugs4Delivery patients was achieved via purposive sampling of 
those who were prescribed inhalers. Patients prescribed salbutamol and 
beclomethasone would be assumed to be asthmatics, however, it was soon 
realised that several of these patients were prescribed an out-dated or incorrect 
treatment regimen for COPD. In order to avoid the risk of not capturing eligible 
patients, all patients on inhalers were asked their diagnosis via telephone before 
inviting them to the study. Patients were only included in the study if they had 
previously been diagnosed with COPD or ACOS. Future studies could use a 
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similar recruitment strategy by using their PMR filter to identify all the pharmacy 
patients that use inhalers.  
 
The most notable challenge of this research study was recruiting the required 
number of patients from a single community pharmacy’s patient base. A 
drawback of this study was that just 25 patients could be recruited via this 
method. This was overcome by adapting the approach half way through, via 
advertising more widely in local newspapers. Thus, the recruitment target was 
met. The advertising strategy mitigated against the limitations of the initial 
recruitment strategy and this approach could be incorporated from the outset in 
any larger,  future studies. In addition, those participants that did not turn up to 
their baseline consultation, attended after they were re-scheduled. This finding 
should inform future studies to reschedule missed appointments.  
 
Another strategy employed in this study was to involve clinicians in recruiting 
participants; however, none of the participants were recruited via this route. 
During recruitment, it was challenging to get surgeries to agree to refer patients 
to this study. Those that agreed, in principle, to refer patients to the service, 
wanted authorisation by management first. However, their managers seemed 
reluctant to agree to take part in an unproven service, probably due to it not being 
part of their care pathway. Future studies should be mindful that this could result 
in selection bias as participation in studies is usually accepted by motivated 
patients.  
 
In this study, participants recruited via advertising were either keen to be 
involved in research or were keen to consult a SRP and learn whether there were 
other treatment options available to them. The lack of referrals from general 
practice could potentially be circumvented by presenting the study proposal, in-
person, to all the local surgeries and involving clinicians at an earlier stage in the 
research design. Ideally, future studies should aim for referrals from a range of 
surgeries to counter potential sampling errors as a result of variability in the 
management of COPD across practices.  
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6.3.2 Patient Retention 
A high retention rate was achieved in the study. A source of bias for prospective 
studies is the potential for dropouts, which was low in this study (positive effect), 
as significant efforts were made to avoid this. These included, negotiating 
treatment decisions with the patient and conducting the clinics in a professional 
setup as advocated by Ali Murshid and Mohaidin (2017). Other factors that may 
have contributed to the low number of participants being lost to follow-up could 
have been existing rapport with Drugs4Delivery patients and informing 
participants that they would be reassessed in 6-months’ time in order to 
determine any change in their condition. This latter information may have 
motivated them to find out about whether they had gained any benefits from the 
interventions after 6-months.  
 
These strategies could be used to inform the design of future multi-centred 
studies in order to minimise attrition, although recruiting via the pharmacy’s 
patients should be interpreted with caution, as a larger study involving multi-
centres may vary from this single-site study. Although, the multi-site approach 
improves recruitment and retention potential compared to single site, factors 
such as managing research, ensuring consistent processes and high-quality 
data, and having clear communication processes between 
researchers/clinicians, become crucial. These issues require a significant 
amount of planning and meetings for each research site, which involves going 
through protocol, standard operating procedures and processes (Lijmer et al., 
1999).  
 
6.3.3 Acceptability of Tele-Consultations 
An anonymised feedback questionnaire was administered to each participant (in 
both groups) in order to offer their opinions of the clinic. From the questionnaire 
used, it was determined that participants in the TC group were more receptive 
to using TC after having experienced its convenience during the study (see 
Figure 7 for the actual numbers). It was thought that the older participants would 
be resistant to TC. However, this study found they became more amenable once 
they had been supported through the process of using it. From the study, it was 
evident that patients generally felt more comfortable talking from within the 
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comfort of their home than in-person within a consultation room. Patients 
generally commented on the value of having a TC, especially during an 
exacerbation or for immobile patients. This was supported by Vitacca, Montini 
and Comini (2018) who reported that the best outcomes came from those 
dedicated to more severe cases, frequent exacerbators with multimorbidity and 
limited community support. Thus, selecting these ideal candidates could be the 
key to optimising the use of TC in future RCTs. 
 
The research literature on TCs is sparse, but has begun to accumulate (Armfield 
et al., 2015). Sorknaes et al. (2011) reported high patient satisfaction, which was 
also reported in other earlier studies (Mair et al., 2005; Rahimpour et al., 2008; 
Whitten and Mickus, 2007). Although these studies had a similar demographic, 
Rahimpour et al. (2008) and Whitten and Mickus (2007) also included patients 
with congestive heart failure. Tatari (2016) reported that 12% of patients 
experiencing TCs for the first time thought they would benefit more from an IPC 
than a TC and 9.5% did not consent to having a TC, as they preferred to have 
an IPC; however, this was not specific to COPD patients, and were a younger 
demographic on average (see Figure 36 and Figure 37 in Appendix 19). Of the 
185 patients screened during this feasibility study, only 8 (4.5%) specifically gave 
the reason of not wanting to use TC, however, this could have been more since 
35 patients did not give a reason for declining to participate. Offering a tablet 
device to those without Skype access may have led to a higher acceptance rate 
(see Figure 35 in Appendix 18). Participants in a study by Gund et al. (2013) also 
reported positive experiences with TCs, and patients found the technology easy 
to use and better than ordinary phone calls, although, this was not always the 
case with motivating staff. Future research should uncover patient’s views on 
‘TC’ and ‘the acceptability of this complex intervention for the management of 
COPD’ to add to the limited body of knowledge, from a qualitative perspective.  
 
There were some notable differences experienced by the pharmacist between 
the two groups; most notably, during an IPC when the patient smelt of smoke, it 
was likely that they were either a smoker or they experienced passive smoking. 
However, this cannot be picked up when conducting TCs. Furthermore, for TC 
to be successful, a clear uninterrupted transmission is required, a significant 
limitation of this medium. Losing transmission means the consultation cannot 
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take place and must be rescheduled. From the pharmacist’s perspective, 
organising the IPC was a great deal easier than the TCs, especially if the 
participant did not have TC access or did not know how to work it. IPCs are the 
norm for patients when seeing their HCP, whereas TC seemed overwhelming if 
they were new to the concept.  
 
6.3.4 Practicalities of study implementation 
This research study delivered a complex intervention to assess the feasibility of 
a community pharmacist conducting a COPD clinic via TC and comparing this 
with IPC. Complex interventions are interventions that contain several interacting 
components, but they have other characteristics that evaluators should take into 
account, for example, the number of interacting components within the 
experimental and control interventions (Craig et al., 2008). There are a number 
of intervention components that have been shown to be effective in the literature 
review (see Chapter 3); these include advice on trigger avoidance, adherence, 
inhaler technique, education on COPD and education on medication.  
 
A complex intervention is delivered using a protocol and individual patients’ 
knowledge, understanding, adherence etc are responded to according to the 
protocol. Considering that each participant may require different aspects of their 
condition to be addressed, interventions were expected to differ between 
participants. Craig et al. (2008) discussed the importance of the reproducibility, 
of a complex intervention, however ‘complicated’ it may be. They stated that “a 
full description of the intervention is required, and an understanding of its 
components, so that it can be delivered faithfully during the evaluation, allowing 
for any planned variation.” In the context of this trial, TC was the ‘intervention 
arm’ used (planned variation), whereas ‘usual care’ was conducted via IPC.  
 
The management of COPD should be based on individualised assessment, 
ensuring personalisation to the individual needs of the patient (Singh et al., 
2017). Thus, COPD may be treated differently by different physicians or 
depending on the patient’s symptoms on that day, due to the variability of the 
condition. A limitation of intervening with the COPD condition is that certain 
recommendations to the prescriber may not be how they would like to treat their 
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patient (having access to patient notes would indicate the prescriber’s 
intentions).  
 
This study sent recommendations via postal mail for both groups and lack of 
uptake brings into question whether some recommendations actually reached 
the prescriber and were actually read. Until read-write access to patient notes is 
implemented, future studies could try alternative communication channels such 
as phoning the practice pharmacist or emailing the surgery. Future studies 
should also look to establish the reasoning for not acting upon the 
recommendations. 
 
In a bid to improve uptake of recommendations, there were occasions where the 
SRP empowered patients to take the recommendations forward with their 
GP/RNS. This appeared to improve uptake of interventions in several instances, 
however, communicating via patients is not the recommended pathway. In these 
scenarios, the SRP felt frustrated for the patient, and despite having a 
prescribing qualification, there is no current pathway to prescribe an alternative 
inhaler device on the NHS in a community pharmacy setting. Zermansky et al. 
(2006) demonstrated that GPs have implemented higher percentages of 
pharmacist recommendations, however, these consultations were care home-
based and included more minor interventions, such as generic switching or 
altering quantities, which this research study did not record as an intervention. 
This was similar in the Lenaghan et al. (2007) study, which involved one general 
practice where consultations were home-based.  
 
There are potentially multiple reasons for the GP not acting on the 
recommendations offered to them. These include: disagreeing with the 
recommendations, considering an unnecessary interference from a pharmacist, 
not logistically receiving the recommendations, considering the 
recommendations as unnecessary, questioning the pharmacist’s clinical 
knowledge, not having time to read the letter or ignoring the letter. One study 
(Wilcock and Harding, 2008) explored the perception of 58 GPs regarding the 
usefulness of the information and advice from the pharmacist; it revealed that 
60% of pharmacists’ recommendations were generally useful, though only 20% 
considered the recommendations to be a priority. Clear limitations of this study 
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were the relatively small sample of GPs surveyed and the high response from 
GPs from dispensing practices (considered to have a different view of community 
pharmacy).  
 
The GP(s) may feel that, since this is an innovative study with no evidence base, 
there is no need to be involved until it is part of the community pathway. The 
GP(s) may feel that engaging with such clinics could take responsibility away 
from the repertoire of services they provide and could lead to other services 
being provided by pharmacy e.g. influenza vaccination. Also, since the 
investigating pharmacist had no access to patient notes, the recommendations 
offered may have previously been trialled by the patient without success.  
 
Of the recommendations made to the GPs/RNP, approximately a quarter were 
actually implemented (see Table 17 in Appendix 15). This relatively low uptake 
could be due to the pharmacist working remotely and not having access to the 
patient’s notes (See Section 6.4.5 for comparisons to a comparative study). 
These barriers could be circumvented by building stronger relationships with the 
local surgeries and agreeing a suitable communication avenue. Obtaining read-
write access would enable better transparency for the pharmacist and thus 
inform their recommendations. It was found that this study had a higher uptake 
of recommendations from surgeries that had an existing strong working 
relationship with the pharmacy. Future studies should look to build on these 
relationships and obtaining read-write access to help increase the uptake of 
recommendations.  
 
Uptake of interventions not requiring a prescriber, which were made directly to 
the patient, (see Figure 24 in Appendix 15 for the actual numbers) were only 
slightly more than the uptake of recommendations made to the prescriber (see 
Figure 23 in Appendix 15). In order to shed light on this finding, it is necessary 
to analyse and compare the nature of the recommendations made directly to the 
patient with those made to the prescriber (see Table 17 in Appendix 15). The 
recommendations made directly to the patient included smoking cessation as 
advocated by van Eerd et al., 2015 and lifestyle advice, both of which required 
personal willpower to implement, in contrast to their prescriber altering their 
medication regimen. The relatively low intervention uptake may have also been 
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the result of the pharmacist not prioritising these interventions ahead of the 
medication review. In this study, smokers were referred to smoking cessation 
services whereas a future trial may address this in-house by scheduling a 
separate consultation within the pharmacy.  
 
Currently, no treatments aside from lung transplantation, oxygen therapy (when 
appropriate) and smoking cessation have been shown to improve lung function 
or decrease mortality (Safka and McIvor, 2015). During the study, similar 
numbers of patients from the TC group quit tobacco smoking compared to the 
IPC group, which suggests that TC was not a barrier in this regard. This is even 
more important as tobacco smoking is a common risk factor for many co-
morbidities, including coronary heart disease, heart failure and lung cancer. Only 
one person was recommended oxygen therapy by the pharmacist due to their 
oximetry readings and later went on to commence therapy. Pulmonary 
rehabilitation is a key non-pharmacological component that shows improvement 
in QoL in patients with COPD (Lacasse et al., 2006). There were referrals to 
pulmonary rehabilitation either directly or via the GP. Directly referring patients 
achieved a 100% success rate in attendance, whereas only a third attended via 
the GP. However, direct referrals to pulmonary rehabilitation are not customary 
practice in community pharmacy.   
 
Apart from Wright et al. (2015), studies that conducted similar pharmacy clinics 
(Jarab et al., 2012; Khdour et al., 2009; Tommelein et al., 2014; van Boven et 
al., 2016; Weinberger et al., 2002) did not indicate the number of referrals made. 
Although the study by Wright et al. (2015) did not involve conducting TCs, the 
type of intervention and context were comparatively similar; they referred 18.2% 
of patients following a pharmacist consultation compared to 4.2% within this 
study. This difference can be explained by the current feasibility study making 
actual recommendations to the prescriber via a letter, rather than just referring 
the patient for the GP to decide on a recommendation, as was the case in the 
study by Wright et al. (2015). This feasibility study considered referring each and 
every time a recommendation was made, which may have increased the uptake 
of interventions, however, this idea was discounted as it would have likely 
compounded the footfall into general practice, a challenge this study was 
seeking to alleviate. Another notable difference between this and the other 
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studies reviewed within the ‘COPD consultations’ domain was the recording of 
whether or not the advice given to the patient was actually implemented once 
the intervention had been made. None of the studies monitored the number of 
NMSs conducted subsequent to a medication review.  
 
The number of recommendations made to the prescriber in this feasibility study 
was lower than previous studies involving pharmacy services (e.g. Wilcock and 
Harding, 2008). Wilcock and Harding (2008) conducted a study monitoring the 
uptake of MUR recommendations, which demonstrated that 56.3% had been 
acted upon by the GP. When Wilcock and Harding (2008) referred patients for a 
medication review, this was classed as a recommendation, whereas the current 
feasibility study actually conducted the medication review (via an IPC/TC). If they 
had not included the 18.4% of medication review referrals as a recommendation, 
it would have brought their recommendations in line with this study, even though 
their study was not specific to COPD (only 3.9% of their recommendations were 
classed as respiratory-related).    
 
Interventions were not documented by Schou et al. (2013), Sorknaes et al. 
(2011) or Udsen et al. (2017), which were the 3 studies included in the literature 
review (Chapter 3) that examined the effects of HCPs conducting TCs. From the 
studies within the literature review that focused on pharmacist interventions on 
COPD control, only Wright et al. (2015) documented the specific detail and 
number of interventions, however, adherence to these interventions at follow-up 
was not recorded. Furthermore, smoking cessation advice was given to 36.3% 
(Wright et al., 2015), compared to 39.6% in this study. Lifestyle advice was given 
to 33.3% (Wright et al., 2015) of participants compared to 31.3% within this 
study.  
 
During the PC of this current study, the appropriateness of patient’s inhaler 
device(s) was assessed using the In-Check DIAL meter. This device helps to 
establish the suitability of the inhaler device based on the patient’s inspiratory 
force capabilities. If their inhaler device was inappropriate, an alternative inhaler 
device was suggested to their GP.  A barrier to TCs was in the assessment of 
patients’ inspiratory force using this device; from a practical perspective, this 
measurement had to take place in-person for all participants, as the pharmacist 
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needed to instruct the patient on its use. Wright et al. (2015) documented that 
99.5% of inhaler checks were made, of which 68.3% resulted in changing their 
inhaler technique, compared to the 100% and 58.3%, respectively, made for all 
patients within the current feasibility study. These results are similar and 
demonstrate the importance of inhaler checks.  
 
Again, these results are fairly consistent and provide some assurance that TCs 
are not a barrier for pharmacists to making interventions/recommendations when 
compared to IPCs and give an indication of what can be expected in future 
studies. These findings are of importance, particularly when reviewing immobile 
patients, who are harder-to-reach and often deprived of pharmaceutical advice. 
To enable an all-inclusive NHS, pharmacists who may otherwise only access 
these patients via telephone or a rare domiciliary visit, could use TCs when 
advising immobile patients with its visual advantage over telephone 
communication and bearing in mind the time and costs of travel that domiciliary 
visits inevitably incur (see Figure 16 in section 5.5.4).  
 
As a SRP, the researcher conducted the consultations and mitigated against 
potential sources of bias by concealing the randomisation of participants, as well 
as using validated and objective tools wherever possible. The process of 
randomisation into the respective groups proved acceptable to patients, thus will 
be feasible to conduct in a future definitive trial.  Employing an independent SRP 
to conduct these clinics or analyse the data would be ideal if funding was not a 
barrier. This would also reduce the risk of ‘vested interest bias’ that could be 
attributed to the researcher. It is crucial to mitigate against the risks that ensue 
in having an inside researcher. Also, it was not possible to blind the SRP or the 
participant to which group they were allocated (open-labelled trial). This issue 
was mitigated against by keeping systematic differences between the two groups 
to a minimum (performance bias); this was achieved by observation by another 
pharmacist and standardising the consultations of the two groups, where the only 
major variability was conducting the consultation via IPC or via TC.  
 
The practicalities of study implementation will be elaborated on further, within 
Section 6.4 
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6.3.5 Data collection 
6.3.5.1 Inhaler technique 
With the current wealth of new inhalers available, the need for insight into optimal 
education on inhaler use is more important than ever. There is no official training 
to validate that a HCP can train patients on the use of their inhaler, however, 
models exist, such as the four step Peyton model (Nikendei et al., 2014), which 
are designed for a 1:1 teacher: student ratio. Conversely, there are no validated 
inhaler technique courses for HCPs (Basheti et al., 2014). With that in mind, 
HCPs’ knowledge regarding inhaler technique seems to be inadequate 
(Baverstock et al., 2010). It is the duty of all HCPs to check patients’ inhaler 
technique.  There are no known comparisons between inhaler technique training 
between different HCPs, however, since ‘medication optimisation’ is the essence 
of a pharmacist’s role, it is a task that the pharmacy profession should take a 
lead in.   
 
During TC, inhaler technique was successfully demonstrated, by being side-on 
or at an angle to the camera (in order to keep an eye on the patient and so that 
the patient could clearly view each step). A barrier to TC was if the patient was 
out of view of the camera. This occurred on two occasions and they were asked 
to re-demonstrate their technique. In future trials, patients should be advised that 
if they can see their face in the corner of the screen, then that indicates they are 
within view of the camera.  
 
Poor inhaler technique is a critical factor preventing patients with COPD from 
receiving the optimal benefits from their prescribed medications (Aggarwal and 
Gogtay, 2014), and this increases with age and with COPD severity 
(Wieshammer and Dreyhaupt, 2008). However, educating patients on the correct 
inhaler technique is often overlooked by busy HCPs (Bonini and Usmani, 2015). 
The findings in this study, that inhaler technique could be demonstrated and 
checked during TCs, are substantial for the preparation of future, multi-centred 
RCT/s designed to assess the effects of HCPs looking to optimise the use of 
remote patients’ medicines, whilst saving on travel time and cost of travel. Unlike 
telephone consultation (Pothirat et al., 2015), it is possible to see the patient 
demonstrate their inhaler technique. Also, GOLD (2017) guidelines recommend 
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that inhaler technique should be checked at each consultation with a HCP, 
however, each consultation may be infrequent and often patients forget to bring 
their inhaler(s) to clinic. TC would remedy this problem, as their inhaler is likely 
to be at home. To the immobile patient, it would enable the option of checking 
their inhaler technique between domiciliary visits.  
 
There were no patients with 4 or more inhalers at endpoint as a result of SRP’s 
interventions in both groups. All recommendations made were evidence-based 
and followed the GOLD (2017) guidelines, which mirrored the local guideline. 
Prior to any recommendations made to the prescriber regarding appropriate 
inhaler device(s), participants were encouraged to engage in the decision, and 
their preference was strongly considered, as this could significantly affect the 
effectiveness of their inhaler (Hodder and Price, 2009). The findings of this study 
suggest that there is little difference between the two groups regarding the 
prescribers’ uptake of recommendations. However, a notable limitation of TC 
was that the patient’s inspiratory flow rate could not be assessed, unless the 
patient was provided with, and knew how to use, an In-Check DIAL. Even though 
it may be established that a patient has adequate inspiratory force for a device, 
due to the progressive nature of the condition, this may not be the case at a later 
date as the condition can deteriorate. Thus, it was learnt that TCs should not be 
used in isolation, but rather between IPCs.  
 
In order to provide patients with the best advice, all HCPs involved in respiratory 
care must be trained to provide inhaler technique education. It is an enormous 
failing of the NHS that a substantial amount of money is being spent on inhalers, 
yet it is common that HCPs themselves do not have the knowledge to educate 
patients on the exact use of their devices. That said, there are no standardised 
and validated training events to remedy this. However, following the baseline 
interventions of the study, a framework called ‘Inhaler Standards and 
Competency Document’ was published (UK Inhaler Group, 2017) to set, assess 
and support the standards of those initiating inhaler devices. However, it does 
not provide a specific checklist for each inhaler type, but rather, a general 
checklist that differentiates between the pMDI and DPI. This document could be 
useful for future studies.    
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As a profession, pharmacists should see it as their duty to regularly check the 
inhaler technique of patients, especially during MURs in primary care. This study 
demonstrated the need for such education, whether it is conducted in-person or 
via TCs. Once optimised at baseline, inhaler technique score dipped at the 6-
month follow-up point in both groups. This indicated the necessity to re-check 
technique at regular intervals. This study found that inhaler technique was 
generally taught and checked by nurses, which concurs with the results of other 
studies. This should be reinforced by pharmacists, as the expense of incorrect 
inhaler technique will be substantial, especially since the cost of inhalers are 
amongst the highest expenditure amongst medications in the NHS (Mäkelä et 
al., 2013). Klijn et al. (2017b) recommend periodical intervention reinforcement 
and longer follow-up studies.  
 
6.3.5.2 Adherence 
COPD is a disease of aging and elderly patients, who may suffer from cognitive 
impairments, physical, hearing or visual impairment, that may all contribute to 
affect their ability to adhere to their medication regimens (Bonini and Usmani, 
2015). They typically suffer from multiple chronic co-morbidities (see Figure 20 
in Appendix 8) with the associated poly-pharmacy, which itself poses a risk for 
poor adherence. Non-adherence potentially causes increased symptom severity 
and even an increased incidence of exacerbations. Although there are short-
term financial savings when patients do not adhere to their medication (since 
expensive inhalers are not ordered), the long-term financial implications can be 
considerable (Job F.M. van Boven et al., 2014). Thus, counselling on adherence 
to this patient demographic is essential.  
 
Although the long-term decline of lung function in patients with COPD cannot be 
reversed by pharmacotherapy, medications are available to prevent and control 
symptoms, improve health status and reduce the frequency and severity of AE-
COPD (COPD, 2017). Thus, adherence is a crucial factor to achieve these 
clinical benefits, particularly for chronic use. Education must focus on the 
importance of regularly and pertinently using the inhaler (Dhamane et al., 2016). 
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The MARS questionnaire was selected to assess patients’ medication 
adherence in this study, as it offers high validity and reliability (Thompson et al., 
2000). It was successfully administered in both groups and the completeness of 
MARS was checked by the pharmacist. It was found to be user-friendly in this 
setting and was used in many of the included studies within the literature review 
(Chapter 3). However, acquiescence bias may occur in subjective methods, and 
the patient must be encouraged to be open and honest. Where possible, these 
results were validated against objective measures e.g. PMR (discussed further 
in 4.2.7).  
 
Although not adequately powered, there were minimal between-group 
differences in adherence. Thus, early signs suggest TC may not be a barrier to 
adherence. Pharmacists play an important role in improving adherence to 
medication. This is supported by most studies, including Jarab et al. (2012), who 
demonstrated a significant decrease in the proportion of non-adherent patients 
in the intervention group when compared to the control group (28.6% vs. 48.4%) 
at the 6-month follow-up (p=0.05). This was also the case for the study by Khdour 
et al. (2009), where a higher proportion of patients in the intervention group who 
received counselling on adherence, exhibited higher adherence scores than the 
control group patients (no counselling) (81% vs. 63% and 77.8% vs. 60%, at 6-
month and 12-months, respectively) which was also similar in the Weinberger et 
al. (2002) study. Wright et al. (2015) and Tommelein et al. (2014) demonstrated 
significantly increased adherence levels (after counselling on adherence) at the 
end of the study (p=0.001 and p<0.0001, respectively). The only study involving 
pharmaceutical interventions that had no significant effect on adherence was van 
Boven et al. (2016). Their reasoning for this was due to the difference in focus 
of the programs, the type of medication administration and the type of 
interventions. 
 
6.3.5.3 COPD Assessment Test  
COPD control was measured using the CAT, a valid and reliable questionnaire 
with worldwide relevance (Tsiligianni et al., 2012). In a potential future, definitive 
study, the primary outcome measure is likely to measure whether there is a 
difference in COPD control between the two groups, which could be measured 
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using CAT. This study found that the CAT questionnaire was easy to administer 
in both groups. However, for TC, the CAT questionnaire was given to the patient 
during PC along with a self-addressed envelope (or, if a tablet was provided to 
the patient, it too would be collected by the pharmacy driver). To improve 
practicality, future studies could look to administer the questionnaire online. 
However, being able to collect CAT score data via TC is crucial for future studies 
and was feasible to do so from the evidence gained within this study.  
 
A future, main RCT may find an association between adherence and COPD 
control. Again, it is important to be mindful that COPD is not fully reversible and 
is slowly progressive (GOLD, 2017), however the symptoms may themselves 
improve given the correct medication regimen. During this study, patients who 
had been exacerbation-free in the last 12-months who were at low risk of 
exacerbations underwent a stepwise approach and were advised to be taken off 
the ICS component by generally switching from ICS+LAMA to a LABA+LAMA 
(GOLD, 2017). It is worth noting the overprescribing of ICS+LABA when 
prescribing for COPD patients with mild to moderate disease when there is a low 
exacerbation risk (Drivenes et al., 2014).  
 
Although not sufficiently powered, the findings of this study suggest that both 
groups were similar with regards to the impact on COPD control. Similarly, 
Wright et al. (2015) and Tommelein et al. (2014) showed that CAT score 
improved over a 6-month period and was also not significant (p = 0.078, p = 
0.973, respectively). From the studies included in the literature review (Chapter 
3) that conducted TCs, Schou et al. (2013) reported non-significance in SGRQ 
between intervention group and control group (p=0.05) after 3-months; COPD 
control was not measured in the Sorknaes et al. (2011) or the Udsen et al. study 
(2017). 
 
Future studies should bear in mind that no change in COPD control could be 
considered a positive outcome, as, with time, patients’ lung function declines and 
cannot be reversed. In addition, this study took place during the winter period, 
where a higher incidence of exacerbations take place, which have important 
consequences for patients in terms of increased morbidity and mortality 
(Donaldson and Wedzicha, 2014). This is consistent with the TORCH study 
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(Jenkins et al., 2012), which demonstrated that winter is associated with an 
increased risk of AE-COPD, and that a cold, damp environment, as well as 
increased exposure to the influenza virus during winter may partly explain 
seasonality. The mechanisms responsible are complex and interrelated. It 
imposes a considerable burden for patients and healthcare services, which are 
often overstretched during winter (Wilkinson et al., 2017). Future studies should 
be conducted over a 12-month period to account for the widely acknowledged 
seasonal variability that occurs in COPD symptoms.  
 
6.3.5.4 Lung function 
The FEV1 was measured for all participants using spirometry. TC was a barrier 
to measuring lung function as it had to be conducted in-person (during PC) on 
all patients in order for the pharmacist to instruct the patient on the use of 
spirometry. A recommendation for a future study would be not to measure the 
patient’s lung function as it is no longer a requirement in the management of 
COPD (See Section 6.3.5.6). 
 
Other studies that focused on pharmacist interventions relating to patient’s lung 
function, include Jarab et al. (2012) and Khdour et al. (2009), which showed that 
there was no significance after 12-months (p=0.55, p=0.13, respectively). Future 
studies could consider this to be a positive outcome. This can be justified by the 
fact that COPD is a progressive condition characterised by irreversible damage, 
and hence FEV1 was unlikely to improve as a result of the intervention 
programme (Fletcher and Peto, 1977). A systematic review and meta-analysis 
revealed that only 1 in 7 studies reported a significant improvement in FEV1 in 
patients with COPD (Rea et al., 2004). In addition, this study took place during 
the winter period, where a higher incidence of exacerbations is likely, which 
impacts on the rate of lung decline (Williams et al., 2017). AE-COPD results not 
only in a significant increase in the rate of decline in lung function but also an 
increase in respiratory impedance (Kamada et al., 2017; Pérez-Padilla et al., 
2017). 
 
The importance of TCs showing similarities in outcomes to IPCs in relation to 
lung function is that pharmaceutical care can be provided to those patients who 
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are inaccessible. This is without compromising on safety, as unlike medical care, 
pharmaceutical care generally does not require co-location of patient and 
pharmacist. Also, this study showed the significant input community pharmacists 
can have in conducting these clinics as part of the multidisciplinary team, caring 
for COPD patients.  
 
6.3.5.5 Exacerbations 
AE-COPD is a significant prognostic factor and imposes the largest proportion 
of the total COPD burden on the NHS (GOLD, 2017). The pharmacist ensured 
the collection of exacerbation data and hospital admission data were completed 
for all participants at baseline and those retained at follow-up. Since a barrier to 
this study was not having access to patient notes, the number of exacerbations 
and hospital admissions were based on patient recall, which may not have been 
accurate. Future studies should try to have general practice involvement in the 
study, in order to increase the likelihood of gaining access to this information.  
 
The treatment regimens between the two groups were similar, apart from the 
IPC group having many more participants taking mucolytic agents than the TC 
group (11 vs. 4, respectively). There is moderate confidence that treatment with 
mucolytics may produce a small reduction in AE-COPD and a small effect on 
HR-QoL (Poole et al., 2015). So, given its small advantages, it was less likely 
that this difference would have influenced the outcomes of this study and if it did, 
it would advantage the IPC group.  
 
The Van Boven et al. (2016), Wright et al. (2015) and Weinberger et al. (2002) 
studies all showed no significant differences in exacerbations, over time. 
However, this was in direct contrast to Khdour et al. (2009), who found that there 
was a 50% reduction in A&E visits, 59% reduction in hospital admissions and 
39% reduction in unscheduled GP visits in the intervention group compared to 
control over a 12-month duration period; there was no identifiable reason for this 
difference. Tommelein et al. (2014) showed an annual hospitalisation rate of 
72% lower in the intervention group compared with the control group (p=0.003), 
however, there was no significant difference in the rate of A&E visits (p=0.20). 
Jarab et al. (2012) indicated that A&E visits were not significant between the 
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control and intervention group after 6-months (p=0.79). The number of hospital 
admissions for AE-COPD was significantly fewer than the intervention group 
(p=0.031). However, these studies were all insufficiently powered, and their 
control group monitored patients’ usual care, as opposed to this research study, 
where patients were actively managed. Thus, a sufficiently powered, future 
definitive study is recommended to determine whether optimising medication can 
reduce exacerbations.   
 
The study by Sorknaes et al. (2011) study, which conducted TCs, claimed that 
there was a borderline significant absolute reduction of about 10-14% in the early 
readmission risk when compared to no intervention. However, their study 
targeted discharged COPD patients to reduce early readmissions, and not being 
designed as a randomised study was a significant flaw. Unlike this research 
study, Sorknaes et al. (2011) had a control group that was not actively managed, 
but rather underwent their usual care. The other two studies conducting TCs 
were Schou et al. (2013), which indicated that there were no significant 
differences in AE-COPD between TC and usual care, and Udsen et al. (2017), 
which did not monitor exacerbations. Thus, these studies indicate that TCs are 
safe to conduct.  
 
Caution must be exercised when comparing studies of different populations. 
Owing to the heterogeneous nature of COPD, geographical differences and the 
specific population under study, caution is advised when comparing 
exacerbation rates between trials (Seemungal et al., 2009). Moreover, as 
mentioned in Sections 6.3.5.3 and 6.3.5.4 exacerbations rise in the winter 
months. This coincides with increased pathogen presence, as well as an 
interaction between non-typeable Haemophilus influenzae airway infection and 
activity of viral infection (Wilkinson et al., 2017). TCs may prove useful during 
periods of poor weather conditions and may provide a useful alternative to the 
time-consuming domiciliary visits or telephone consultations, which lacks the 
face-to-face counselling.    
 
It was imperative to monitor the number of exacerbations of COPD, as they have 
short-term and long-term implications. Seemungal, Hurst and Wedzicha (2009) 
reported that approximately 50% of exacerbations in the community returned to 
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baseline symptoms within 7 days, however, in 14% of these events, symptoms 
did not return to baseline 35 days subsequent to their onset, a proportion of 
which would not ever return to baseline. Periodic exacerbations are linked with 
increased deterioration in lung functionality. Donaldson et al. (2002) determined 
that patients who suffered recurrent exacerbations had a decline in FEV1 of 
40.1ml per year (95% CI 38-42) against 32.1ml per year (95% CI 31-33) with 
those suffering from infrequent exacerbations (p<0.05). Vestbo et al. (2011) 
revealed that exacerbations had a decline of 2ml per year (p<0.001) during a 3-
year longitudinal study. It is widely known that recurrent exacerbations are linked 
with decreased physical activity (Donaldson et al., 2005), poor QoL and 
increased mortality (Soler-Cataluna, 2005). Nonetheless, the only proven 
interventions that actually extend life expectancy are smoking cessation and 
oxygen therapy (GOLD, 2017). Thus, future studies should focus on COPD 
control and management rather than life expectancy.  
 
6.3.5.6 ABCD assessment tool 
The ABCD assessment tool is used to assess a patient’s symptoms (using CAT 
score) and risk of exacerbations (history of exacerbations) to help guide 
treatment decisions. Being able to collect this data is important for future studies 
and is feasible to do from the evidence gained from this study.  
 
During this research study, GOLD (2017) guidelines refined the ABCD 
assessment tool by removing spirometric grades, which now places emphasis 
on a patient’s symptom burden when evaluating disease severity. Thus, 
pharmacological recommendations will now be derived exclusively from patient 
symptoms and their exacerbation risk (without the need for spirometry). 
Subsequently, pharmacological therapy has been shifted towards a more 
personalised approach, reflecting the ongoing process towards comprehensive, 
patient-tailored management (Roversi et al., 2017). Accordingly, 
recommendations made during the study were partly based on previous 
guidelines (e.g. GOLD, 2016), and as such, could have been out-dated by the 
time the GP reviewed the patients. However, since the SRP was aware of the 
accumulating recent evidence within COPD management e.g. LABA-LAMA use 
ahead of LABA-ICS, recommendations were made according to this knowledge, 
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which GPs/RNS may not have been aware of. As such, this may have lowered 
the likelihood of intervention-uptake. This new policy will be used to inform future 
studies.  
 
Inputting data from the study into the ABCD assessment tool demonstrated a 
clear shift in quadrant, primarily from the top half (C and D) to the B quadrant 
(positive effect). There were no studies in the literature that used the ABCD 
Assessment Tool within the topic of ‘pharmacists contributing to the 
management of COPD’ or ‘how HCPs have utilised TCs within their practice 
when caring for patients with COPD’, therefore, this study provides further 
valuable new data. It would be recommended that future studies categorise 
patients based on this assessment tool and present this data.  
 
Recognition and validation of COPD phenotypes has an important role to play in 
the selection of evidence-based targeted therapy in the future management of 
COPD, but regardless of the diagnostic terms, patients with COPD should be 
assessed and treated according to their individual treatable characteristics. 
 
The risk of COPD lies in the interaction between genetic features and the various 
array of environmental exposures (Mannino and Buist, 2007). This results in 
considerable variation from person to person and is heterogeneous in nature 
with regards to the disease history, lung pathology, systemic effects and co-
morbidities (Rennard and Vestbo, 2008). This recognition will have a role in 
future treatment selection and if this information is included in patient records, it 
can help inform treatment.  
 
Han et al. (2010) defines a COPD phenotype as “a single or combination of 
disease attributes that describe differences between individuals with COPD as 
they relate to clinically meaningful outcomes (symptoms, exacerbations, 
treatment response, progression of the disease or mortality)”. In future, 
classifying patients in such a concise way should lead to guiding therapy and 
thus clinically meaningful outcomes. Their phenotype may be determined by the 
cellular or molecular fingerprint, radiography, physiology or symptoms before 
their relevance to clinical practice is determined (Pinto et al., 2015). However, it 
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must be conceded that any phenotype may be aetiologically heterogeneous, 
where multiple phenotypes may well manifest.  
 
6.3.5.7 Health-Related Quality-of-Life 
Collection of HR-QoL data were completed for all participants at baseline and all 
remaining participants at follow-up (see Figure 34 and Table 23 in Appendix 16). 
It has been documented that the EQ-5D-5L questionnaire is not sensitive to 
minor changes in COPD symptoms unlike CAT and it may suffer from a ceiling 
effect (Boland et al., 2015). However, it should still be used in future studies as 
it is a validated preference-based instrument that can measure the health utilities 
of patients in economic evaluations. Also, it has been used in the studies 
mentioned below and was feasible to use in TC. 
 
Other studies (Jarab et al., 2012; Khdour et al., 2009; Tommelein et al., 2014; 
Weinberger et al., 2002) suggest that there is no significant difference in HR-
QoL between the intervention group and control group (p=0.51, p=0.17, p=0.19, 
p=0.31, respectively). However, their control group comprised of usual care 
which was in contrast to this research study where TC was compared to IPC. 
Thus, in future studies, it is expected that there will be no significant difference 
in HR-QoL between the two groups, since the same type of active management 
should be carried out in both groups. The only difference being IPC versus TC.  
 
If anxiety disorder develops, it is associated with increased AE-COPD, lower 
exercise tolerance and QoL (Eisner et al., 2010), which supports the need to 
collect HR-QoL data in future studies. Anxiety disorder is defined as a chronic 
condition, characterised by an excessive and persistent sense of apprehension 
with physical symptoms (e.g. sweating, palpitations, stress) and encompasses 
numerous abnormal and pathological fear and anxiety states, such as 
generalised anxiety disorder, obsessive-compulsive disorder, agoraphobia and 
panic disorders. There is an increased incidence of anxiety disorders among 
patients with COPD (Maurer et al., 2008), which ranges from 13-51% (Brenes, 
2003).  Accessing remote patients via TCs may help alleviate patients’ anxiety 
and insecurities associated with COPD (Mathar et al., 2015) which was 
experienced during the study.  
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So, since the EQ-5D-5L questionnaire provides valuable information and was 
easily administered, it should be included in future studies. 
 
6.3.6 Economic implications  
Unexpectedly, the total NHS cost of offering this COPD pharmacy clinic is more 
during the 6-month study duration than the 6-months prior to the study for both 
the IPC and TC group (see Figure 16, Figure 17 and Figure 18 in section 5.5.4). 
The increased cost of the study (~£25 per participant over 6-months) was due to 
the setup costs and duplicating tests that may have already been carried out in 
general practice, such as spirometry (see Table 13 and Table 14 in section 
5.5.4). A solution would be to have access to patients’ notes, which would 
indicate when these measurements (e.g. oximetry) were next due to be 
measured. It should be borne in mind that this feasibility study was carried out 
during the winter months, where the frequency of expensive exacerbations was 
expected to have a marked increase. Also, since COPD is a progressive disease 
characterised by irreversible damage, stabilisation of symptoms may be the best 
that can be hoped for when optimising medication.  
 
Crucially, this feasibility study indicated that TC had the potential to be markedly 
better value for money than conducting domiciliary visits if there is access to 
patient records (see Table 13 and Figure 16 in section 5.5.4Error! Reference 
source not found.). The importance of this finding is that it indicates where costs 
could be reduced in future research using TC as an alternative to IPC. 
Furthermore, TCs should incur lower costs for patients as they are spared the 
cost and inconvenience of travel. There were no other studies that could be 
found in the literature that measured cost differences of TCs to the conventional 
IPCs in COPD.  
 
In the study by Wright et al. (2015), the mean total cost pre-intervention was 
higher compared with that in the study period. Van Boven (2014), however, 
reported non-significant cost-differences. The authors ascribe this to the fact that 
their interventions were targeted at HCPs instead of patients and the relatively 
small potential for improvement in the patient population, given the overall good 
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level of treatment. A notable limitation of the van Boven (2014) study was that 
there was no control group or randomisation, but rather, the patients were 
compared with their own historical control (pre-post design). Udsen et al. (2017) 
findings, however, were aligned with this research study, where they concluded 
that TC is unlikely to be a cost-effective addition to usual care, if offered to all 
COPD patients.  
 
This study demonstrated cost savings to prescribing habits when comparing all 
participants at baseline with the endpoint. Cost savings occurred where there 
were duplicates of the same medication (on six occasions with inhalers), from 
not requiring an ICS (due to a low exacerbation risk) or when a cheaper 
alternative was recommended. There were occasions where patients’ COPD 
medication regimen was stepped up to match their symptom severity and lung 
function profile, which increased costs, however, this was after ensuring 
adherence and inhaler technique were optimised, in accordance with the 
evidence base.  
 
However, as the study progressed, patients were increasingly adherent to their 
medication (see Section 6.3.5.2), which ensured that they were following the 
prescriber’s directions. This potentially increased the cost, as patients required 
more repeat medication but also decreased potential waste. However, this could 
not be determined, as access to PMR data was only available for Drugs4Delivery 
pharmacy patients. Therefore, access to PMRs or GP records will be required if 
future studies are to calculate costs accurately. If a future definitive study has 
general practice involvement, this will increase the likelihood of gaining access 
to the information required to calculate costs. Although this study used patient 
recall for this information, the formula for calculating costs is the same and can 
be used to inform the design of a future study.  
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6.4 Critical appraisal of the strengths and limitations of the 
study 
6.4.1 Aims and objectives 
This feasibility study was conducted with patients randomised to intervention or 
treatment as usual, in a community pharmacy-based COPD clinic. The strategy 
for this 6-month study will be critically analysed in the proceeding sections. 
Important strengths and limitations have been identified and require careful 
consideration in study methods, procedures and protocol development for a 
proposed definitive study.     
 
6.4.2 Literature review 
As discussed in the literature review (Chapter 3), the method used to review the 
literature was based on the principles proposed by the Cochrane Collaboration 
for Systemic Reviews of Interventions (Higgins et al., 2011), as this resource is 
internationally recognised as the highest standard of evidence to inform 
healthcare decisions with a view to minimising bias. However, since this 
literature review forms part of an academic award for the Doctor of Pharmacy 
programme, it was carried out independently. Limitations in funding also meant 
that articles were only included if they were written in English.  
 
Carrying out the literature review independently may have led to appropriate 
studies not being identified, and thus, risking overlooking significant studies. 
However, the process was clearly recorded and auditable. There were a limited 
number of studies in the TC domain, and consequently, it was necessary to 
explore further afield, and also focus on the pertinent matter of how pharmacists 
contribute to the management of COPD.  
 
The literature search only identified 6 studies that focused on pharmacists 
managing COPD. These studies demonstrated the clear benefits of having 
pharmacist involvement, however, the literature review (Chapter 3) exposed 
limitations in the design of these studies. There was clearly a gap in the literature 
for robust studies within this field. Thus, this research was the first to study the 
feasibility of carrying out a COPD medicines management service from a 
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distance-selling internet pharmacy that monitors spirometry, oximetry and 
inhaler technique.  
 
There were only three studies that met the inclusion criteria that utilised TCs 
within a HCP’s practice when managing patients with COPD. This research 
study sought to add to this domain by presenting original research that reviewed 
patients with COPD using TCs with the patient at home and the pharmacist 
residing in the consultation room of their community pharmacy. It was also the 
first to compare COPD TCs to IPCs. 
 
6.4.3 Methodology and methods 
6.4.3.1 Randomisation technique 
A notable strength of this feasibility trial was that it tested a randomised 
controlled study approach. Randomisation methods are the most rigorous 
means of determining whether a cause-effect relationship exists between 
treatment and outcome, as well as assessing the cost of the intervention group. 
This technique, although considered more time-intensive, ensured that no 
systematic differences between the IPC and TC groups existed in factors, known 
and unknown, that could have affected outcomes. In pragmatic studies, it is not 
feasible to blind the SRP. However, both groups were treated as equally as 
possible apart from conducting the clinic in-person or via TC by having a service 
specification. This interventional study used random permuted block allocation 
to ensure that each group consisted of very similar patient characteristics. This 
study learnt that participants were willing to be randomised (even though this is 
not a requirement in a feasibility study) after it was explained that the advice 
would be the same regardless of which group they were allocated. This study 
can inform a future definitive study involving a similar complex intervention. 
 
RCTs are considered the most reliable form in the hierarchy of evidence. 
Participants are allocated at random to either the control or experimental group 
in order to minimise bias and spurious causality between the two groups. The 
challenge for a future, large scale study will be for the study population to 
accurately represent the overall patient population with the purpose of accurately 
inferring what would happen in reality, so that the results are generalizable. 
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Conducting a qualitative process evaluation was beyond the capacity and 
parameters of the trial. 
 
6.4.3.2 Setting  
A strength of this study was that it used a community pharmacy setting, where 
clinics were strategically based to offer further medicines-related counselling to 
patients and to offer medicines optimisation. The limitation was that future 
studies are likely to be multi-centred and consistent duplication of this single-
centred study cannot be predicted elsewhere.  
  
Currently, pharmacies offer clinical services such as MURs and influenza 
vaccinations, however, medication review clinics would be a more specialised 
service that could save time for general practice and improve accessibility to 
patient care. In this study, in order to optimise the medication of patients, it was 
necessary to assess lung function, oxygen saturation levels and inspiratory force 
in the PC. It was a limitation that the PC took place at the pharmacy, rather than 
at the patient’s home as, in practice, a domiciliary visit would be required to 
access housebound patients. Once these factors were measured, the actual 
clinic itself could take place, where patients were randomised to the two groups 
– a superior design to the pre-test post-test comparison. Within the consultation, 
the findings were discussed with the patient. A limitation was that information 
was gathered solely from the patient, such as discussing previous treatments 
that were used. This information could not be corroborated with patient records, 
since this is not accessible to community pharmacy, although this was 
circumvented by encouraging all participants to bring along medical paperwork, 
such as discharge summaries, which occurred in the majority of cases. However, 
this did not prevent intervention duplication occurring as the information 
participants provided was not sufficiently detailed. Thus, it was evident from this 
study, that limited access to records was a significant barrier to this research.  
 
Detection bias was a high risk in this study, as the pharmacist was also the 
outcome assessor, which potentially could have influenced outcome 
measurements thus creating bias; although, blinding of outcome assessors is 
less of an issue in objective outcome measures, such as lung function tests and 
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exacerbations. The study also mitigated against these risks by administering 
patient-completed validated questionnaires/assessment tools, such as CAT and 
EQ-5D-5L. However, these questionnaires could still have been receptive to 
skewed interpretation. Funding permitting, future studies could separate the data 
collection and analytical process from the pharmacist conducting the clinics.  
 
Bias could have ensued if the pharmacist subconsciously favoured either of the 
two groups, however, the use of objective measures minimised this. Also, bias 
was monitored by randomly allowing a second pharmacist to sit in on a quarter 
of the consultations, in a bid to detect variability.   
 
However, a future, multi-centre trial would have the ability to randomise a greater 
number of participants over a larger geographical area, thus improving 
generalizability. Issues to do with managing research, high quality data and 
having clear communication between pharmacists, become vital in a multi-centre 
study. Pharmacists conducting the clinics must strictly adhere to the clinic 
protocol. Also, a future study could have an independent SRP who verifies all 
the information and documents their recommendations/interventions for 
comparison with those of study pharmacists. However, these tasks were not 
possible to execute as funding was a limiting factor for this research.  
 
6.4.3.3 Population and sample 
A key limitation was that the patient sample recruited patients of all COPD 
severities which included, but was not exclusive to housebound patients. The 
sample had to attend a PC in the pharmacy consultation room for the initial 
measurements. The sample for this study had to include all COPD patients, in 
order to achieve the required number of participants. However, a truer and more 
appropriate control representation would be to test the intervention on a sample 
made up of housebound COPD patients only. A future, sufficiently powered, 
multi-site study should have the capability to recruit housebound patients only, 
whilst achieving recruitment targets, using a larger geographical area.       
 
All forty-eight participants entered into the study, satisfied the study inclusion 
criteria and when comparing the baseline characteristics of the sample with that 
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of the COPD population in the UK, it revealed similar attributes, although the 
socio-economic status was significantly lower than the UK COPD population as 
a whole. Otherwise, the results related to a representative sample of the COPD 
population within the UK.  
 
Any bias may be reduced by using a more diverse recruitment strategy, such as 
referrals. Future studies could involve collaborating with influential clinicians 
within general practice and involving them in the study design in order to increase 
the likelihood of their participation. This would likely have aided the recruitment 
of potentially eligible participants and offer an alternative recruitment stream 
whilst improving on this study’s limited intervention implementation.  
 
A criticism of the study was that patients were presumed to have COPD based 
on information obtained from the patients. Having access to patients’ medical 
notes would have resolved this. As mentioned in the Introduction (see Chapter 
2), approximately two-thirds of COPD sufferers have not been diagnosed with 
COPD (NICE, 2010). This could be due to the condition being difficult to define 
and thus diagnose. Although measures, such as FEV1, have been developed to 
form the diagnosis and grade the severity of COPD, the criteria fail to account 
for the complexity and heterogeneity of the condition (Vestbo et al., 2016), as 
certain symptoms can be more emphysematous, bronchitic or asthmatic in 
nature. There was a risk that a proportion of participants had an incorrect 
diagnosis of COPD, and thus there was a risk that any recommendations that 
were made to their GP were based on a false COPD diagnosis or the participant 
having ACOS.   
 
6.4.3.1.1 COPD phenotypes  
Patients that were recruited to the study via advertising generally had more 
severe COPD, and some had treatment-resistant COPD, thus possibly 
responded to a lesser extent than usual. Several had complex co-morbidities 
and were under the management of various consultants who may have already 
tried the medication regimen suggested by the SRP. Having complex patients 
included in the study could have masked the impact of the interventions, since 
these patients may have already been prescribed optimal therapy by their 
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clinician(s) (and may have previously trialled a range of medications). However, 
a strength of this study was that these complex cases were not excluded, and a 
real-life, pragmatic approach was employed.     
 
The aim of this feasibility study was not to distinguish resistant cases of COPD, 
identify patients’ phenotype or complex cases of COPD, but rather take a 
random cohort of participants in the locality and expose them, via TC, to 
pharmacist interventions. As such, future studies are required to uncover 
whether significant improvements in outcomes can be realised. It is worth 
highlighting that COPD severity becomes progressively worse and thus lung 
function improvement is deemed unrealistic. However, correctly using the 
appropriate medication can improve symptoms and contribute to reducing the 
number of exacerbations, which would otherwise have worsened the prognosis 
(Wilkinson et al., 2017). 
 
6.4.3.4 Intervention 
A strength of this study was the use of a real-life complex intervention. However, 
a limitation of this study is that it cannot provide an indication as to how this 
complex intervention might perform in a multi-site study design. A prospective 
study was chosen ahead of a retrospective study design due to community 
pharmacy COPD TCs being a pioneering concept. Also, most of the data 
collected are not routinely recorded, such as spirometry, so this ruled out a 
retrospective study design. The advantage of a prospective design is that it 
usually has fewer potential sources of bias and confounding factors than 
retrospective studies. Also, with a future, definitive study in mind, a prospective 
investigation can make precise estimates of the relative risk of an outcome 
based on exposure. In essence, the interventions provided by pharmacists via 
IPC or TC from a community pharmacy are what will define any future definitive 
study. Considering that each participant required different aspects of their 
condition addressing, interventions were expected to differ between participants.  
 
It was not possible to blind the investigating pharmacist from knowing which 
participants had been assigned to each group, as the SRP was responsible for 
conducting every stage of the study process, from recruitment to endpoint. The 
  
167 
design was an open (non-blind) study, as it was also not possible to blind the 
participants. Ideally the SRP would have been recruited independent of the 
investigator to conduct the consultation, however, this funding was not available.  
To mitigate against the risk of expectation potentially resulting in bias, objective 
rather than subjective measurements were used where possible. Also, to avoid 
selection bias, group allocation for each participant was not revealed until the 
participant had irrevocably been entered into the study. Random number 
creation for allocation was conducted to mitigate against the risk of bias since 
the SRP was solely tasked with recruiting relevant participants into the study. 
 
6.4.3.5 Second pharmacist check 
To substantiate the rigour and robustness of the recommendations made by the 
SRP, a second pharmacist was given all the information obtained from each of 
the participants and asked to document their own recommendations, without 
speaking to the patients. This strategy also gave an indication of what a non-
specialist would recommend, thus providing valuable information to inform 
thinking about whether a community pharmacist (without a specialist interest in 
respiratory therapy) could conduct the clinic. To minimise bias, this was carried 
out without the non-specialist pharmacist being aware of the recommendations 
made by SRP or which group participants had been allocated.  
 
The findings reveal that the second pharmacist corroborated the interventions 
that the SRP had made. It was learnt that conducting external monitoring 
subsequent to the study certified that the interventions made were in accordance 
with the evidence base (Craig et al., 2008), and thus, if the study were to be 
rolled out, it demonstrates that they were not dependent on a SRP but rather on 
that of a registered pharmacist, referring to the GOLD (2017) pocket guide.   
 
6.4.3.6 Data collection 
A strength of this study was in the use of validated tools to measure outcomes, 
which have clinical significance. In the limited body of evidence currently 
available within this domain, the data collected for outcome measures is 
inconsistent and therefore made comparisons difficult. Towards the end of the 
study, a new guideline was released by GOLD (2017), which advocated the use 
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of the validated ABCD tool, which assessed COPD symptom burden and now 
guides pharmacological therapy. Thus, treatment is now centred exclusively on 
respiratory symptoms and history of exacerbations (Roversi et al., 2017). This 
change in guideline may have adversely affected the uptake of 
recommendations throughout the study. The refined ABCD assessment tool was 
used retrospectively to collate and classify participants into a particular quadrant. 
A positive development for a future definitive study is that spirometric readings 
are no longer required. This increases the practicality of managing COPD via 
TCs, as this data will not need to be collected at the PC, thus saving time and 
money. 
 
Unlike with asthma, patients with COPD do not experience symptoms that vary 
considerably from day-to-day (Rabe et al., 2007), and as such, this study was 
less onerous on the investigator and the participants in that regular monitoring 
was inappropriate. However, there is still circadian variation in lung function, 
even in healthy individuals, so it is unsurprising that patients with COPD 
experience variations in symptoms throughout the day, with more severe 
symptoms taking place during the morning and night (Roche et al., 2013). To 
account for this slight variation, participants should have been booked in at 
follow-up, ideally at the same time of day as their baseline consultation, however, 
this was impractical for every participant as the SRP had a limited number of 
days to hold the clinics and the participants may not have been available at 
specific times.  
 
A limitation of the data collection process was that information was not requested 
on all NHS and personal social service items, even though a wide range of NHS 
services were taken into account (see Figure 15) and are in line with other 
economic studies (Gray, 2011; Wright et al., 2015). Future studies should look 
to capture all this data.  
 
6.4.4 Pharmacist interventions 
Medicines optimisation is the safe and effective use of medicines to enable the 
best possible outcomes (NICE, 2015). It aims to ensure that medicines provide 
the greatest possible benefit to people by encouraging medicines reconciliation, 
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medicines review and the use of patient management plans. Hospital 
pharmacists generally tend to lead in the medicines optimisation concept 
(Geeson et al., 2017), however, this study proved that community pharmacy can 
potentially accommodate this concept and be delivered via TCs.  
 
To be successful in optimising the patient’s medication, it was important to obtain 
information on their medication-taking behaviour and about their medication 
beliefs. This information was used to construct a patient management plan which 
they could take away and refer to. The plan had information on symptoms, 
triggers and when to use their treatment. Lenferink et al. (2017) reported that 
self-management interventions are associated with improvements in HR-QoL 
and a lower incidence of hospital admissions. However, there was a small but 
significantly higher mortality rate compared to controls. Lenferink, et al. (2017) 
used the SGRQ as opposed to the CAT (used in this study), which, although 
they have similar discriminative properties, the reliability and score distribution 
of both instruments is identical (Morishita-Katsu et al., 2016). Furthermore, 
Stacey et al. (2017) found that patients exposed to a personalised management 
plan feel more knowledgeable, better informed, have more accurate risk 
perceptions and may improve values-congruent choices. However, they failed to 
include lower literacy populations, which is typical within COPD.  
 
The GOLD (2017) guidelines recommend ongoing self-management and 
education programs. In retrospect, although patients were given self-
management plans, not all information they received was written down for them. 
Since time was limited in clinics, written information could have been posted out 
to the patient’s address to aid the patient’s recall, especially if several 
interventions had been made. Future studies could offer patients more COPD 
information for further reading i.e. leaflets from organisations such as the British 
Lung Foundation. Also, during TCs, the pharmacist could send useful links to 
websites that can help facilitate their COPD management (e.g. videos on inhaler 
technique). Future studies should look to capitalise on sharing this information.  
 
It was not categorically known whether the interventions made during this study 
were attributable to the pharmacist or whether these interventions would have 
occurred irrespectively, since this factor was not the main focus of the research; 
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rather it was to determine the feasibility of TC. However, the majority of the 
literature in COPD (also see Chapter 3) suggests that pharmacist interventional 
studies impact on patient knowledge and medication usage, but not necessarily 
outcomes; although, as previously mentioned, this is unlikely due to the 
condition’s slowly progressive nature (GOLD, 2017). Comparing the IPC and the 
TC groups with a third group not exposed to the clinic be useful to determine this 
in a future, main study. However, since this research assessed the comparison 
between IPC to TC, this did not result in ‘comparison choice bias.’ Also, recruiting 
48 patients to this study proved challenging; a further 24 patients would have 
been unattainable unless further advertising was undertaken, or a multi-site 
approach was used.  
 
The delivery of the intervention in both arms by the same person introduced bias 
as there may have been a risk of expectation influencing findings, especially if 
there was subjectivity in assessment, leading to biased results (Day and Altman, 
2000). This is not challenging the integrity of the investigator or patients, but bias 
associated with knowing the variable is often subconscious (Lijmer et al., 1999). 
This bias was mitigated against by using objective measures wherever possible 
e.g. CAT score. Also, the same person conducting the consultations, collected 
data, analysed and reported the results. This introduced ascertainment bias 
which can be minimised in future trials, by keeping the data analysts and the 
person reporting on the trial unaware of the identity of the study groups.  
 
6.4.4.1 Inhaler technique education 
The SRP used the manufacturer’s instructions to provide a checklist for each 
inhaler in order to demonstrate their use. All participants in the study were taught 
inhaler technique by the same pharmacist, which minimised variation. However, 
in case the pharmacist subconsciously favoured one group, especially since 
there can be a degree of subjective interpretation, a second pharmacist sat in on 
8 (16.6%) consultations (4 per group) to identify whether both groups were 
treated equally. This was supposed to be 6 per group, however, 4 of these 
patients had rescheduled. This helped quality assure the clinics, which 
minimised the risk of the SRP unintentionally or unconsciously favouring either 
group. The second pharmacist vouched for the accuracy and completeness of 
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the data and the reliability of the study to the protocol. However, this pharmacist 
was not involved in research, and as such, may not have been aware of the 
controls in place to the extent that an academic would have been. Had greater 
resources been in place, an academic pharmacist could have sat in on a 
proportion of clinics (with the participant’s consent), then a second academic 
pharmacist could have analysed the anonymised data.  
 
A clear limitation of TC was the fact that a PC was required to measure the 
patient’s inhaler technique using the In-Check-DIAL device. Based on the result 
from the In-Check-DIAL, the patient was then counselled via TC. However, not 
having the patient there in-person takes away the option of re-testing the 
patient’s inspiratory force using the In-Check-DIAL device, even though this was 
unnecessary in the study. A solution would be to provide an In-Check-DIAL 
device to all patients who find inhaler technique a challenge.  
 
From analysing the results, it seemed that some patients were confused with the 
steps in using their inhalers, so they occasionally confused similar steps with 
different inhaler devices. The pharmacist also considered the importance of the 
patient having the same device, if they required more than one inhaler. Though 
this was not always possible, as many devices only exist with a limited number 
of medicines, it is common to have several different types of inhaler devices.  
 
It was common for patients to have at least two different inhaler devices. This 
presented a challenge to data collection, since it was problematical to 
interchange between the various different devices, which had different steps. 
This issue was circumvented by calculating the percentage of correct steps from 
each inhaler device (see Section Error! Reference source not found.). The 
inhaler technique score has been utilised in many studies to determine the 
significance of not undertaking each particular step. Not following certain steps 
will result in no dose, and thus is categorised as a critical error, and as such, a 
greater prominence was placed on this. However, this is not necessarily accurate 
since each device has a different number of steps and each step is not 
necessarily the same value in terms of significance. Notwithstanding, there are 
still drawbacks to this method as there are a range of inhaler devices that require 
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a different number of steps and different steps to operate; for example, the new 
inhalers tend to be designed to be easier to use with generally less steps.  
 
It is convenient to calculate each step as having the same weight in significance, 
regardless of the inhaler device used, in spite of the noteworthy limitations this 
produces. To get around this issue, inhaler technique was summarised in terms 
of whether the patient fell into one of the following categories: unsatisfactory, 
satisfactory or optimal inhaler technique (Klijn et al., 2017b) (see Section Error! 
Reference source not found.).  
 
The limitations of these assessment techniques are evident and could have been 
overcome by only choosing to investigate participants on one particular type of 
inhaler device, such as the pMDI. However, since this was a real-life, pragmatic 
study, it was essential to mirror the usual clinical practice, given the array of 
inhaler devices used by patients. Furthermore, this would have significantly 
reduced the pool of participants eligible for the study and would be a key concern 
in recruitment, bearing in mind the challenges that were faced recruiting 48 
participants to this study. When comparing inhaler technique competencies 
between the two groups, the population size of the study was far too small to 
compare participants using each different inhaler device. However, when 
comparing the inhaler techniques for all the inhalers pooled together, there was 
little difference between the IPC group and the TC group. 
 
6.4.4.2 Inhaler preference 
It was imperative to question patients’ suitability and preference for their device, 
as this could impact on adherence (Hodder and Price, 2009). In this study, 
patients were asked about their preferences for their device in order for them to 
feel their view was an important aspect of the inhaler selection process. When 
reviewing the evidence of studies that consider inhaler device preference for 
patients, the study sponsors were noted, since they are likely to manufacture 
inhaler device(s) or another financial interest in the study, which could introduce 
bias.  
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A limitation of this study was that the pharmacist did not go through the range of 
different inhaler devices with each patient; this would have taken a significant 
duration of time in the consultation and would have been impractical. Also, drugs 
are only available in certain inhaler devices, and thus, the device type may only 
be an afterthought in the prescriber’s choice of treatment. Another option would 
be to present alternative devices within the same medication group (e.g. 
ICS/LABA), which would not have been as time-intensive. Instead, the SRP 
learnt to establish which device the patient preferred, whether they had more 
than one type of device and whether the device prevented them administering 
the dose in any way.  
 
6.4.4.3 Adherence 
Adherence to respiratory medication is crucial to achieving the desired treatment 
outcomes, but epidemiological studies suggest adherence remains suboptimal 
in most patients (Feehan et al., 2015). Adherence was measured using patient 
reporting questionnaires and accessing their PMR. Using two such methods 
improves the rigour, even though there are limitations to both methods. However, 
viewing prescription records is regarded as a more reliable and robust 
assessment than self-reporting adherence rates (Lam and Fresco, 2015), as 
acquiescence bias is minimised when objective measures are used, such as 
PMR and/ Summary care records.  
 
The comparison between participant’s adherence in the IPC and TC groups 
could only be made via their PMR if the participants were obtained from 
Drugs4Delivery pharmacy. Trying to retrieve the information from other 
pharmacies would have proved to be a conflict of interest as they could 
potentially have seen this as a threat to their business. Also, it would seem very 
doubtful that the other pharmacies would release this information, fearing they 
would breach patient confidentiality or even lose business to a rival pharmacy. 
However, a multi-site study would lessen this issue, as there would be a larger 
pool of pharmacies involved.  
 
Drugs4Delivery pharmacy obtained access to the summary care records 6-
months prior to baseline. This was thought to be beneficial as it would enable 
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access to view the ordered prescriptions of participants using other pharmacy 
services. Thus, with those using other pharmacies, adherence was checked 
every month using patient’s summary care records, but only once the 
participant’s consent was gained. Checking patient’s summary care records was 
a laborious process as it showed the most recent items ordered, however, it did 
not show whether this was dispensed or administered by the patient. Future work 
needs to consider a more pragmatic approach to collecting adherence data from 
patients that are using other pharmacies. This could be retrieved from the 
patient’s general practice; however, engaging GPs in the study will be paramount 
to its success.  
 
Patients are thought to be anxious about not adhering to their medication when 
discussing this with their HCP (Bukstein, 2016). Since patients completed the 
adherence questionnaire during the clinic (IPC and TC), it would have been 
impractical to assess the results during the consultation, thus, all patients were 
counselled on adherence, regardless of whether they conformed to taking their 
medication or not; this should also be the case for advising patients on 
adherence in future studies. As the evidence suggests that patient-reported 
adherence with inhalers is slightly higher than their actual adherence (Bukstein, 
2016). Also, if a patient had been admitted to hospital at any point, they may 
have received medication from the hospital, and thus may have affected the 
PMR/ summary care records adherence assessment. This was, however, 
unlikely as admission rate was relatively low and those patients, who were 
admitted, were asked if they had received additional medication as an inpatient.   
 
Assessing both the PMRs and SCRs showed the number of occasions the 
patient ordered their repeat prescription, however, this did not mean the patient 
actually received or administered the dose. They may not have collected the 
medication from their pharmacy, or they may have been accumulating 
medication at home, especially if this was ordered automatically by their 
pharmacy, thus checking non-collection of medication and asking the patient if 
they have excess stock at home may have been more accurate. Also, adherence 
does not take into consideration their inhaler technique and whether the active 
ingredient actually reached the site of action, thus, adherence must be 
considered alongside their inhaler technique.  
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Adherence may have been improved by the patient feeling the beneficial effects 
of their medication, possibly due to their improved inhaler technique. It may also 
be due to the fact that each participant was motivated by the fact that they would 
be reassessed at the 6-month follow-up, and thus adhered to all the advice 
offered (Hawthorne effect) (McCambridge et al., 2014).  
 
6.4.4.4 COPD control measures 
Bearing in mind that COPD is progressive in nature, a future main study is likely 
to not show improvement in outcome measures from baseline to endpoint in 
either group, which would actually indicate a favourable outcome. 
Extrapulmonary co-morbidities were also monitored, as they influence the 
prognosis of patients with COPD. The similarity between most of these 
extrapulmonary manifestations is chronic systemic inflammation. Co-morbidities 
include systemic venous thromboembolism, anxiety, depression, osteoporosis, 
obesity, metabolic syndrome, diabetes, sleep disturbances and anaemia. The 
co-morbidities have no evident pathophysiological relationship with COPD; 
however, peripheral artery disease and malnutrition are directly caused by 
COPD. Co-morbidities make the management of COPD complex and need to 
be evaluated and treated adequately (Cavaillès et al., 2013). During the study, 
the SRP always considered co-morbidities when recommending the adjustment 
of medication, however, the final decision was with the GPs, as they had the full 
clinical picture and were aware of the medical history. It is important to note for 
future studies, that participants treated under the care of a consultant were less 
likely to have the SRP’s recommendations considered by the GP, however, 
future studies could look to record this data.  
 
6.4.5 Uptake of recommendations  
An uncontrolled variable in this study was whether or not GPs were receptive to 
the recommendations offered to them, and whether this resulted in an 
adjustment of treatment regimen in response to the pharmacist’s advice. It would 
have been useful to have an understanding of the GPs’ thoughts regarding the 
COPD clinic. An anonymised questionnaire could have been sent to the patient’s 
GP to obtain feedback and decipher what influenced their uptake of 
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recommendations. It would be useful to obtain this information in a future pilot 
study to inform a definitive study.  
 
Having a lack of uptake of the recommendations in a future, definitive study may 
result in a lack of impact on outcome measures. In order to remedy this lack of 
response, this study could have been conducted in collaboration with one 
surgery, having full clinician involvement in the study. However, restricting the 
study to one surgery would limit the spread of patients geographically (see 
Figure 21 in Appendix 8, for the number of patients per surgeries spread across 
the North East Lincolnshire region), which would affect the patient demographic 
and thus the generalisability of the study. If resources and time were not limited, 
it would have been useful to compare this study with the one surgery setup using 
a prescribing pharmacist and with full clinician support.  
 
Although this research study provided valuable and novel insight into the 
practicalities of conducting clinics from a community pharmacy, both using IPC 
and TC, it did not illustrate the feedback from general practice and why certain 
recommendations were not accepted or even seen. Future pilot studies could be 
designed to investigate this dynamic further.  
 
Also, accessibility to patient notes could improve the clinical precision of 
recommendations offered to general practice as a patient’s history will be more 
accurate, instead of basing it on a patient’s recall. In having access to notes, 
more appropriate recommendations would be made, which could influence the 
trust in the service, and potentially improve outcomes. In this study, there was a 
risk of recommending treatments that had already been tried out in the past, 
without the pharmacist being aware. Consequently, the pharmacist relied on 
patients’ recall of information in the 6-months before the study, which of course, 
may have been unreliable. Patients recorded information (e.g. number of 
exacerbations) throughout the study and comparing this data with the potentially 
unreliable data for the 6-month period prior to the study may have been 
erroneous. Obtaining the information from both the patient and their GP would 
have improved the reliability; however, this has previously proven difficult to 
obtain (Tatari, 2016). 
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If the pharmacist was misinformed by the patient and this formed the basis of 
their recommendation, it may have jeopardised the credibility of the study. Within 
future studies, it would be useful to find out whether having the ‘read and writing’ 
access to the notes improves the uptake of the recommendations made by the 
pharmacist. If the patient history could be viewed, subsequent recommendations 
could potentially be more clinically appropriate compared to the 
recommendations within this study.    
 
The study demonstrated the array of different recommendations and 
interventions that were patient-specific. However, the drawback of this was that 
there was no consistency in the type of interventions/recommendations 
performed for the study population (complexity bias), thus their individual 
contribution to the outcome measures cannot be quantified. Moreover, 
consistent duplication of these interventions in future studies is less likely to be 
predicted. 
 
6.4.5.1 Communication between pharmacist and prescriber 
It is the duty of all pharmacists to ensure that patients are prescribed the most 
suitable medication at the most relevant dose and frequency. If there is a more 
suitable dose, frequency or medicine, there must be a system in place to be able 
to advise the prescriber in a timely fashion. This could involve stepping up or 
stepping down treatment, as well as informing on any side effects or interactions 
that maybe occurring. 
 
An effective communication pathway must be developed in order to enable this 
pharmacy service and other similar services to support the primary care 
workload. This study model aimed to provide support to the generally 
overstretched general practice by reducing their traffic. Offering this diversity and 
choice to the patient helps to promote and maintain quality; however, 
collaborative and coordinated working amongst HCPs must be a fundamental 
component to the process.  
 
A limitation of the study was that there was no case discussion between 
pharmacist and physicians, an issue that has been longstanding (Bradley et al., 
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2008; Kolhatkar et al., 2016). Instead, letters were sent to general practice (one-
way) as a means of providing recommendations to the GP/RNS. Communication 
via NHSmail, would have been more secure and reliable than via postal mail, 
and may have resulted in a higher uptake of interventions. Future studies should 
look to not only develop relationships between the pharmacists and GPs, but 
also develop two-way communication to manage patient care more effectively.  
 
Liang et al. (2017) have recognised the benefits of collaborative working and 
have designed and implemented a care model that centres around an 
interdisciplinary approach to COPD management, aimed at reducing the burden 
of smoking and COPD in Australian primary care settings. This proposed 
‘RADICALS’ trial aims to provide patient-centred care through collaborative 
working relationships between a range of HCPs.   
 
6.4.6 Pharmacy clinics  
Bearing in mind that pharmacists are deemed to be experts in medicines, it is 
unsurprising that the vast majority of interventions made were medication-related 
(70.7%). Since the research pharmacist was a SRP, it was expected that a 
significant proportion of interventions were related to patients’ respiratory 
treatment (85.3%). The advantage of offering such a service using a pharmacist 
is that they can focus on the patients’ medicines to ensure that the medicines 
were optimised.  
 
The drawback of recommending alterations to patients’ medication was that the 
patient may not have been able to retain the new information given to them, 
which may have adversely affected their treatment. However, this was identified 
in the methodology and it was decided that offering a NMS to support the patient 
was an evidence-based intervention that ensures improved uptake of information 
(Elliott et al., 2014). Tying this study to the NMS was fundamental to aid 
medicines adherence and provided continued support for long-term conditions 
such as COPD. However, a significant limitation of this study was that a NMS 
could only be conducted by the pharmacy that dispensed the patient’s 
medication, thus, a proportion of participants could not have been offered a NMS 
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by the same pharmacist. The NMSs that were offered by the SRP were 
conducted in both groups, via telephone. 
 
Practically, for pharmacy clinics to come to fruition, the pharmacist’s time must 
be freed up. The service must be sufficiently incentivised for pharmacy 
contractors to pursue alongside their other pharmacy services. In such cases, 
future studies could utilise accuracy checking technicians to back fill the 
checking element of the dispensing process and free up pharmacist’s time.  
 
6.4.6.1 Patient feedback  
The general feedback from patients participating in the study regarding a SRP 
conducting clinics from a community pharmacy was that the clinics were very 
useful and that they benefitted significantly from the consultations. A limitation of 
the questionnaire was that, although it was anonymous, the patient may have 
felt obliged to give positive feedback as it was sent back to the research 
pharmacist (see Appendix 14 and 15 in Sections 9.17 and 9.18). In a future 
study, participants could send the responses to an independent person to 
analyse and participants would be assured that the data was anonymised from 
the pharmacist conducting the clinic. 
 
The length of these consultations was favourable, and the participants seemed 
contented that a HCP had the time to listen to them and offer useful medication-
related advice. In future, if community pharmacy is able to access patient 
records, many of the tests may not be necessary, such as oximetry, as this 
information may have recently been obtained by their general practice and so 
will shorten the consultation length. If these clinics became part of routine 
practice, pharmacists would focus specifically on patients’ needs, as opposed to 
checking all parameters (e.g. spirometry) for the sake of a research study, which 
will improve time efficiency. In addition, if pharmacists get access to patient 
notes, clinic time can be reduced further as they would not require a PC if the 
tests have already been carried out.   
 
It was concerning to hear that several COPD patients had deprived themselves 
of the healthcare system to date. Four patients last visited their surgery over 5 
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years ago. A recruitment bias may have been created, as patients that had not 
visited their GP may have felt more comfortable visiting a pharmacy. Some 
participants may have taken part in the research to obtain an alternative opinion. 
Conversely, other patients commented on being keen to be a part of research.  
 
6.4.6.2 Pharmacists in clinics 
Although conducting a single pharmacist study created a consistent approach to 
the consultations, especially since the knowledge of the SRP does not vary 
considerably between consultations, it was unlikely to mimic a future definitive 
trial where there would be variation between sites. Another drawback was that 
the pharmacist conducting the clinics had specialist respiratory therapy 
knowledge, which is not typical in community pharmacy. Thus, this single-
specialist pharmacist study may not be predicted and consistently duplicated 
elsewhere. 
 
There is increasing evidence that medication review improves process outcomes 
of prescribing, including reduced polypharmacy, more appropriate medicine 
selection and formulation (Blenkinsopp et al., 2012). Delving further into clinical 
roles, pharmacists can offer pragmatic solutions to certain patients, especially 
given the over-reliance on GP practices and A&E services, where, in certain 
circumstances, pharmacist’s expertise is appropriate to advise the patient. This 
can reduce the pressures on these services and free up space for the more 
serious conditions. To help ease such pressures, there could be a mechanism 
whereby patients are referred to prescribing pharmacists residing in community 
pharmacy and once assessed, there should be a pathway to prescribe 
appropriate ailments within the pharmacist’s competence. Supporting the GP 
and A&E operations are key, especially during the winter period, where at times, 
these services fail to meet demands.   
 
Pharmacy clinics should be conducted by prescribing pharmacists since they 
have a comprehensive qualification that appreciates the risks in prescribing, as 
well as addresses consultation styles. Pharmacists conducting specialist clinics 
could eventually undergo extra specialist training to offer COPD clinics. With 
regards to this study, the SRP had been trained on the motivational interviewing 
  
181 
techniques which may have helped encourage patients to stop smoking or 
adhere to certain instructions and where a concordant approach was used where 
they were encouraged to participate in therapy.  
 
Future work that is to be undertaken across multiple sites will require a practical 
solution to enhance intervention fidelity. This could be assessed using audio 
recording especially if a multi-site approach is used, as a barrier to this study 
was that it became difficult negotiating a suitable time for both the participant and 
the second pharmacist (observer). Also, future definitive studies should recruit 
pharmacists of different experiences working in diverse range of community 
pharmacies in order to understand the practicalities and barriers to offering these 
clinics.  
 
6.4.6.3 Practicalities of Tele-Consultations 
A notable drawback to the use of TC was the inconvenience of providing a tablet 
and the additional setup time for each participant in the TC group. However, it is 
thought that once they have familiarised themselves with its use, it would 
become an efficient means of communication and save pharmacist’s time on 
domiciliary visits. Society is increasingly evolving to become IT competent as 
gradually more people are using smart technology. Future studies should offer a 
tablet device to those unable to access SkypeTM in a bid to maximise recruits 
whilst minimising selection bias. However, from a practical perspective, this may 
pose a logistical challenge over multiple sites.  
 
The obvious disadvantages of TCs are that they may deter patients who are 
technology-illiterate, as well as those not having the facilities to access TCs, 
however, this did not affect this study as both training and equipment were 
provided when necessary, which was a strength of the study design. It is also 
not possible to measure patients’ BMI, oximetry or use the In-Check DIAL 
remotely, unless each patient is provided with the equipment. Other issues of 
conducting TC include that it may dissuade patients from leaving their home and 
privacy is not always guaranteed from the patient’s side, so a strength was that 
this was checked with the patient before commencing the consultation.  
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A limitation of the study was the interrupted transmission, which can be caused 
by a slow internet connection, firewall settings, computer software or a busy 
network at either the pharmacy or the patient’s home. During one interruption, 
the TC had to be rescheduled, which inconveniently caused a 30-minute loss of 
productivity for the pharmacist and patient. Also, during key moments (e.g. 
demonstrating inhaler technique) there were several instances where the patient 
moved away from the camera view. When this occurred, patients were asked to 
demonstrate their inhaler technique again whilst ensuring they were in front of 
the camera. Apart from those instances, the transmission was otherwise 
uninterrupted and was of high quality, making tasks such as inhaler technique 
demonstrations effective.   
 
Other studies experienced some technical difficulties but did not elaborate on 
this any further. Reports of TCs becoming delayed, unsynchronised or 
compressing the video, so that facial impressions were hard to interpret are 
particularly likely when users have other applications running that are using a 
large amount of bandwidth (Greenhalgh et al., 2016). Studies beyond the 
medical literature have shown that the quality of bandwidth may be imperative 
to some kinds of clinical consultation (Krout et al., 2010). However, generally the 
findings suggest that the TC approach would also be beneficial in other fields.  
 
6.4.6.4 Conducting a New Medicines Service  
A NMS was conducted via telephone for both groups. It is recommended to 
conduct these via telephone in future studies as it proved to be much easier than 
arranging another Skype™ meeting and saved time. Comparing TCs to 
telephone consultations was outside the scope of this study; however, further 
studies should seek to investigate this. It was more favourable to conduct a NMS 
to reinforce the participant’s progress regarding adherence and patient 
understanding; however, it was outside the scope of this study to indicate 
whether this translated to increased adherence in comparison to those not 
having a NMS.  
 
A limitation was that the research pharmacist could not carry out a NMS on all 
patients involved in the study, since 23 participants were not using the 
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Drugs4Delivery pharmacy service. From patient recall it was established that 
none of these participants from other pharmacies reportedly received a NMS or 
MUR within the 6-month study period.  
 
When designing the study, it was considered to write to all their pharmacies to 
inform them of this study and to ask whether they would conduct a NMS if their 
patients were prescribed a new medication. The NMS follows a specific protocol, 
so having this conducted by another pharmacy and pharmacist should be a 
negligible variable. However, it was considered that this method would not 
guarantee them conducting a NMS; also, from a logistical perspective, and given 
the time constraints of carrying out this operation, it was unrealistic to afford too 
much time to chase up the NMS for this study.  
 
The number of NMSs potentially could have been higher had Drugs4Delivery 
pharmacy offered to conduct them on their behalf, via telephone and without 
Drugs4Delivery pharmacy receiving reimbursement for the service. However, if 
the participant is using another pharmacy, the research pharmacist would not 
have been aware of the newly prescribed medicine to invite them for a NMS. A 
future multi-centred RCT will be able to work with the other pool of pharmacists 
to capture more patients to conduct a NMS. A possible solution to conducting 
the NMSs would be to provide funding to the practice pharmacist to conduct the 
NMS regardless of whether the patient belongs to their pharmacy or not. This 
will provide the pharmacist an incentive to conduct them. 
 
6.5 Implications for practice 
Community Pharmacy Forward View (PSNC, 2016) has stated that community 
pharmacists have a central role to play in finding solutions that can secure the 
best possible future for the NHS and the public’s health. They invite and 
challenge community pharmacy owners and leaders to demonstrate their 
potential and find new ways of supporting a high performing and affordable NHS, 
despite similar financial pressures to other providers within healthcare, with 
pharmacy contractors experiencing approximately 15% reduction in income 
(Connelly, 2016). Consequently, many contractors fear their businesses may no 
longer be viable. In the midst of the unprecedented strain on both resources and 
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demand, community pharmacy must adapt to the continually evolving NHS and 
utilise the professional knowledge and expertise of their community pharmacists 
and their associated teams.  
 
Conducting this research supports the GOLD (2017) objectives, which advocate 
that various approaches to managing this essential public health condition must 
be researched. GOLD (2017) also recommends the use of inter-professional 
care management throughout all levels of care. The NICE guidance for COPD is 
in development with an expected publication date of 28th November 2018. 
Essentially, this research study highlighted a number of key matters that could 
support the management of patients with COPD. These consist of medicines 
optimisation, patient education, the development of a training program to validate 
pharmacists to conduct such clinics, read-write access to patient notes, more 
formal systems for linkage to GPs and TCs. The innovative notion of this study 
is conducting pharmacy clinics via TCs. In theory, pharmacists generally do not 
require the patient to be physically examined or be in co-location, so the principle 
of conducting TCs is appropriate when patients cannot be accessed.  
 
Accessibility is a fundamental component of community pharmacy. However, 
this is not the case for a proportion of patients that are incapable of accessing 
their pharmacy. This study has demonstrated the feasibility of utilising TC to 
access these harder-to-reach patients, who potentially require more support 
from their pharmacist with regards to their medicines use.  
 
In the provision of community pharmacy COPD clinics, the study determined the 
feasibility of the rate of patient recruitment, retention, acceptability of TC, 
practicalities and completeness of data collection for outcome measures. Thus, 
providing crucial data to inform a definitive trial to test the impact of pharmacist 
interventions via TC amongst patients with COPD, whilst reducing health 
inequalities. If TC proves to be secure, safe and as effective as IPC in all 
outcome measures, then TC could be incorporated into the services offered 
within community pharmacy.  
 
Working with general practice, GPs could refer the harder-to-reach patients to 
community pharmacy, for a TC. Alternatively, these patients could be identified 
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from the pharmacy’s customer base (for example, those receiving a delivery 
service) and booking relevant hard-to-reach patients in for a Skype appointment. 
The pharmacist should initiate the TC call. If there are any issues or technical 
difficulties, the pharmacist could telephone the patient/carer to advise them. This 
study demonstrated that during the TC, it is feasible for the patient to receive 
guidance on their COPD condition and medication and an assessment of the 
appropriateness of their medication and/ device. It has also been shown that 
patients can be educated on how to manage exacerbations with their rescue 
pack. Services such as pulmonary rehabilitation, smoking cessation and 
vaccinations could also be considered. A COPD management plan can be made 
and emailed to the patient. The pharmacist may still deem that an IPC is required 
to help the patient further. Any recommendations and/ interventions made could 
be sent to the GP via the secure NHSmail system. Then, if the GP acts on the 
recommendations, a COPD- specific MUR/NMS could be conducted via 
telephone in order to help embed the information they received and check they 
are adherent to their treatment regimen.   
 
The contribution this COPD TC clinic might make to patient care is significant, 
as it could target those that rarely access their pharmacy and arguably most at 
need of pharmaceutical care. It could be particularly useful during an 
exacerbation or between GP visits. TC could, in theory, enable better 
communication with the patient than via telephone, whilst maintaining the remote 
accessibility. Such COPD-specific interventions would enable medicines 
optimisation, which helps assure the NHS that this significantly large investment 
in medication is used optimally by patients.  
 
This research study demonstrated the educational benefits a community 
pharmacist can offer to their patients. This study demonstrated the different skill 
set pharmacists have to other HCPs and how this can be used in the provision 
of interventions and personalised action plans; it also addressed adherence and 
inhaler technique issues and signposted to other services. Having either a IPC 
or a TC must be a negotiation between the patient and HCP depending on the 
type of circumstance, e.g. clinical need or patient preference. Currently, there is 
no commissioned service for medication review that pharmacists provide which 
is specific to COPD. However, in future, such IPC could be set up within the 
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community pharmacy consultation room and offered to patients opportunistically 
i.e. while waiting for their prescription; they could also be referred by a HCP, or 
given appointments, as per this study.  
 
This study found that 35% of participants in the IPC group would not like to use 
TCs, although this was lower in the TC group (29%) after having experienced it. 
In terms of preparation, it was easier to phone a patient as this is customary 
practice, however, if and when TCs become more prevalent, this study has 
shown that individuals are likely to become accustomed to it and therefore less 
preparatory work from the pharmacy staff will be required. Most importantly, TCs 
could potentially make pharmaceutical care more accessible to the immobile or 
inaccessible patient to enable an all-inclusive NHS. Currently, pharmacists only 
access these patients via telephone or a rare domiciliary visit. TC offers the 
visual advantage over a telephone consultation and saves time and money over 
domiciliary visits.  
 
The convenience this technology affords to the HCP is vital as it means that they 
will reduce their domiciliary visits and thus time spent on the road, which would 
lower costs (see Figure 16 in section 5.5.4). Although supported by Udsen et al. 
(2017), it was still unexpected that the total NHS costs of offering this COPD 
pharmacy clinic was significantly more during the 6-month study duration than 
the 6-months prior to the study, for both the IPC and TC groups. However, the 
pharmacy clinics were proved cheaper than conducting domiciliary visits. Also, 
the expense of pharmacy clinics can be reduced by not duplicating all the tests 
that general practice may have carried out. A solution to this would be to grant 
community pharmacy access to patients’ notes. Also, there was a cost accrued 
for its setup that has been factored into these clinics.  
 
At a time of economic uncertainty, commissioners will be drawn to methods that 
enhance patient care whilst lowering service costs. There is plenty that can be 
learnt from this research; however, this work should only be considered the 
beginning for conducting pharmacy COPD clinics with the additional option of 
utilising TC for inaccessible patients. Rolling out this model across the NHS will 
support the optimisation of patients’ regimens, which in turn should help lower 
traffic in general practice (as shown in Figure 14 in section 5.5.4). It is important 
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to note that, currently, any recommendations made by the pharmacist may only 
be implemented if the participant visits their GP/RNS. It is envisaged that this 
service would actually save money, once the prospective read-write access to 
patient’s shared care record is in place and a pathway is created for prescribing 
community pharmacists to utilise their prescribing skills. It would then be more 
appropriate for the prescribing pharmacist to implement any interventions they 
would like to make alongside access to patient notes. It is predicted this will 
reduce the referrals made to GPs where pharmacists can competently deal with 
an issue, which should lower the traffic into general practice for both IPC and 
TC.  
 
The feasibility study can contribute considerably to the development and 
evaluation of a definitive study to test medication review services within a 
community pharmacy. It also reinforces the recommendation for the introduction 
of medicines optimisation, patient education, read-write access to patient 
records and better communication systems to general practice.  
 
Fears have been expressed that TCs may be clinically unsafe (Greenhalgh et 
al., 2015), which is more likely to be true for medical consultations requiring 
patient examination and thus co-location of patient and practitioner is usually 
necessary in these instances (McLean et al., 2010). This is in contrast to 
pharmacists, who predominantly only require visual confirmation of a patient’s 
symptoms to provide pharmaceutical care, although there are instances where 
co-location of patient and pharmacist are required, such as administering the 
influenza vaccine. Thus, from a practical perspective, TCs are not acceptable to 
all patients, and they bring significant technical, logistical and regulatory 
challenges (Greenhalgh et al., 2015). 
 
If pharmacy COPD clinics prove favourable to the healthcare arena, there may 
be an opportunity to fully utilise the skills of pharmacist prescribers within these 
clinics. However, before this is considered, an IT infrastructure must be fully 
developed to enable read-write access to patient notes as well as a more efficient 
two-way communication network that links community pharmacy to general 
practice. Additionally, it is feasible for all pharmacists to counsel on correct 
inhaler technique, adherence, trigger avoidance and healthy living. Many 
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pharmacies already provide smoking cessation advice and influenza 
vaccinations. Monitoring of COPD control could be performed by all community 
pharmacists using the simple validated tool, CAT. However, these clinics include 
the provision of management plans and suggestions to optimise medication, 
which would require more specialist knowledge.  
 
The ultimate purpose of these pharmacy clinics will be to optimise 
pharmacotherapy in a bid to stabilise COPD control. This study has 
demonstrated the feasibility and provided an insight into the practicalities of 
conducting COPD clinics via TC. With respect to COPD control, proceeding to 
full-scale studies will be required to ascertain whether TCs are deemed non-
inferior to IPCs, and thus be utilised as supplemental to a pharmacists’ 
consultation armoury in a bid to access harder-to-reach patients who may 
otherwise have been deprived of pharmaceutical care.    
 
The next chapter will summarise the progress which has been made in achieving 
the aims of the research and its contribution to knowledge.  
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7. Conclusions and further areas to be explored 
7.1 Conclusions 
COPD is a major cause of chronic morbidity and mortality worldwide. It is 
regarded as one of the most expensive diseases to treat in the UK and accounts 
for more time off work than any other condition. Its symptoms often cause 
anxiety, insecurity, immobility and social isolation; these are related to a lack of 
control and vulnerability (Mathar et al., 2015). Immobility and social isolation are 
important factors that need to be addressed if we wish to provide accessible 
healthcare to all patients with COPD. The use of assistive technology to offer 
consultations e.g. Skype™, is seen as one possible solution to circumvent 
accessibility issues and the feeling of isolation when individuals with COPD are 
suffering at home.  
 
Currently, a proportion of inaccessible COPD patients can only be reached via 
telephone, which lacks the visual communication feature, or a domiciliary visit, 
which is time-consuming. So, this feasibility study was conducted with patients 
randomised to ‘intervention’ or ‘treatment as usual’ in a community pharmacy-
based COPD clinic. The study aimed to establish further work required to 
proceed to a definitive trial to test the impact of pharmacist interventions via TC 
amongst patients with COPD. The objectives were to determine feasibility of the 
rate of patient recruitment, retention, acceptability of TC, practicalities and 
completeness of data collection for outcome measures used to assess COPD 
control and management. The innovative aspects of the study include: a 
thorough review of patients with COPD using TCs with the patient at home and 
the pharmacist residing in the consultation room of their community pharmacy; 
comparing COPD TCs to IPCs; and carrying out a COPD service from a 
distance-selling internet pharmacy. 
 
In order to situate this new way of working against existing knowledge, the 
literature search reviewed two key areas: how pharmacists contribute to the 
management of COPD and how HCPs in general have utilised TCs within their 
practice when caring for patients with COPD. There was particular focus on 
measureable aspects, namely, interventions, adherence, inhaler technique, lung 
function, exacerbations, HR-QoL, acceptability of TCs and cost. The limited 
  
190 
literature within this domain has shown that a number of interventions are 
effective in the management of COPD, including educating patients on their 
medication, adherence, inhaler technique and self-management. There were 
only three studies found in the literature search that utilised TCs within their 
practice when managing patients with COPD. This study has substantially 
contributed to research in this field by demonstrating the feasibility of reviewing 
patients with COPD using TCs.  
 
The outcome measures were adherence (measured the MARS questionnaire), 
inhaler technique (measured using inhaler checklists), lung function (measured 
using spirometry), exacerbations (measured by establishing the provision of 
rescue medication), acceptability of TC (measured using an acceptability 
questionnaire), QoL (measured using EQ-5D-5L) and cost-effectiveness of the 
interventions (measured using calculations that were based on Wright et al., 
2015). Both groups received personalised interventions from the same SRP 
using evidence-based practice to ensure best outcomes. The validated outcome 
measures used were relevant to routine practice and were recommended 
endpoints for most clinical COPD studies (Paap et al., 2016) as well as the 
international guideline (GOLD, 2017), ensuring the study was comparable and 
remains relevant. 
 
This feasibility study was conducted from a single pharmacy with a single SRP. 
Twenty-four patients were randomly assigned to the IPC group and 24 to the TC 
group. Twenty-five participants recruited over 2½ months from the pharmacy 
customer base (equating to 27% of those eligible to enter) and a further 23 
recruited from local advertisements over an additional 1½ months. Thus, the 
recruitment target of 40-participants was exceeded by 1-participant (15% attrition 
rate), which demonstrates that patients can be recruited to future, larger studies 
via their pharmacy patients and by wider advertising in the local media. The study 
recruited a representative sample of participants with COPD; however, this 
sample had a lower socio-economic status when compared to the COPD 
population in the UK. One patient (2.1%) was a never smoker, 58.3% were ex-
smokers and 39.6% were current smokers. Twenty-five (52%) of the 48 
participants were men. The IPC group had a marginally worse mean CAT score 
of 26.04 compared to 23.96 (Note:  2 units is a clinically significant difference 
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in CAT score). A multi-centred approach would be required to recruit sufficient 
numbers for a definitive study.  
 
Participants were randomly assigned, using the random permuted block 
randomisation technique (in a 1:1 ratio), to the two study groups after this was 
explained to them. Randomisation was acceptable once participants were 
informed that both arms would receive the same treatment and TC was more 
acceptable one participants had experienced the process.  
 
The results of this study demonstrated that the management of patients with 
COPD through the provision of pharmaceutical care using TCs from a 
community pharmacy-based SRP is feasible and indicated completion of the 
collection of all COPD outcomes, including COPD control, COPD management, 
inhaler technique, adherence, lung function, exacerbations and acceptability of 
TC. This study found that 41.7% of participants in the IPC group would prefer 
IPC over TCs, although this was significantly lower in the TC group (29.2%) after 
having experienced its convenience during the study. In the study, Skype™ 
transmission was affected on several occasions, however, it is expected that 
these technicalities will improve over time as internet connections improve. Other 
practical barriers were not having access to patient records and patient being 
out of view of the camera during transmission. Despite this, the study’s 
objectives all confirmed the feasibility of TC and should now progress to a multi-
centred pilot study.  
 
This research showed a marked decrease in the number of participants visiting 
their GP as well as a significant increase in the number of participants visiting a 
community pharmacy during the study period.  
 
Unexpectedly, the total NHS costs of offering this COPD pharmacy clinic were 
significantly more than the 6-months prior to the study, for both groups, however, 
this was significantly less than providing domiciliary visits. The increased costs 
of running a pharmacy clinic can be explained by the duplication of tests that 
was carried out (which would have been avoided by being granted access to 
patient notes). These clinics are, however, considered cost efficient as there is 
an initial setup cost accrued that has been factored into these clinic costs. 
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Additionally, since COPD is progressive, severity is expected to increase over 
time and especially considering follow-up was during the winter period, both of 
which increase costs.  
 
This study exhibits proof of concept of a SRP conducting COPD clinics via TCs, 
with the eventual aim of supporting general practice and helping to sustain the 
healthcare system as a whole. The idea of these clinics is to keep symptomatic 
patients out of hospital and treated in primary care longer during the winter 
period, in a season where there is a higher incidence of exacerbations and 
admission rates, which overstretches healthcare services. Interventions during 
this study included education of the condition and medication, adherence, inhaler 
technique training, self-management strategies, signposting and medicines 
optimisation, which aided the stabilisation of COPD. A protocol enabled 
standardisation of the complex intervention (See Appendix 6 and 7 in Section 0 
and 9.7). Patient feedback regarding pharmacy clinics were positive.  
 
The feasibility study has identified the need for a multi-centred pilot study prior 
to progressing to a full-scale definitive study. This should resemble the main trial 
in many respects, particularly in study design. The main study will aim to provide 
definitive evidence as to whether TCs are non-inferior to IPC. It is expected that 
TCs will not replace the IPC but will serve as an additional option. Since, IPC 
allows the pharmacist to observe full body language. While some body language 
is visible in a Skype™ format, typically only the upper body and face, telephone 
consultations offer no visual communication. As a community pharmacist, full 
body language is generally not required, although body language cues, such as 
nervousness conveyed by hand behaviours, could be lost.  
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7.2 Recommendations for future research, policy and 
clinical practice 
TC warrants further investigation as a potentially promising medium to deliver 
consultations to patients with COPD. Further studies should pilot a multi-centred 
collaborative approach with more pharmacists involved and with a more 
integrated approach with GPs. These prospective positivist studies should 
include an additional arm, which compares usual care (not exposing patients to 
pharmacy clinics) with IPCs (this time, conducted from the patient’s abode rather 
than the pharmacy consultation room) and TCs, in order to verify the significance 
of pharmacy clinics. However, recruiting another group in a much larger study, 
may prove particularly challenging in a 4-month recruitment timeframe, and so 
is likely to require a longer recruitment window, conducted on multiple sites. Also, 
since future studies will involve multi-dimensional outcomes, they will present a 
range of options for analysis, thus statistical advice should be sought early on.   
 
Funding permitting, future studies could consider the following: separating the 
data collection and analytical process from the research pharmacist, recruiting 
only the immobile or inaccessible participants and a pharmacy technician 
conducting a PC (BMI, In-Check DIAL and oximetry) followed by a pharmacist 
conducting the TC to optimise the medication of patients. The GOLD (2017) 
guidelines have suggested that it is no longer a requirement to measure lung 
function (spirometry) to manage patients with COPD. Also, prospective TC 
studies should focus on longer-term studies (12 months) that centre on COPD 
and other long-term conditions, e.g. diabetes, in order to make more accurate 
assumptions.  
 
An outcome from this feasibility study was the lack of read-write access to 
patient’s records from community pharmacy, and thus establishing a 
communication network between general practice and community pharmacy 
was challenging. This issue of communication has been looked into by 
authorities who are encouraging community pharmacies to register with an NHS 
email address (NHSmail) in order to receive secure information between HCPs 
e.g. hospital discharge information. Community pharmacies are beginning to 
develop an infrastructure to offer such pharmacy COPD clinics; for example, 
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there is at least one consultation room installed in the vast majority of 
pharmacies. More comprehensive research is needed in this area, particularly in 
trialling a prescribing pathway for prescribing pharmacists within community 
pharmacy, which would necessitate read-write access to patient notes to 
improve the communication pathway. A model whereby community pharmacists 
prescribe must involve greater collaboration with HCPs, such as GPs and RNS, 
where there is scope to discuss particular cases for the betterment of patient 
care. There may be greater success in forging effective communication avenues 
with the practice-based pharmacist. A model such as this would encourage 
communication between community pharmacy and general practice, and if 
proven successful, could unlock the support of 2,400 prescribing pharmacists 
working in community (~8% pharmacist prescribers of 30,000 community 
pharmacist workforce) (Prescribers survey report, 2016). Creating a mechanism 
for community pharmacists to prescribe is likely to increase the number of 
prescribing pharmacists working side-by-side with a responsible pharmacist and 
bridging the gap with, general practice. This model would provide medicines 
management support for patients with long-term conditions, which in turn, would 
support the capacity in general practices. 
 
Pharmacists must continue to focus on adherence and inhaler technique during 
MUR/NMS in order to ensure treatment is optimised. In view of the fact that the 
majority of interventions and recommendations made during this study were not 
picked up during the usual activities of a community pharmacist, holding COPD 
clinics whereby a SRP resides in the consultation room makes it more conducive 
to detecting issues and offering interventions to patients and recommendations 
to their GP. This model not only utilises the skill set of pharmacists away from 
the demanding dispensing process, but also offers the NHS a solution to the 
intensifying demands placed on general practice; 
 
By the 6-month follow-up, there was a relatively low uptake of recommendations 
by GP/RNP. However, uptake of interventions not requiring a prescriber were 
only slightly more (but not significantly more) than the uptake of 
recommendations made to the prescriber. Thus, a noteworthy limitation of the 
study was not uncovering why the recommendations failed to be acted on. It is 
possible to speculate that low response rates were the result of disengaged GPs. 
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Future definitive studies can address this by maximising GP engagement with 
the intervention/s; this can be achieved by investing the necessary time in 
presenting the study to the surgeries in the locality. Also, their involvement in the 
study design may be telling as well as sharing the study findings at endpoint.  
 
Finally, extensive qualitative studies and mixed methods studies are sparse in 
this domain and future research could be directed at exploring and uncovering 
trends in thought and opinion of how TC affects the users’ identities, 
experiences, expectations, motivations and capabilities to influence interaction 
(Greenhalgh et al., 2016). Thus, the researcher gains in breadth and depth of 
understanding and corroboration, while offsetting the weaknesses inherent to 
using each quantitative or qualitative research method by itself.  
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9.8 Appendix 8: Baseline characteristics 
 
 
 
Table 16: Baseline characteristics  
 
IPC, In-Person Consultation; TC, Tele-Consultation; SD, standard deviation; IQR, 
interquartile range; A&E, accident and emergency; FEV1, forced expiratory volume in 
one second; FEV1/FVC, ratio of forced expiratory volume in one second against the 
forced vital capacity; SABA, short-acting β-agonist; SAMA, short-acting muscarinic-
agonist; LABA, Long-acting β-agonist; ICS, inhaled corticosteroid; LAMA, long-acting 
muscarinic-agonist; PDE4 inhibitor, phosphodiesterase-4 inhibitor; A1AT, σ-1 antitrypsin 
augmentation therapy.  
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It is important to mention that the previous GOLD assessment system 
incorporated spirometry, however, at the individual patient level, FEV1 loses 
precision and thus cannot be used alone to determine all therapeutic options 
(GOLD, 2017); as a result, it has now been dissociated from the severity 
classification (GOLD, 2017). Current pharmacologic treatment algorithms dictate 
that group C start with a LAMA and escalate to the preferred LAMA-LABA or 
LABA-ICS if exacerbations persist. Group D start with the preferred LAMA-LABA 
(or LAMA monotherapy or LABA-ICS) and escalate to LAMA-LABA-ICS if 
symptoms persist. A macrolide can be added if further exacerbations occur 
(GOLD, 2017).  
 
 
Figure 19: The Gold Assessment 
 
The process of classifying patients into quadrants starts with the mMRC and CAT, which 
is used to determine whether the patient belongs to the left (less symptoms) or right 
(more symptoms) side of the box. Then, risk of exacerbation should be assessed to 
establish whether the patient belongs to the lower (low risk) or upper (higher risk) 
quadrant (Demeyer et al., 2016). In this study, the baseline data for the number of 
participants falling into each quadrant were indicated at the top of each quadrant. 
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Figure 20: Shows the number and percentage of the study populations’ co-
morbidities at baseline. 
 
 
 
 
 
Figure 21: The number of patients per surgeries spread across the North-
East Lincolnshire region.  
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Figure 22: The patients’ mean Inspiratory Flow Rate via various inhaler 
devices prior to being counselled at baseline. The bars indicate the correct 
inspiratory flow rate for each device.  
 
IPC, In-Person Consultation; TC, Tele-Consultation; MDI, pressurised metered dose 
inhaler; Acc, Accuhaler; TH, Turbohaler; EB, Easi-Breathe; EH, Easyhaler; Resp, 
Spiriva respimat; Ell, Ellipta; Spir, Spiromax. 
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9.9 Appendix 9: COPD Assessment Test  
CAT score 
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9.10 Appendix 10: Visual Analogue Scale  
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9.11 Appendix 11: Modified Medical Research Council 
Dyspnoea Scale 
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9.12 Appendix 12: Medication Adherence Questionnaire 
(MARS) 
 
 
 
 
 
 
  
  
252 
Medication Adherence Questionnaire 
(A template to record answers to MARS) 
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9.13 Appendix 13: Morisky Adherence Scale 
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9.14 Appendix 14: Inhaler technique checklist 
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9.15 Appendix 15: Interventions 
9.15.1 Interventions during baseline COPD clinic 
Table 17: Interventions during COPD clinic at baseline  
 
 
 
IPC, In-Person Consultation; TC, Tele-Consultation; n, number of participants; ICS, 
inhaled corticosteroid; PR, pulmonary rehabilitation; GP, general practitioner.  
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Aside from incorrect inspiratory rate and a lack of co-ordination, the other notable 
error arose in priming the Accuhaler and Turbohaler devices. With the MDI, the 
main error was in demonstrating inadequate coordination of inspiration with 
inhaler activation (Figure 28). However, patients with spontaneous breathing, 
good dexterity and poor inspiratory flow benefitted from a MDI. There were also 
failures in priming the Turbohaler device in the vertical position, as well as 
priming the Accuhaler during, rather than prior to, inhalation.  
 
Patients with more severe COPD had difficulties achieving the minimum 
inhalation rate required for a DPI and were advised to switch to a more suitable 
device, while those with inadequate co-ordination but sufficient inspiratory flow 
favoured the DPI or a MDI with a spacer (Broeders et al., 2009). A spacer was 
recommended to those with severe airflow obstruction, patients for whom low 
confidence is related to diminished inspiratory flow, or those having difficulties 
using inhaled devices due to hand strength, impaired cognitive function or 
manual dexterity (Barrons et al., 2011).   
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9.15.2 Interventions requiring a prescriber 
 
Figure 23: The number of recommendations related to COPD medication 
made to a prescriber versus the actual number of implemented 
interventions by the prescriber over the 6-month study duration.  
 
IPC, In-Person Consultation; TC, Tele-Consultation 
 
 
A second pharmacist, employed by Drugs4Delivery pharmacy, reviewed the 
data for all participants retrospectively. He was blinded to knowing their allocated 
group and documented his own recommendations, based on all the information 
provided, without seeing the recommendations made by the SRP. The idea of 
this was to give an indication of how a non-specialist might be able to conduct 
the clinics. These interventions included switching inhaler device, stopping a 
medicine, addition of a medicine, optimising a medicine and issuing a rescue 
pack (all of which can only be carried out by a prescriber).  
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9.15.3 Interventions not requiring a prescriber 
 
 
Figure 24: The number of interventions not requiring a prescriber, that 
were implemented by the patient at the 6-month follow-up.  
 
IPC, In-Person Consultation; TC, Tele-Consultation; PR, pulmonary Rehabilitation; GP, 
General Practice.  
 
 
As above, a second pharmacist reviewed the data for all participants 
retrospectively. He was blinded to knowing the allocated group of the participants 
and documented his own recommendations without seeing the 
recommendations made by the SRP. These interventions relate to smoking 
cessation, lifestyle advice, adherence, side-effects and inhaler technique, and 
did not include provision of COPD self-management plans or referrals to 
pulmonary rehabilitation, GP or secondary care.  
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9.16 Appendix 16: Before and after comparisons  
9.16.1 Inhaler Technique Score 
 
Figure 25: Effect of inhaler technique counselling on inhaler technique 
score between the IPC and TC groups.  
 
IPC, In-Person Consultation; TC, Tele-Consultation.  
 
The inhaler technique score is the number of step(s) performed correctly when 
using the inhaler device. Since the data is non-parametric, a Wilcoxon signed-
rank test is used to compare the difference in inhaler technique.  
 
The percentage inhaler technique scores significantly improved from baseline 
(before counselling) to the 6-month follow-up for both IPC (p = 0.001) and TC 
groups (p < 0.001). In fact, on most occasions, the data showed that the mean 
inhaler technique for TC improved to a greater extent than IPC, however, this 
improvement was not significant (see Figure 25). These results are broadly 
consistent with other studies that focus on pharmacist interventions to improve 
inhaler technique (Tommelein et al., 2014; Wright et al., 2015), however, since 
this was the only study that counselled on inhaler technique via TCs, there was 
nothing found in the literature to make direct comparisons to. Also, adherence to 
participants’ medication had almost doubled in both groups over the 6-month 
study duration.  
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Table 18: Summarising Suitable Inspiratory Flow Rate when using each 
Inhaler Device 
 
 
Adapted from Haidl et al. (2016)  
pMDI, pressurised metered dose inhaler  
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At baseline, the most prescribed device was the pMDI (85), followed by the 
HandiHaler (21), then the Easi-Breathe (20) for patients in both IPC and TC 
groups; at 6-month follow-up this changed to 77, 22 and 26, respectively. Also, 
at endpoint, there were a total of 5 more inhalers prescribed in the IPC group 
compared to 9 more in the TC group when considering all devices (see Table 
19). At baseline, patients were most frequently prescribed 2 inhalers (10 patients 
in IPC versus 11 in TC). Also, only 3 patients had 4 inhalers in the IPC group 
compared to 1 in the TC group; no patient had 4 inhalers at endpoint. 
 
Table 19: Prescribed Inhalers, prior to the Baseline Recommendations and 
at the 6-month Follow-up. 
 
 
 
IPC, In-Person Consultation; TC, Tele-Consultation; pMDI, pressurised metered dose 
inhaler. 
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Table 20: Inhaler technique education prior to and after clinic 
 
 
IPC, In-Person Consultation; TC, Tele-Consultation; HCP, healthcare professional; GP, 
general practitioner; RNS, respiratory nurse specialist.  
 
There was little difference between the different types of inhalers prescribed 
between the two groups at baseline (T = 0), however, there were 29.2% using a 
spacer in the IPC group compared to 4.2% in the TC group (see Table 17). At 
the 6-month follow-up visit (T = 6-months), 33.3% of the IPC group used a spacer 
compared to 20.0% in the TC group. Only 10.4% of patients from both groups 
had not previously received any inhaler technique training (Table 20). Almost 
two-thirds (64.6%) had received inhaler technique training from a primary or 
secondary care nurse. Most notably, the frequency of inhaler technique training 
by community pharmacists was relatively low (10.4%), however, after this study’s 
baseline consultations, this rose to 100% due to the pharmacist’s intervention. 
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Figure 26:  A comparison of the Inspiratory Flow Rates of both IPC and TC 
groups prior to counselling at baseline and at follow-up using an In-Check 
DIAL.    
 
IPC, In-Person Consultation; TC, Tele-Consultation; MDI, pressurised metered dose 
inhaler; Acc, Accuhaler; TH, Turbohaler; EB, Easi-Breathe; EH, Easyhaler; Resp, 
Spiriva respimat; Ell, Ellipta; Spir, Spiromax; Baseline (before counselling), tested prior 
to being counselled; Follow-up, tested at the 6-month follow-up without subsequent 
counselling.  
 
 
At baseline, before counselling, the average inhaler technique score across both 
groups was 77.2%. At baseline, after counselling, this rose to 97.6% for all 
patients and fell to 91.8% at the 6-month follow-up (see Figure 25). The 
percentage inhaler technique scores (SD) improved from baseline (before 
counselling) to the 6-month follow-up for both IPC [from 80.0 (5.92) to 92.4 (3.74) 
%; Wilcoxon -3.397, p = 0.001] and TC [from 74.2 (8.16) to 90.0 (3.91) %; 
Wilcoxon -3.608, p<0.001] groups. At follow-up, there was a slight difference 
between the percentage inhaler technique score for IPC (92.4 %) and TC (90.0 
%) (Mann-Whitney U 56.0, p = 0.094) (see Figure 25Error! Reference source not 
found.). Data collection using inhaler technique checklists were completed for all 
patients. 
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At baseline, 12 patients in the IPC group and 9 patients in the TC group 
demonstrated an inspiratory flow rate that was too fast for MDIs (see Figure 22 
and Figure 27). Immediately after counselling, only 4 and 1 patient(s) 
demonstrated an inspiratory flow rate that was too fast in the IPC and TC group, 
respectively; this increased slightly to 5 and 3 at the 6-month follow-up visit, 
respectively. The Accuhaler device had 1 and 2 participants with a slow 
inspiratory flow rate in the IPC and TC group, respectively. However, after 
counselling and at follow-up, these participants maintained the correct 
inspiratory flow. With the Turbohaler device, both groups had 2 participants with 
insufficient inspiratory flow rate. In the IPC group, the 2 participants in question 
were still unable to reach adequate inspiratory flow, even after counselling, due 
to their COPD severity, and this was the same reason for 1 participant in the TC 
group. After recommending an alternative device to their prescriber, only one 
patient was switched to an alternative device. At the 6-month follow-up, the 3 
remaining patients could still not reach the required inspiratory flow rate. This 
was similar with the Spiromax inhaler, however, far fewer patients were 
prescribed this device. The Easibreathe and the Respimat were used 
satisfactorily or optimally by all patients throughout the study.  
 
At baseline (before counselling), patients prescribed a MDI had a quicker mean 
inspiratory flow rate in the IPC group compared to the TC group 69.1 (IQR = 
51.6) L/min versus 53.4 (41.8) L/min; Mann-Whitney U 29.0, p = 0.024 (see 
Figure 26, Figure 27 and Figure 28). At follow-up, 6-months after educating on 
the required rate of inspiratory flow through a MDI, both the IPC and TC groups 
had lower means of inspiratory flow rate compared to baseline. IPC; 25.6 (IQR 
= 13.7) L/min; Wilcoxon -3.458, p < 0.001), TC; 33.2 (17.9) L/min; Wilcoxon -
3.174, p < 0.001). Also, at follow-up, both the IPC and TC groups had higher 
means of inspiratory flow rate through a Turbohaler compared to baseline. IPC; 
76.5 (IQR = 18.4) L/min; Wilcoxon -3.490, p < 0.001), TC; 72.8 (22.3) L/min; 
Wilcoxon -3.528, p < 0.001) (see Figure 27 and Figure 28).  
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Inspiratory Flow Rate 
 
 
Figure 27: The effect of pharmacist interventions on the number of patients 
with too slow, too fast or correct inspiratory flow rate through their inhaler 
devices between IPC and TC groups.    
 
IPC, In-Person Consultation; TC, Tele-Consultation; MDI, pressurised metered dose 
inhaler; Acc, Accuhaler; TH, Turbohaler; EB, Easi-Breathe; Resp, Spiriva respimat; Ell, 
Ellipta; Spir, Spiromax; Baseline, tested prior to being counselled; Baseline + counsel, 
tested after being counselled; Endpoint, tested at endpoint without subsequent 
counselling.  
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Inspiratory Flow Rate 
 
Figure 28: The effect of pharmacist interventions on the number of patients 
with unsatisfactory, satisfactory and optimal inhaler technique at baseline, 
between IPC and TC groups.    
IPC, In-Person Consultation; TC, Tele-Consultation; MDI, pressurised metered dose 
inhaler; Acc, Accuhaler; TH, Turbohaler; EB, Easi-Breathe; Resp, Spiriva respimat; Ell, 
Ellipta; Spir, Spiromax; Baseline, tested prior to being counselled; Baseline + counsel, 
tested after being counselled; Endpoint, tested at endpoint without subsequent 
counselling. Unsatisfactory inhaler technique equates to making at least one critical 
error; Satisfactory inhaler technique allows for several minor but no critical mistakes; 
Optimal inhaler technique equates to no mistakes when using device. 
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Unsatisfactory inhaler technique equates to making at least one critical error; 
satisfactory inhaler technique allows for several minor but no critical mistakes; 
optimal inhaler technique equates to no mistakes when using device (Klijn et al., 
2017a; Sandler et al., 2016; van Boven et al., 2016).  
 
At baseline, 62.5% and 70.8% had unsatisfactory inhaler technique using their 
MDI in the IPC and TC group, respectively. Also, a quarter of participants or less 
across both groups had optimal inhaler technique using their MDI, Accuhaler and 
Turbohaler devices (16.7% vs. 25.0% vs. 0%, respectively, in the IPC group and 
16.7% vs. 0% vs. 0%, respectively, in the TC group). After counselling during the 
baseline consultation, the majority (or at least half) of patients achieved optimal 
inhaler technique using their MDI, Accuhaler and Turbohaler (66.7% vs. 75.0% 
vs. 50.0%, respectively, in the IPC group and 54.2% vs. 75.0% vs. 50.0%, 
respectively, in the TC group). At the 6-month follow-up there were at least 50% 
more patients with optimal inhaler technique in both groups than baseline, using 
the MDI, Accuhaler and Turbohaler (33.3% vs. 40.0% vs. 20.0%, in the IPC 
group and 37.5% vs. 50.0% vs. 40.0%, in the TC group, respectively). The low 
numbers of the newer devices, such as the Spiromax, made comparisons 
needless. Figure 28 summarises patients’ inhaler technique by categorising 
them as unsatisfactory, satisfactory or optimal. 
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9.16.2 Adherence 
 
Figure 29: The mean number of participants within each group revealing 
their medication-taking behaviours between IPC and TC, using the MARS 
questionnaire.  
MARS, Medication Adherence Report Scale; IPC, In-Person Consultation; TC, Tele-
Consultation; PRN, when required; 0m, 0 months; 6m, 6-months.  
 
 
There was a slight difference between the two study groups for adherence within 
the 76-100% band at baseline (IPC: 9/24. TC: 7/24; 2 0.704, p = 0.572) or follow-
up (IPC: 15/21. TC: 13/20; 2 0.758, p = 0.496). At baseline, only 37.5% and 
29.2% had an adherence rate of between 76-100% in the IPC and TC arms, 
respectively, and increased at follow-up, to 71.4% and 65.0%, respectively. The 
frequency distribution of the histogram in Figure 29, shows that the distribution 
changes from platykurtic (negative kurtosis) at baseline to leptokurtic (positive 
kurtosis) at the 6-month follow-up.  
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Table 21: Inhaler adherence using the MARS questionnaire  
 
 
 
MARS, Medication Adherence Report Scale; IPC, In-Person Consultation; TC, Tele-
Consultation; SD, Standard Deviation.  
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9.16.3 CAT score 
 
 
Figure 30: Change in mean CAT score over the study duration. This type 
of data could be presented in a future, definitive study to compare COPD 
control between the IPC and TC groups. 
 
CAT, COPD Assessment Test; IPC, In-Person Consultation; TC, Tele-Consultation 
 
 
For both IPC and TC groups, there was an improvement from baseline to follow-
up in COPD control. More specifically, apart from ‘usual activities’ and 
‘pain/discomfort’ within the IPC’s arm of the EQ-5D-5L assessment, both groups 
improved from baseline to the 6-months follow-up (see Figure 34). However, 
both groups showed that these changes were not statistically significant. Also, 
for both IPC and TC groups there were improvements from baseline to follow-up 
in lung function (Figure 11 and Figure 32), and exacerbations, however, these 
were not significant (see Figure 33) However, this may be considered a positive 
outcome, as with time, patients’ lung function declines and cannot be reversed, 
due to the progressive nature of COPD. In addition, this study took place during 
the winter period, where a higher incidence of exacerbations take place and has 
more important consequences for patients in terms of increased morbidity and 
mortality. 
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Figure 31: A box-plot to show the distribution of CAT scores at 6-month 
follow-up between the two groups. In sufficiently powered, future studies, 
scores can be used to show any differences between study arms, when 
controlling for baseline CAT, 
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Lung Function 
 
Figure 32: The mean change in lung function (FEV1/FVC post 
bronchodilation) when comparing IPC and TC groups, over the study 
duration.  
 
IPC, In-Person Consultation; TC, Tele-Consultation; FEV1/FVC, ratio of forced 
expiratory volume in one second against the forced vital capacity. 
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Monitoring Exacerbations 
 
Figure 33: The mean number of steroid courses and hospital admissions, 
when comparing IPC and TC groups, 6-months prior to baseline and during 
the 6-month study.  
IPC, In-Person Consultation; TC, Tele-Consultation. 
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Table 22: The mean and standard deviation of EQ-VAS. 
 
 
 
IPC, In-Person Consultation; TC, Tele-Consultation. 
 
The European Quality of Life Visual Analogue Scale (EQ-VAS) is a subjective 
assessment used to seek an overall measure of health status (Feng et al., 2014). 
The EQ-VAS was presented as a horizontal line, marked from 0 (worst 
imaginable health state) to 100 (best imaginable health state) where participants 
were asked to draw a line to indicate how they feel in their opinion. It is a useful 
tool that is quick to administer and can be used along with the more objective 
EQ-5D-5L test.  
 
 
Table 23: Effect of interventions on COPD control 
 
 
 
IPC, In-person consultation; TC, Tele-consultation; CAT, COPD Assessment Test; SD, 
standard deviation; IQR, interquartile range; A&E, accident and emergency; FEV1, 
forced expiratory volume in one second; FEV1/FVC, ratio of forced expiratory volume in 
one second against the forced vital capacity; EQ-5D-5L, five-level version of the 
EuroQol five-dimensional questionnaire; *, Independent samples t-test.  
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Figure 34: The mean HR-QoL profile of the research population at baseline 
and endpoint, using the EQ-5D-5L assessment. 
 
IPC, In-Person Consultation; TC, Tele-Consultation; HR-QoL, Health-Related Quality of 
Life. A score of 1 equates to having no problems in that domain; 2 equates to having 
slight problems; 3 equates to having moderate problems; 4 equates to severe problems; 
5 equates to having extreme problems.  
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9.17 Appendix 17: Patient experience questionnaire 
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9.18 Appendix 18: Patient experience results  
 
 
Figure 35: A graph summarising patient experience after the baseline 
consultation in both groups.  
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9.19 Appendix 19: Conducting MURs via TC (Proof of 
concept) (Tatari, 2016) 
A significant proportion of patients are unable to visit their community pharmacy. 
In such circumstances, their pharmacy will order their medicines, collect their 
prescription and then dispense and deliver their medication to their homes 
(repeat prescription service). As expected, this service is considered essential 
amongst the immobile, disabled, homecare and the care home population who 
would otherwise find obtaining their medicines arduous. As these patients are 
not visiting their pharmacy premises, they are being deprived of the benefits an 
MUR service offers (unless of course the pharmacist sought NHS England’s 
approval for a telephone or a visit their home, for each and every visit). To date, 
this dilemma has not been comprehensively resolved.  
 
To summarise the one-month proof of concept carried out in January 2015, most 
patients had access to Skype™ through their Smartphone or computer. Of the 
25 patients contacted via telephone, 17 (68%) gave consent and had Skype™ 
access. Only 3 patients did not respond, representing an 88% response rate.  
 
Figure 36: A pie chart illustrating the number of patients accessible via 
Skype™ 
 
 
17
2
1
1
Consenting patients with Skype
access
Consenting patients without
Skype access
Non consenting patients
without Skype access
Non consenting patients with
Skype access
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The pharmacist conducted the MUR in the pharmacy consultation room with the 
patient transmitted on screen. There was no significant difference in the quality 
of MURs between Skype™ and the usual in-person pathway. Only 2 of the 17 
patients (12%) thought that they would benefit more from an IPC than Skype™ 
and 15 out of 17 (88%) patients would have another tele-MUR in future.  
 
 
Figure 37: A bar chart showing the results of a patient questionnaire 
 
From a positivist perspective, there were clear benefits to the number of tele-
MURs conducted rather than travelling to the patients’ homes, which can only 
assist the NHS financially. 3 patients (18%) did not know how to install or use 
Skype™, however, this was installed for them and they were trained on its 
application. It was found that, on balance, the benefits of this technology are 
substantial and can act as a supplement when MURs cannot be carried out in 
the pharmacy premises.  
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9.20 Appendix 20. Sample size calculation for future non-
inferiority study 
The primary outcome measure of the study is COPD control, measured by CAT. 
The CAT ranges from 0 – 40 (continuous outcome), with a change of 2 points 
being the minimum clinically important difference (Kon et al., 2014). The mean 
standard deviations of the CAT in similar populations was 2.55 (P. W. Jones et 
al., 2009; Pinto et al., 2014). In order to establish that TCs was non-inferior to 
IPCs, it was necessary to calculate the correct sample size using a continuous 
outcome non-inferiority trial equation below (Julious, 2004): 
 
n = f(α, β) x 2 x σ2 
       d2 
 
N Total sample size required for a continuous trial non-inferiority 
trial 
Σ Standard deviation of outcome 
D Non-inferiority limit 
Alpha Significance level (5%) 
1-beta Power (80%) 
f(α, β) [Ф-1(α) + Ф-1(β)]2 
Ф-1 Cumulative distribution function of a standard normal deviate 
 
∴ n = (1.65 + 0.84)2 x 2 x (7)2 
             (2)2 
 
 n = 6.2 x 2 x 49  
      4 
 
 n = 152 participants / group 
 
 
In keeping with similar studies, this study allowed for a projected 20% attrition 
rate. Therefore, 364 participants (182 per group) was the sample size required 
to ensure that a minimum of 40 participants could be evaluated in order to 
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provide the study with a power of 80% to determine the non-inferiority among 
the TC group, as compared to the IPC group. 
 
Measuring the level of dyspnoea is vital to assess disease severity and to assist 
in the selection of treatment for patients with COPD. To quantify and assess the 
impact of dyspnoea, the Medical Research Council assessment tool was first 
developed (Bestall et al., 1999) and later replaced by a slightly modified version, 
mMRC, which is a validated tool that is widely used in clinical practice, mainly to 
define functional status (van der Molen et al., 2014). The mMRC has a scale of 
0 to 4, where the absence of breathlessness is given a score of 0 and too 
breathless to leave the house or when dressing is given a score of 4 (Román-
Rodríguez et al., 2016). There has been no minimum clinically significant 
difference identified with the mMRC scale (de Torres et al., 2002). 
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9.21 Appendix 21: Publication history and future plan 
 
 
Target Journal / 
Conference 
 
Title 
 
When/where 
 
Acute Medicines 
Journal 
 
An Audit showing the Impact of 
Pharmacist Independent 
Prescribing on the Admissions 
Ward at Diana, Princess of 
Wales Hospital 
 
Research Audit and 
Clinical Practice. 
2013. 12 (4), 185 – 
252 
 
Pharmacy Voice 
 
How Skype™ can enable 
pharmacists to help more 
patients 
 
May 2016. Issue 2, 
page 6 
 
Pharmacy Show 
 
The Impact of Pharmacist 
Interventions via TCs on COPD 
control and QoL amongst COPD 
sufferers 
 
7-8th October 2018 
NEC Birmingham 
 
International 
Journal of COPD 
 
The Impact of Pharmacist 
Interventions via TCs on COPD 
control and QoL amongst COPD 
sufferers 
 
12th November 
2018 
 
International 
Journal of Clinical 
Pharm 
 
Comparing TCs to IPCs in COPD 
medication review clinics 
 
19th November 
2018 
 
International 
Journal of 
Telemedicine and 
Clinical Practices 
 
The effects of reviewing patients 
with COPD using TCs 
 
26th November 
2018 
 
Pharmacy 
Practice Journal 
 
Conducting a COPD service from 
a distance-selling internet 
pharmacy. 
 
3rd December 2018 
 
